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Summary
This thesis addresses the question of whether certain control 
mechanisms responsible for metabolic regulation in mammalian tissues 
such as liver, adipose tissue and muscle, are also functional in 
mammary tissue.
Cyclic AMP-dependent phosphorylation is considered ubiquitous in 
animal tissues and has been demonstrated to be capable of regulating 
numerous major metabolic pathways (see section 1.). In mammary 
tissue, cellular metabolism is dominated overwhelmingly by 
lactogenesis: the biosynthesis of lipid is a principal pathway in the 
collection of activities comprising this function. The cyclic 
AMP-dependent regulation of this and other metabolic pathways of 
particular relevance to mammary cell function is discussed at length 
in section 1., highlighting the apparent necessity for control 
mechanisms analogous to those found in other cell types. A review of 
these mechanisms demonstrates the potential importance of cyclic AMP 
as a regulator of mammary cell metabolism and raises many interesting 
questions. One of the most intriguing of these is whether or not 
mammary cell cyclic AMP levels are subject to the same regulatory 
influences as have been described for tissues such as liver and 
adipose tissue. An obvious extension of this is whether modulation 
of intracellular cyclic AMP levels provokes the same metabolic 
response, in mammary tissue, as has been observed in these other 
tissues. Both of these questions have been addressed and the results 
are presented here.
XThe discovery that the activity of a high affinity form of cyclic 
AMP-phosphodiesterase found in adipose tissue and liver can be 
modulated by hormones such as insulin has stimulated a great deal of 
interest since it provides a possible mechanism for at least some of 
the metabolic effects of this hormone. Mammary tissue also contains 
"high affinity" cyclic AMP-phosphodiesterase and its regulatory 
properties, particularly with respect to insulin-sensitivity, have 
been investigated. The results show that rat mammary high affinity 
cyclic AMP phosphodiesterase activity is stimulated by treatment of 
isolated acinus preparations with insulin but that the effect cannot 
be reproduced in a broken-cell system. These results are discussed 
with reference to similar studies in other tissues.
Although intracellular cyclic AMP concentrations can be raised 
many-fold by treatment of mammary cells with agents such as forskolin 
and (3-adrenergic agonists (in the presence of a phosphodiesterase 
inhibitor), no discernable effect on the activity of key enzymes such 
as acetyl-CoA carboxylase (known to be phosphorylated and inactivated 
by cyclic AMP-dependent protein kinase) has been observed. 
Consequently, the existence, in mammary tissue, of a competent 
combination of cyclic AMP-dependent protein kinase and endogenous 
substrate has been investigated. Complementary to this, a preliminary 
survey of the existence in mammary tissue, of three other 
effector-dependent phosphorylation systems (governed by 
calciunv/calmodulin-dependent protein kinase, protein kinase C and 
polyamine-dependent protein kinase) has been conducted. The major 
finding was that rat mammary tissue does indeed contain competent
xi
kinase/endogenous substrate combinations for at least two known 
effectors of metabolic regulation. One of these is Ca2+/calmodulin 
but of greater significance to the present study, the other is cyclic 
AMP, for which phosphorylation was shown to display a dose-dependent 
relationship (in the physiological range) with at least two 
endogenous substrates. The molecular weights of these and other 
endogenous substrates for effector-dependent phosphorylation in 
mammary tissue are compared with substrates for similar 
phosphorylations already identified (in the literature) in other 
tissues.
11. INTRODUCTION
The only property of cAMP recognised to be important in the 
control of animal cell metabolism is its ability to activate 
cAMP-dependent Protein Kinase (cAMP-PrK) but by this action alone it 
is able to regulate a number of major metabolic pathways including 
glycogenolysis, glycolysis/gluconeogenesis and fatty acid synthesis. 
By virtue of its broad substrate specificity, cAMP-PrK has the 
potential to regulate the function of numerous cellular proteins of 
which many are either enzymes themselves or modulators of enzyme 
activity such as inhibitor 1 (see section 1.3.8.(i)a). In 
recognition of its role as link between external stimuli and 
intracellular response, cAMP is termed a second messenger. This 
nucleotide was the first agent found to possess such a property and 
is arguably the most important mediator of acute metabolic regulation 
by external stimuli yet discovered. The control of its accumulation 
within the cell has, therefore attracted a great deal of interest and 
as a consequence, the regulation of intracellular cAMP levels is 
relatively well understood. By the same token, cAMP-dependent 
phosphorylation has also been extensively characterised in several 
enzyme systems (see sections 1.3.1.-1.3.7. and 1.3.8.(i)a). The 
synthesis and degradation of cAMP (represented in Figure 1) is 
governed by the two enzymes adenylate cyclase and cAMP 
phosphodiesterase (PDE) respectively, both of which are subject to 
regulation by various agents.
Figure 1 cAMP Synthesis,Degradation
and Action
Pyrophosphate
ATP CAMP > AMP
ADENYLATE cAMP-PDE
CYCLASE
V
Inactive ^ ----------------- Active
cAMP-dependent cAMP-dependent
Protein Kinase Protein Kinase
21.1. Adenylate Cyclase
In recent years in has been established that the activity of 
adenylate cyclase is subject to dual control mediated by a pair of 
guanine nucleotide binding proteins (here referred to as G-proteins 
but also known as N-proteins) termed Gg (stimulatory) and G. 
(inhibitory). The catalytic moiety (C) of adenylate cyclase is 
essentially inactive in the absence of Gs but adenylate cyclase 
preparations free of Gg can also be activated by the diterpene 
forskolin [691] suggesting that this compound interacts directly with 
C. However forskolin induced activation of C is enhanced in the 
presence of Gs [145] and there is evidence that interaction with 
intact G-protein is necessary in order for full activation by 
forskolin to be expressed [145]. Fluoride ions also activate 
adenylate cyclase in the presence of Al3+ and Mg2+ but in this 
instance the presence of Gg is an absolute requirement for activation 
[712].
Purification of C, a hydrophobic and apparently very labile 
protein, has recently been achieved using forskolin-Sepharose 
affinity chromatography [606, 607] but many of the properties of the 
catalytic component of adenylate cyclase remain poorly characterised. 
Both Gg and G. have been purified and studied in some detail by 
Gilman et al. [253 and references therein]. In most tissues Gg is 
described as a dimer consisting of a 45kDa ar-subunit and a 35kDa 
^-subunit although variable amounts of a 52kDa subunit have also been 
identified in G from rabbit liver [571, 731]. G. is also described
S ' 1
as a heterodimer and appears to share the same (3-subunit [508, 712] 
but its a-subunit is distinct and has a molecular weight of 41kDa 
[253]. Both a-subunits contain a high affinity guanine nucleotide
3binding site and a site susceptible to NAD-dependent ADP-ribosylation 
by bacterial toxins. Recently, comparable G-protein purifications 
conducted by Birnbaumer and co-workers [109] have yielded broadly 
similar results but this group describe Gs and G£ complexes with 
identical molecular weights (95kDa), each composed of a 35kDa 
3-subunit, a 42kDa a-subunit and a 10-15kDa y-subunit. As previously 
described, the 3-subunits are identical and the a-subunits although 
now proposed to share the same molecular weight, are distinct; 
however, a third small (y) subunit to which no function has yet been 
assigned, is thought to also be an integral part of both Gg and G£. 
The subunit composition of the G- proteins would then be a3y, 
analagous to that of the related signal-transducing protein of 
retinal rod outer segments, transducin, which has been shown to share 
the same 3-subunit as Gs and G. [362].
Both purified G-proteins have been reported to be activated in 
an essentially irreversible manner by the non-hydrolysable GTP 
analogue GTPyS (guanine 5'-(3-O-thio)triphosphate) [253] suggesting 
that GTP hydrolysis is not necessary for either Gs mediated 
stimulation or G. mediated inhibition of adenylate cyclase. Although 
activation of G. by non-hydrolysable GTP analogues is a widely 
observed phenomenon [363, 712], fundamentally contradictory results 
demonstrating that G. mediated inhibition of adenylate cyclase can 
not be induced by such analogues are reported with equal confidence 
[127, 425]. Activation of Gs is much less controversial and it is 
generally accepted that non-hydrolysable GTP-analogues are effective 
substitutes for GTP itself in this respect [127, 712]. The generally 
accepted mechanism of Gs mediated adenylate cyclase activation and 
the alternatives proposed for inhibition of adenylate cyclase under
Figure 2
Gs a » ot-subunit of stimulatory G-protein (Gs). 
GA a = a-subunit of inhibitory G-protein (Gi).
3 = (3-subunit common to both Gg and GL. 
c = catalytic subunit of adenylate cyclase.
Figure 2 Schemes Proposed for Modulation 
of Adenylate Cyclase Activity by 
G-Proteins
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4the influence of its counterpart, G., are illustrated in Figure 2. 
G-protein activation results from dissociation of the holo-protein 
but whereas the adenylate cyclase stimulatory activity of Gs resides 
in the a-subunit, the inhibitory activity of G£ appears to be 
accounted for, largely, by its 0-subunit though G. a does possess 
weak inhibitory activity. However, whether 0-subunit inhibition 
results predominantly from direct interaction with C or is achieved 
indirectly via binding of free Gs a is uncertain [235]. The relative 
contributions of the two G-proteins to regulation of adenylate 
cyclase activity can be probed using cholera toxin and pertussis 
toxin (also termed Islet-activating protein [IAP]). Cholera 
toxin-mediated ADP-ribosylation of Gs blocks GTP hydrolysis and thus 
allows persistent activation of Gs by GTP as observed in equivalent 
untreated preparations exposed to non-hydrolysable GTP analogues 
[127, 712]. Treatment with pertussis toxin, on the other hand, 
promotes ADP ribosylation of G. and as a result blocks hormonal 
inhibition of adenylate cyclase in a wide variety of cell types [712] 
while also often potentiating the effects of stimulatory agonists 
[300, 390]. This modification presumably blocks Gi dissociation and 
consequently prevents the expression of its inhibitory activity. The 
same ultimate effect is implicit in the mechanism for pertussis toxin 
action proposed by Jakobs et al. [614] involving inhibition of the 
GDP/GTP exchange required for activation of G. (see Figure 2). Mg2+ 
is required for activation of both G-proteins but while the 
concentrations required for Gg activation of adenylate cyclase are in 
the millimolar range [665], micromolar concentrations of this ion are 
sufficient to allow G. mediated inhibition [362, 365].
5Many hormones and neurotransmitters are able to modulate 
adenylate cyclase activity by interaction, via their specific 
cell-surface receptors, with the G-proteins. Stimulatory receptors 
include, among others, those for ^-adrenergic agonists, ACTH and 
gonadotrophins while inhibitory effects are initiated by binding of 
somatostatin, -adrenergic agonists, muscarinic agonists, dopamine 
and opioids [253, 712, 109]. Binding of agonist to its receptor 
results in activation of the G-protein associated with that 
particular receptor type. Whether the response is stimulatory or 
inhibitory in terms of adenylate cyclase activity therefore depends 
on the type of receptor involved, while the magnitude of that 
response may depend on the proportion of G. to Gs present in the 
membrane. The latter is particularly important for hormones such as 
adrenaline which bind to both a and |3 adrenergic receptors and whose 
cellular effects will therefore be very much dependent on the 
predominant G-protein in the target cell membranes. Tissue specific 
responses to such agents may therefore be achieved either by 
differences in the proportion of 3 (stimulatory) and (inhibitory) 
receptors or by differences in the membrane complement of Gs and G..
A further mechanism potentially capable of modulating the response of 
adenylate cyclase to hormonal regulation has been revealed by recent 
work with phorbol esters in human platelets [364, 389]. Tumor 
inducing phorbol esters are direct activators of protein kinase C 
(PrkC; see section 1.3.8.(i)b) and have been found to impair hormone 
induced inhibition of adenylate cyclase activity [364]. This effect 
appears to be mediated by PrKC catalysed phosphorylation of the 
a-subunit of G. [389]. Since PrKC is activated by agents that 
increase phosphatidylinositol turnover such as o^- adrenergic
6agonists, angiotensin II, vasopressin and thrombin (see section
1.3.8.(i)b) this system confers the potential for complex 
interactions between hormones whose actions are mediated by changes in 
cAMP levels and those whose primary actions result from an apparently 
unrelated sequence of events. The response to adrenaline alone is also 
further complicated since ^-adrenergic stimulation of adenylate cyclase 
may be reinforced by the PrKC induced suppression of G. resulting from 
-adrenergic stimulation of phosphatidylinositol turnover. The 
inhibitory stimulus of occupancy would then be rendered ineffective. 
Thus, assuming this system operates in vivo, the degree of adenylate 
cyclase activation observed following exposure to adrenaline will 
depend on the abundance of receptors as well as the factors already 
discussed above. An additional regulatory feature of the p-adrenergic 
system, suggested by work with avian erythrocyte receptors [705, 396, 
723, 744, 557, 704] and confirmed, recently, in hampster lung [41] is 
mediated by both cAMP-dependent protein kinase and protein kinase C and 
involves phosphorylation of the ^-adrenergic receptor, resulting in 
reduced receptor-Gs coupling and, consequently, desensitisation of 
p-adrenergic response. Amongst other potential physiological 
functions, this system would represent a means of imposing 
negative-feedback control on the cellular response to binding of 
|3-adrenergic agonists.
In 1983 Heyworth and Houslay [311] presented evidence that 
insulin receptors are coupled to a G-protein with properties 
resembling those of G. and that via this mechanism, insulin is able 
to inhibit glucagon stimulated adenylate cyclase in hepatocyte 
membranes. The same G-protein is proposed to be involved in insulin 
stimulation of a high affinity membrane bound species of hepatocyte
7cAMP-PDE [312, 310] see section 1.2.2.(ii)). The G-protein 
transducin which mediates between rhodopsin and PDE and has a subunit 
structure apparently very similar to that of the adenylate cyclase 
G-proteins (see earlier) also bears functional similarities to these 
regulatory proteins. The a-subunit (molecular weight 39kDa) of 
transducin binds GTP and can be ADP-ribosylated by either cholera or 
pertussis toxins though at distinct, independent sites. Guanine 
nucleotide analogues cause dissociation of a from £.y subunits and 
the free a subunit activates PDE.
Modulation of the activities of the two enzymes responsible 
for cAMP synthesis and degradation in cell membranes appears, then, 
to be achieved by mechanisms involving a common class of regulatory 
proteins, the guanine nucleotide binding proteins.
1.2. Mammalian cAMP-Phosphodiesterase
Despite the regulatory similarities between the adenylate cyclase 
system and a particular form of membrane bound PDE, the PDE enzyme 
system, of which membrane bound activity is often a quantitatively 
minor though perhaps functionally significant (see section 1.2.2) 
component, represents a much more diverse group of enzymes both 
structurally and functionally.
In recent years, a great deal of attention has been focussed on 
the properties and intracellular distribution of cyclic 3'5'adenosine 
monophosphate phosphodiesterase (cAMP-PDE), an interest which arises 
from its role as the only enzyme known to be capable of catalysing 
degradation of the second messenger, cyclic AMP. As such, cAMP-PDE 
plays an important part in the regulation of all cellular processes 
influenced by cAMP and variations in its activity and distribution may,
therefore, have profound effects, particularly in relation to hormonal 
regulation of cellular activities. As a result of the widespread 
interest in this enzyme, several reviews of work relating to the 
characterisation of the various phosphodiesterases and their roles in 
the modulation of cellular activities have been compiled [including 
203, 738, 774, 833], that produced by Thompson and Strada [774] in 1978 
being one of the most recent of these. In this short review I have 
summarised contemporary information gained as a result of recent work 
by various authors against the background of earlier work.
The bewildering diversity of PDE forms reported in recent years 
appears to defy categorisation into mutually exclusive groups although 
attempts have been made at more general classifications [774, 203, 235, 
841, 833] on the basis of substrate affinity and specificity. The most 
widely recognised distinction is that made between high-affinity (low 
Km ) and low affinity (high Km ) cAMP-PDEs. Although Km values are often 
not quoted for the particular PDE being studied, most of the 
experimental work published to date assumes that activity measured at 
/i/M or sub fM cAMP concentrations reflects mainly, if not exclusively, 
the activity of high affinity cAMP-PDE and that measured at 100/yM or 
above represents the activity of low affinity cAMP-PDE. In some cases, 
such assumptions may be made with a reasonable degree of safety, 
particularly if the two types of enzyme are known to have very 
different K values but it must be remembered that unless effectivem
purification techniques have been applied, activity measured at a 
substrate concentration chosen to highlight high affinity activity is 
likely to include a certain amount of low affinity activity and PDE 
activities measured at higher cAMP concentrations (for example, 100yt/M) 
will inevitably represent some (depending upon Km ) low affinity
9activity and effectively all high affinity activity [833]. A highly 
activated form of either enzyme might, therefore, easily make a 
significant contribution to activity measured at a substrate 
concentration chosen for study of the activity of the other, 
particularly if the activation involves a large increase in Vmax of 
high affinity cAMP-PDE or decrease in Km of the low affinity enzyme.
The potential inaccuracy of these assumptions is highlighted by a 
review of the range of Km values reported for cAMP-PDE. High affinity 
cAMP-PDEs have been described by various authors as having Km values 
ranging from 0.2-0.3/;M in rat adipose tissue [878, 506] and rat liver 
[489] to between 5 and 6/vM in rat liver [13, 717] and rat heart [13]. 
Low affinity cAMP-PDEs have been reported with Km values between 
approximately 9/;M [830] and 300/;M [421] or over [315], So, instead 
of a population of enzymes falling into two discrete and easily 
recognised groups possessing characteristically high or low Km values, 
the PDE forms found in various mammalian tissues present an apparently 
near continuous range and it would, therefore, be unrealistic to expect 
to separate the higher Km high affinity PDEs from the lower Km low 
affinity PDEs on the basis of Km alone. Despite this, for convenience, 
the group headings of high and low affinity will be retained although 
other factors such as substrate specificity and mechanism of activation 
may be more important in determining the group to which any particular 
PDE is assigned.
1.2.1. Low Affinity cAMP-PDE
Low affinity cAMP-PDEs generally have Km values over about 10/vM but 
the range is wide and values vary depending on the tissue under 
investigation, typical values for rat liver [13, 302, 509, 41] and
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adipose tissue [506, 770] being 25-40/vM though figures of around 
90-100/vM and 60^ 14 have been quoted for rat [547, 710] and mouse [14] 
liver, respectively. Bovine brain PDE appears to display a 
particularly high Km with figures between 150 and over 310yi/M [421,
545, 697, 784] although low affinity PDE of rat brain [14, 146, 674] 
appears to have similar Km values to those of rat liver.
Low affinity cAMP-PDE is known to be predominantly a cytosolic 
enzyme [841] and accounts for the major part of soluble PDE activity 
[235] but membrane bound low affinity cAMP-PDE may also make a 
significant contribution to total low affinity activity and has been 
found in particulate fractions of rat liver [719, 835, 841], heart 
[235] and brain [766]. In some tissues, for example rat heart [235], 
particulate low affinity cAMP-PDE may represent 50% of total low 
affinity activity, although in adipose tissue and kidney the proportion 
of this activity in particulate fractions is apparently low [674, 774].
The possible roles of low affinity cAMP-PDE as a cytosolic 
enzyme, predicted by the theoretical models of Fell [212] are discussed 
later (section 1.2.4.).
Low affinity activity is often reported to coincide with cGMP 
hydrolysing activity [29, 146, 421, 545, 547, 675, 833], The low 
affinity enzyme system is, therefore, sometimes described as consisting 
of cyclic nucleotide-PDE [29, 235, 547], to indicate its lack of 
specificity for either substrate, and cyclic GMP-PDE when activity with 
cGMP exceeds cAMP hydrolysing activity and the proportion of total 
cellular cGMP hydrolysing activity accounted for by this enzyme is 
sufficient to justify such a description [13, 91, 235, 378] even 
though, when assayed at high substrate concentrations (millimolar), 
activity with cAMP is greater than with cGMP [378]. One of the most
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reliable criteria for distinguishing low affinity cAMP-PDE is the 
susceptibility displayed by certain of this type of enzyme to 
activation by Ca2+/calmodulin. This property seems to be unique to 
those enzymes classified as low affinity but it is not a property 
shared by all such enzymes, since cyclic nucleotide-PDEs have been 
described with high Km values for both cAMP and cGMP that may [841] or 
may not [146, 378] exhibit activation by Ca2+/calmodulin; however, all 
the members of this latter group are activated by cGMP at micromolar 
concentrations [146, 378, 841]. Two soluble low affinity PDEs have 
been isolated from rat cerebral cortex by Davis [146], one of which is 
Ca2+/calmodulin-dependent and described as a cGMP-PDE, while the other 
is a Ca2+/calmodulin-independent, cGMP-stimulated cyclic nucleotide- 
PDE. The Ca2+/calmodulin-independent form appears to represent either 
a single enzyme with an allosteric site for cGMP binding and two 
distinct active sites, one for cAMP and one for cGMP, or two separate 
enzymes sharing the same allosteric site [146]. Enzymes with a greater 
affinity for cGMP than cAMP have, however, been reported to possess 
only one catalytic site for both substrates [421, 545]. It seems, 
therefore, that low affinity cAMP-PDEs may be divided into two groups. 
One type possesses two distinct active sites [794], one specific to 
cAMP, the other to cGMP, both with similar, low substrate affinities. 
This type is the previously described cyclic nucleotide-PDE [13, 29, 
547, 841] and is subject to allosteric activation by cGMP. The second 
type of low affinity cAMP-PDE is probably more accurately described as 
cGMP-PDE, as discussed earlier, and possesses only one active site 
[545] capable of the hydrolysis of both cAMP and cGMP. This type of 
enzyme is activated both by Ca2+/calmodulin and by limited proteolysis 
[146, 675, 784]. Kakiuchi et al. have found representatives of both
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types of low affinity cAMP-PDE in the same tissue preparation (derived 
from rat cerebral cortex), a situation found by Mullaney and Clegg 
[549] to be duplicated in rat mammary tissue.
2 +1.2.1.(i) Ca /Calmodulin Activation
Calmodulin is an anionic protein of molecular weight approximately 
17-18kDa possessing four calcium binding sites. It has been 
suggested that binding of Ca2+ to all four of these sites produces a 
molecule capable of activating PDE [134, 814] but that binding to only 
two of the four may result in the formation of an adenylate cyclase 
activator [814]. Such a distinction is made possible by the existence 
of two classes of Ca2+ binding site in the calmodulin molecule with 
distinct dissociation constants (1CT6M and 10-4M) [423]. The 
inability of calmodulin alone to active cGMP-PDE is thought to be due 
to masking of a hydrophobic region required for binding to the enzyme. 
Binding of Ca2+ to the calmodulin molecule is thought to expose this 
region, allowing binding to and activation of the PDE [146, 458, 761].
A mechanism for the activation of calmodulin-dependent cAMP-PDE 
and other calmodulin dependent enzymes has been proposed by Gietzen 
et al. [247] and involves interaction of anionic amphiphiles, such as 
calmodulin, with a complementary region of the enzyme molecule in such 
a way as to induce a conformational change allowing greater 
accessibility to the enzyme active site as shown in Figure 3. Other 
ionic amphiphiles, such as oleic acid and phosphatidyl serine, have 
also been shown to activate rat brain PDE and compete for activation 
with calmodulin, suggesting that the same activation mechanism is 
common to all three activators [248]. This mechanism also accommodates 
the activation of a bovine brain calmodulin-dependent PDE by limited
Figure 3
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proteolysis described by Tucker et al. [784] (see Figure 3).
Proteolysis catalysed by trypsin or endogenous protease produces an 
enzyme with activity equal to the calmodulin-stimulated enzyme but 
calmodulin will no longer bind to the protease treated enzyme and, 
therefore, no further activation is observed. The proteolytic activity 
cleaves a series of peptide fragments from one or both terminal regions 
of the polypeptide chain constituting the enzyme and calmodulin 
binding is abolished after removal of approximately 120 residues [784].
Activation of PDE by calmodulin has been reported to involve an 
increase in the enzyme's V [625, 684, 832, 842], a decrease in K
m a x  ' m
[58, 263] or both [90, 379, 764].
It has been suggested that the function of the calmodulin 
sensitive enzyme, cGMP-PDE (according to the classification system 
described earlier), is to remove large excesses of cAMP and cGMP that 
may collect in the cytosol [718]. The latter, perhaps, is of 
particular significance since both guanylate cyclase [287] and cGMP- 
dependent protein kinase [448] are cytosolic enzymes in muscle.
1.2.1.(ii) Molecular Structure and Kinetics
Most of the low affinity cAMP-PDEs purified to apparent homogeneity 
have been of the Ca2+/calmodulin-dependent type (cGMP-PDE) and have 
been isolated from bovine brain [697, 421, 545] and heart [329, 457, 
558]. There is broad agreement on the molecular weight of the purified 
enzyme with values, in each instance, being between 121kDa and 135kDa 
[329, 421, 545, 558, 697] and also that of the catalytically active 
subunit with figures quoted at 58kDa [697], 59kDa [329, 421, 558] and 
63kDa [545]. However, opinion is divided as to the subunit composition 
of the purified enzyme. A dimeric structure comprising two identical
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catalytic subunits, each capable of binding one molecule of calmodulin 
has been suggested [380, 457, 545, 697] but Klee et al. [421] have 
isolated three subunits of molecular weights 59kDa, 61kDa and 15kDa of 
which only the 59kDa unit has catalytic activity and binds calmodulin, 
the other subunits being described as inhibitory peptides.
The molecular weights of 400kDa and 250kDa determined for 
cyclic nucleotide-PDE [265, 769] suggest that this enzyme form has a 
more complex subunit structure than cGMP-PDE but, as yet, there is no 
information relating to the number and nature of its constituent parts 
and the possibility therefore exists that such high molecular weights 
may represent artifactual aggregations.
Anomalous kinetics reported to be displayed by some of the cGMP- 
and cyclic nucleotide-PDEs are returned to normal Michaelis-Menten 
kinetics by calmodulin [329, 833] or cGMP [29, 133, 509] respectively.
A cGMP-stimulated low affinity cAMP-PDE found in rat liver has a 
hydrophobic binding site, binding of which to a hydrophobic matrix 
results in a reduction in the positive cooperativity of the enzyme 
[133]. Perhaps if bound to a biological membrane, its activity might, 
therefore, conform to normal Michaelis-Menten kinetics allowing it to 
be classified as a low affinity intrinsic enzyme of the type described 
by Marchmont and Houslay [510] in rat liver membranes. Similarly, a 
cyclic nucleotide-PDE is reportedly released from rat liver membranes 
following treatment with detergent [841].
Although grouped loosely together, for the purposes of this 
review, under the heading of "Low affinity cAMP-PDE", the so-called 
cGMP- and cyclic nucleotide-PDEs have little more in common with each 
other than they have with "high affinity cAMP-PDEs" and it may 
therefore be more accurate to recognise them as individual groups in
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their own right, as has often been acknowledged in the past [13, 235, 
833, 841, 774] and as the proposals for interrelation of enzyme forms 
presented in section 1.2.3 might suggest.
1.2.2. High Affinity cAMP-PDE
High affinity cAMP-PDE does not represent as diverse a group of 
enzymes as those constituting the group termed low affinity and may be 
readily subdivided into two major categories. The two groups share 
similar physical and kinetic properties and are most easily identified 
by their response to hormonal stimuli which, in fact, forms the basis 
of their classification. Enzymes representative of the first group 
show no response to such stimuli and are therefore termed 
hormone-insensitive while the second group, hormone-sensitive PDE, has 
been shown to include enzymes capable of responding to a wide range of 
hormones (see later; section 1.2.2.(ii)) and has consequently attracted 
a great deal of interest in the field of metabolic regulation.
1.2.2.(i) General Properties
High affinity (low Km) cAMP-PDE is the major membrane bound form of PDE 
[212, 841] but soluble forms of the enzyme have also been reported 
[274, 742, 772, 830] and may constitute a considerable proportion of 
the total cellular high affinity PDE in many tissues [235]. 
Phosphodiesterases classified under the heading of "High affinity" have 
Km values below 10/yM in the vast majority of mammalian tissues 
studied, with typical values for rat liver [13, 14, 489, 509, 512, 717] 
and adipose tissue [506, 878] ranging from 0.2/;M to 6.0/vM. Neither 
membrane bound nor soluble high affinity cAMP-PDEs are activated 
directly by Ca2+/camodulin or cGMP but interactions involving
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G-proteins analogous to those of the adenylate cyclase system have, as 
mentioned earlier (section 1.1), been implicated in the expression of 
hormonal influences on the plasma membrane bound form of this enzyme.
Many partially purified preparations of high affinity cAMP-PDE 
display non-linear kinetics [670, 770, 774, 833], suggested by some to 
imply the presence of multiple enzyme forms. However, doubts have been 
expressed as to the probability that this is a valid explanation on 
grounds that the degree of contamination by other kinetically distinct 
enzyme forms required to achieve the observed effects is unreasonably 
high [670] and high affinity cAMP-PDE purified to apparent homogeneity 
has also been demonstrated to display kinetics compatible with negative 
cooperativity [509]. These observations do not, however, preclude the 
possibility that the anomolous kinetics displayed by high affinity 
enzymes in some crude or partially purified preparations are the result 
of multiple enzyme forms since other high affinity cAMP-PDEs purified 
to apparent homogeneity have been found to display normal 
Michaelis-Menten kinetics [193, 194, 538]. A time-dependent loss of 
negative cooperativity, which is prevented by Mn2+ but not Mg2+ has 
been observed in kidney membrane preparations [774]. High affinity 
cAMP-PDEs have been purified to apparent homogeneity from pig [302] and 
rat [509] liver, dog kidney [194, 772] and human lung [542]. These 
enzymes represent a group which, on the whole, appear to share the 
same, or very similar, characteristics despite the range of tissues and 
species from which they have been isolated. The dog kidney and human 
lung enzymes are both described as acidic proteins with molecular 
weights of 48-60.6kDa [772] and 60kDa [542] respectively and have 
much greater affinity for cAMP as a substrate than cGMP. Activation 
has been shown in the presence of Mg2+, Mn2+ [302, 542] and Ca2+ [302]
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but none of the enzymes show any activation by Ca2+/calmodulin. Only 
purine rings are accepted by all but the pig liver enzyme [302] which 
shows equal activity with either cAMP or cCMP as substrate despite 
possessing only one species of active site. Marchmont and Houslay 
[509] suggest that since the purified rat liver peripheral enzyme is 
monomeric, the departure from normal Michaelis-Menten kinetics 
displayed by this enzyme might be explained by the "one substrate, one 
product mnemonic mechanism" proposed by Ricard et al. [647],
Both soluble [737] and particulate [502, 742, 841] high affinity 
cAMP-PDEs are susceptible to activation by an endogenous protease. 
Particulate enzyme solubilised by this and other proteases such as 
trypsin, chymotrypsin and papain [490, 501] displays a lower molecular 
weight than that solubilised by detergent [502] and activation is 
characterised by an increase in V and a decrease in K [774].
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However, prolonged exposure to trypsin results in the obliteration of 
catalytic activity [490]. It has been proposed that the 
proteolytically solubilised enzyme represents the catalytic subunit or 
domain of the particulate enzyme [227, 490] and that it is normally 
associated with an inhibitory domain from which it is released during 
solubilisation by protease but not by detergent [227, 490]. It would 
seem reasonable to assume that proteolytic activation of the soluble 
enzyme is achieved by a similar process but there is, at present, no 
evidence to support such a proposal. The endogenous protease of rat 
renal cortex involved in solubilisation and activation of particulate 
high affinity cAMP-PDE appears to be a lysosomal enzyme similar to the 
thiol protease, cathepsin L, of rat liver [742]. Stimulation of such 
thiol protease activity has been proposed to explain the activation of 
PDE observed in crude adipocyte microsomal fractions incubated in the 
presence of dithiothreitol [502].
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The two major intracellular sites to which particulate high 
affinity cAMP-PDE activity has been attributed in both adipose tissue 
[429, 501] and liver [489, 717, 511] are endoplasmic reticulum and 
plasma membrane although a representative of this group has also been 
described by Houslay and co-workers in a unique "dense-vesicle" 
fraction isolated from rat hepatocytes [845]. Redistribution of 
particulate high affinity cAMP-PDE to the soluble phase appears to 
occur in mouse embryo fibroblasts (line 3T3 balb C) when a quiescent 
culture enters log growth phase [774]. Whether this relocation is 
achieved by a solubilisation mechanism involving the proteolytic 
effects described earlier or should be attributed to some other process 
such as comigration with insulin receptors [326] is not known but 
Smoake and Solomon [718] have observed similar effects in liver cells 
of diabetic rats.
1.2.2.(ii) Hormone Sensitive Phosphodiesterase
Modulation of high affinity cAMP-PDE activity has been observed in 
response to a variety of hormones [22, 192, 720, 738, 793] including 
glucagon [9, 312], catecholamines [64, 597], thyroxine [793] and ACTH 
[597] but most interest has centered around the ability of insulin to 
stimulate the activity of certain species of this enzyme [227, 312,
327, 328, 429, 489, 491, 501, 773, 792]. Since insulin is known to be 
capable of reducing intracellular cAMP concentrations [622, 617], the 
discovery that the activities of representatives of the enzyme system 
responsible for cAMP degradation are raised following insulin treatment 
has lead to speculation that these phenomena are causally linked [491, 
506]. Predictions about the ability of variations in the activity of 
hormone sensitive PDE to modulate cAMP concentrations [212, 646, 313]
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support the proposal that the influence of insulin upon this enzyme 
plays a potentially important role in the regulation of intracellular 
cAMP concentrations.
In adipose tissue [506, 833] and liver [489, 328], hormone 
sensitive cAMP-PDE is predominantly, if not exclusively confined to the 
particulate fraction though a soluble species has also been described 
in adipose tissue [830]. The soluble enzyme is inhibited by steroids 
(thought to have cytosolic receptors [774]) and is found in two forms, 
one of which is stimulated by insulin [670]. Until recently, insulin- 
stimulated activation of PDE could only be observed in whole cell 
preparations but in 1980, Marchmont and Houslay [511] demonstrated 
activation of high affinity cAMP-PDE following incubation of rat liver 
plasma membranes with insulin, ATP and cAMP. Two plasma membrane 
enzymes were identified, an integral PDE and a peripheral PDE of which 
only the latter could be demonstrated to undergo activation in the 
presence of insulin. The insulin-stimulated activation of peripheral 
high affinity cAMP-PDE is accompanied by phosphorylation of the enzyme 
on one site per enzyme molecule [512] and is dependent on cAMP with a 
Ka for this ligand of 1.6/i/M. The observation that similar 
concentrations of cAMP (approximately 1/yM) prevail in intact cells 
[312] explains the ability of such systems to respond to insulin alone 
[327, 328], though, as would be expected, the magnitude of insulin 
induced activation of plasma membrane PDE is increased when 
intracellular cAMP concentrations are raised prior to insulin treatment 
[312]. This activation is also known to involve guanine nucleotides 
[310] and has been suggested to be mediated by a specific G-protein 
with properties similar to those of G. [310, 311, 312] (see section
1.1.). There is evidence that peripheral cAMP-PDE is closely associated
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with and perhaps even bound to plasma membrane insulin receptors [326, 
328, 512] and may, therefore be subject to phosphorylation and 
activation by the same indirect cAMP-dependent mechanism proposed to be 
involved in the serine/threonine phosphorylation of insulin receptor 
3-subunit following insulin binding (see section 1.3.8.(ii)a). There 
is also evidence of close association with the adenylate cyclase system 
[381, 793], suggesting that the components involved in cAMP metabolism 
are ideally arranged for effective interaction and for execution of 
rapid adjustments in net cAMP accumulation. The response of hepatocyte 
plasma membrane high affinity cAMP-PDE to insulin [327, 328] is blocked 
by preincubation with glucagon in a dose-dependent manner [312, 813] 
but insulin sensitivity can be restored by adenosine or its 
non-hydrolysable analogue, PIA (N6 — [phenylisopropyl]-adenosine) [813]. 
Various lines of evidence suggest that the adenosine effect is mediated 
by binding to R-type rather than P-type adenosine receptors [813] and 
the interactions between glucagon, adenosine and insulin in this system 
are analogous to those observed on glucose transport in adipocytes 
[138, 267].
The enzyme responsible for insulin-induced stimulation of PDE 
activity observed by Loten et al. [489] in a crude hepatocyte 
particulate fraction differs, in a number of respects, from the 
peripheral plasma membrane enzyme characterised above [327, 328, 512], 
The enzyme identified in crude membrane preparations appears to 
correspond to an insulin sensitive PDE found to be associated with a 
unique membrane fraction referred to as a "dense-vesicle" fraction 
[312] with identical density gradient migration properties to a 
membrane fraction with which insulin has been reported to be associated 
following internalisation [402, 403]. Unlike the peripheral plasma
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membrane enzyme, the "dense-vesicle" high affinity cAMP-PDE is also 
activated by glucagon and other agents that increase intracellular cAMP 
concentrations [312]; indeed, the activation induced by these agents is 
substantially greater than that achieved by administration of insulin 
alone or insulin and glucagon simultaneously [312]. Interestingly, 
however, pretreatment with glucagon but not other agents that raise 
intracellular cAMP concentrations results in a synergistic effect on 
the activation of this enzyme following subsequent exposure to insulin, 
implying a complex interaction between glucagon and insulin which, 
apparently, is not effected through increased intracellular cAMP 
concentrations [312]. Despite these effects, "dense-vesicle" PDE is not 
thought to play a significant role in the insulin-provoked reduction in 
intracellular cAMP concentrations previously raised by glucagon since 
this phenomenon is observed even under conditions known to inhibit the 
activity of this particular PDE [313]. Activation of "dense-vesicle"
PDE does not appear directly to involve phosphorylation as observed for 
insulin dependent stimulation of the peripheral plasma-membrane enzyme 
and is certainly effected by a distinct mechanism [845]. As might be 
predicted from its sub-cellular location, activation of the 
dense-vesicle enzyme is only observed in intact cells [845], implying 
that the integrity of some as yet undefined messenger system linking 
insulin binding at the plasma membrane to processes localised in 
intracellular structures remote from the initial site of insulin action 
(plasma membrane receptors) is necessary to allow expression of 
insulin's effect on this form of PDE.
While peripheral plasma membrane high affinity cAMP-PDE appears 
to be the major insulin sensitive PDE in liver, the major site of 
insulin-dependent activity in adipose tissue is the endoplasmic
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reticulum [429, 501]. Insulin-sensitive PDE has also been attributed 
to liver endoplasmic reticulum [489] but it has been suggested [312] 
that this enzyme is in fact "dense-vesicle" PDE and although found in 
fractions with very similar density gradient migration characteristics 
to enzymes of the endoplasmic reticulum, it exhibits characteristics 
distinct from the PDEs associated with rough and smooth endoplasmic 
reticulum [87, 844]. In common with "dense-vesicle" PDE, the hormone 
sensitive PDE of adipose tissue is activated by both insulin and agents 
that raise intracellular cAMP levels; however, the adipose tissue 
enzyme displays a susceptibility to oxidation/reduction effects during 
homogenisation not shared by its apparent counterpart [845] in liver 
[227]. Homogenisation of insulin treated adipocytes has been suggested 
to provoke air oxidation of S-H groups resulting in stabilisation of 
the activated enzyme [227]. Treatments that either prevent or reverse 
such oxidation cause substantial depression of the insulin-stimulated 
activity but restoration of stimulated activity cannot be effected by 
subsequent treatment with oxidising agents such as hydrogen peroxide, 
demonstrating that the activation induced by insulin is not achieved by 
oxidation of the enzyme [227]. Incubation of a crude adipocyte 
membrane fraction at high salt concentrations (for example, 0.15M KCl, 
5mM MgCl2) raises the basal activity of hormone sensitive PDE almost to 
the level observed following insulin stimulation (2.5-3 fold increase 
over unstimulated) while low salt conditions lower insulin stimulated 
activity to approaching basal level [501]. Although high salt 
concentrations also raise insulin-stimulated activity and low salt 
concentrations lower basal activity, these effects are small (< 20%) in 
comparison [501]. The reducing agent dithiothreitol returns salt 
stimulated activity to basal levels suggesting that the native enzyme
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normally exists in a reduced form in vivo since the intracellular salt 
composition is probably comparable to that of the high salt condition 
described above and hormone sensitive PDE would, otherwise, be 
permanently activated affording little opportunity for further 
activation in response to hormonal stimuli [501]. Unlike the effect of 
dithiothreitol on insulin stimulated activity, reversal of its effect 
on salt stimulation of basal enzyme activity is readily achieved by 
incubation with hydrogen peroxide [227]. Solubilisation of both liver 
endoplasmic reticulum and adipose tissue hormone sensitive PDE is 
accompanied by an increase in activity of the basal enzyme to the level 
attained following insulin activation but no change in 
insulin-stimulated activity is associated with such solubilisation 
procedures [490, 501]. The solubilised forms of basal and insulin- 
stimulated enzymes show identical physical and catalytic properties 
[227, 489, 490, 501] indicating that the two forms contain identical 
catalytic domains [490] and that hormonal regulation of this PDE is 
therefore probably achieved by modification of the regulatory domain 
such that its inhibitory effect is abolished [227]. Although direct 
involvement of phosphorylation in the hormonal activation of PDE 
associated with membranes other that the plasma membrane (adipose 
tissue endoplasmic reticulum and liver endoplasmic reticulum or 
"dense-vesicle") has not been proposed, there is circumstantial 
evidence to suggest that phosphorylation may participate in some stage 
of the activation process. Adipocytes deprived of ATP by treatment 
with uncouplers of oxidative phosphorylation (for example,
2,4-dinitrophenol or dicumarol) or inhibitors of cellular respiration 
(for example, KCN or sodium azide) fail to show elevated high affinity 
cAMP-PDE activity following exposure to insulin [430] but recover when
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washed and incubated with 2mM glucose, to give a near normal insulin 
response [430, 803]. The requirement for ATP or metabolic energy has 
been confirmed by Zinman and Hollenberg [878] and almost complete 
reversal of insulin stimulated PDE activation has been observed only 
ten minutes after exposure of insulin treated cells to ATP 
depleting agents [430]. This information alone gives no indication of 
the stage(s) at which ATP dependence is imposed on induction of this 
particular response to insulin and therefore sheds little light on the 
precise nature of the mechanism(s) involved. Direct action of insulin 
has sometimes been discounted when discussing activation of PDE 
associated with intracellular membranes [835] but if, as implied by 
Heyworth et al. [312], the "dense-vesicle" fraction represents one of 
the sites to which insulin is directed after internalisation, this view 
may be misguided. However, assuming the major intracellular 
localisation of adipose tissue hormone sensitive PDE remains strictly 
defined as the endoplasmic reticulum which, in contrast, does not 
appear to be a major target organelle for internalised insulin [402, 
403, 503], direct activation would indeed seem unlikely in this tissue. 
The case for an indirect mechanism is further strengthened by the 
observations that adipose tissue PDE retains the ability to respond to 
insulin under conditions known to completely block internalisation 
[503] and that the chemical mediator released from adipocyte plasma 
membranes following insulin binding [411, 690] is capable of 
activating adipose tissue high affinity cAMP-PDE [410]. Various 
proposals for mechanisms mediating in the response to insulin have been 
recruited to explain the diverse short and long term effects of this 
hormone but the systems involved have not yet been characterised and 
remain the subject of a great deal of controversy. Whether involvement
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of one or more of the various kinase activities associated with insulin 
receptor function (see section 1.3.8.(ii)a) in events leading, 
ultimately, to PDE activation provides the explanation for the 
ATP-dependence of insulin induced adipocyte PDE activation or whether 
the ATP-dependent step(s) is/are yet to be identified is a matter for 
conjecture but, interestingly, insulin-dependent phosphorylation of a 
number of proteins whose physiological functions are at present 
uncertain has been proposed as a possible mechanism for communication 
between plasma membrane receptors and the intracellular targets of 
insulin action [18, 39, 221, 464]. In each of four independent 
studies, phosphorylation of at least one of these proteins was also 
stimulated by lipolytic agents, for example, a 46kDa molecular weight 
protein reported by LeCam [464] to be phosphorylated in response 
to both insulin and glucagon. Observations such as these provide an 
attractive solution to the problem of how two hormones with well 
characterised antagonistic effects on cellular metabolism might be 
envisaged to stimulate the activity of the same key regulatory enzyme, 
involving, as they do, mechanisms common, at least in part, to the 
action of both hormones. Evidence for a common mode of activation is 
provided by the observation that PDE stimulated maximally by insulin 
cannot be further activated by any of a variety of lipolytic agents 
[503] but Loten et al. [489] and Pawlson et al. [597] report additivity 
of the effects of such agents on PDE activity suggesting separate 
distinct mechanisms. While activation of PDE by agents such as 
catecholamines, theophylline and ACTH that have little else in common 
but their ability to raise intracellular cAMP levels [22, 597] strongly 
suggesting a mechanism involving cAMP-dependent phosphorylation, the 
factors involved in insulin- dependent activation have yet to be
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determined and in both cases, detailed understanding of the events 
mediating these regulatory phenomena remains elusive.
The apparent paradox of an enzyme whose function is to degrade 
cAMP being stimulated by agents that raise cAMP levels is perhaps not, 
in fact, so surprising since it provides an effective negative feedback 
control of intracellular cAMP levels and would help to ensure that cAMP 
levels, raised during the response to such agents, are returned to 
'resting' levels more rapidly on termination of the stimulus. 
Conversely, dependence of the insulin response on cAMP [511, 830] 
ensures that PDE activity is not stimulated when intracellular levels 
have fallen below a certain threshold, thus protecting against 
excessive depletion of intracellular cAMP during insulin action.
In addition to the acute regulatory mechanisms described above, 
insulin also appears to be capable of exerting longer-term control over 
PDE activity by a process involving protein synthesis [626, 774]. BHK 
(Baby Hamster Kidney) 21 cells, in which delayed (24-48 hour) insulin 
activation has been observed, do not, apparently, possess any 
membrane-bound high affinity cAMP-PDE and high affinity activity is 
only detected in the cytosol after exposure to foetal calf serum or 
insulin [626, 774]. Since such a process is obviously dependent on 
metabolic energy, it might be reasoned that the ATP dependence of 
insulin activation in adipocytes is a reflection of this requirement 
and need not involve phosphorylation after all. However, the length of 
time required for expression of insulin activation by mechanisms 
involving protein synthesis (24-48 hours) would seem to preclude its 
having much, if any, bearing on the very much more rapid activation for 
which the phosphorylation-mediated mechanism was proposed.
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1-2.3. Interrelation of Enzyme Forms
There are, undoubtedly, a number of different forms of cAMP-PDE but, as 
has often been emphasized, many of the enzyme forms reported, 
particularly after partial purification, may in fact be artifacts of 
the preparation or isolation procedures and, therefore, not 
representative of enzymes found in vivo [558, 792, 833]. The apparent 
ease with which various combinations of subunits are seen to associate 
and dissociate under different conditions to produce PDEs with 
different properties [274, 541, 558, 609] and the observation that 
several of these forms cross-react with the same antibody [841] lends 
some support to the idea that the same catalytic subunit may be common 
to both low and high affinity cAMP-PDEs and that differences in 
properties arise from aggregation with other catalytic, inhibitory or 
activating subunits [542, 772].
Although the catalytic subunit of calmodulin-dependent low 
affinity cAMP-PDE (cGMP-PDE) is approximately the same molecular weight 
as the purified high affinity cAMP-PDE, these two enzymes do not share 
the same substrate specificity or affinities and the cGMP-PDE subunit 
binds calmodulin whereas the high affinity cAMP-PDE does not. Perhaps, 
then, there are two basic catalytic subunits, a cAMP-PDE and a 
cGMP-PDE, both of which have high affinity for their respective 
substrates but are also capable of the hydrolysis of each other's 
primary substrate, though with reduced affinity, only the cGMP-PDE 
being capable of binding Ca2+/calmodulin. The purified high affinity 
cAMP-PDE would then represent the fundamental cAMP-PDE catalytic 
subunit and the purified catalytic subunit of calmodulin-dependent, low 
affinity cAMP-PDE would represent the fundamental cGMP-PDE catalytic 
subunit. Cyclic nucleotide-PDE might then be envisaged as a
28
conglomerate composed of both fundamental catalytic subunits associated 
with inhibitory peptides [424, 826] and allosteric binding sites [491] 
to produce the high molecular weight attributed to this enzyme form. 
Cyclic nucleotide-PDE would then have two distinct catalytic sites as 
suggested by Davis [146]. Their reduced substrate affinities could 
easily be explained by conformational changes or other interactions 
resulting from association with the other constituent subunits, one of 
which might also provide the common cGMP-binding allosteric regulation 
site. Proteolytic activation of this enzyme might then simply involve 
partial, if not complete release of the catalytic subunits from 
constraints imposed upon their activities by virtue of association with 
the regulatory peptides contained in the parent molecule. Sulphydryl 
groups and hydrophobic interactions have been suggested to be involved 
in aggregation of enzyme forms and may be responsible for some of the 
variation in PDE forms noted under different separation conditions in 
the same way as pH is known to affect the number of forms isolated by 
DEAE cellulose chromatography [792]. Other factors known to affect the 
form, quantity and substrate affinities of PDE include cell-cell 
contact, cell density and viral transformation [738]. In the light of 
this information, it is clear that, in an attempt to include as many as 
possible of the PDE forms so far discovered in a PDE classification, 
there is a good chance that some of its members will represent forms 
not found in intact cells. However, besides providing apparently 
extraneous and potentially misleading data, they must also reveal some 
clues as to the properties that might be expected to arise from 
different combinations of subunits. Until truly "physiological" 
enzymes have been positively identified and their subunit structure 
determined, predictions about interrelation of PDE forms remain purely
29
speculative but are attractive in that they seem to impart a certain 
degree of ordered simplicity to what appears to be an increasingly 
complicated picture of the PDE enzyme system.
1*2.4. The Role of cAMP-PDE in Regulation of Intracellular cAMP Levels 
A theoretical analysis of the functioning of high and low affinity 
cAMP-PDE in the regulation of intracellular cAMP concentrations has, 
recently, been conducted by Fell [212]. For the sake of simplicity, 
Fell's model treats the cell as a sphere with a single pool of cAMP and 
three populations of enzymes; plasma membrane bound adenylate cyclase 
and high affinity cAMP-PDE and soluble, low affinity cAMP-PDE. With 
adenylate cyclase bound to the plasma membrane, soluble low affinity 
cAMP-PDE activity is sufficient to create a cAMP concentration 
gradient, lowering the steady-state cAMP concentration in the centre of 
the cell. In this situation, although ineffective at controlling cAMP 
concentrations near the plasma membrane, the low affinity form is as 
effective as high affinity cAMP-PDE further inside the cell, and rate 
of approach to a new steady state cAMP level after adenylate cyclase 
modulation is also affected by this form. Because of its proximity to 
the site of cAMP production, membrane bound high affinity cAMP-PDE will 
account for most cAMP hydrolysis and at or near the plasma membrane, 
modulation of adenylate cyclase and/or high affinity PDE alone govern 
cAMP accumulation. The situation is less straightforward in nervous 
tissue where prevailing cAMP concentrations are intrinsically high 
allowing low affinity cAMP-PDE to exercise effective control over 
intracellular cAMP concentrations. The predicted efficacy of low 
affinity cAMP-PDE as a regulator of cAMP concentrations in this tissue 
may explain the apparent preponderance of low affinity cAMP-PDE
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observed in rat and bovine brain [91, 146, 278]. Because brain tissue 
contains much less high affinity cAMP-PDE and much more adenylate 
cyclase than liver or muscle, the simulation predicts that the cAMP 
concentration gradient will be exaggerated with cAMP levels falling to 
almost nothing in the centre of the cell and modulation of high 
affinity activity will only be a third as effective as in liver or 
muscle, allowing modulation of low affinity cAMP-PDE activity to 
execute effective control over cAMP levels throughout the cell, even at 
the plasma membrane. The result is a more rapid return of cAMP levels 
to steady state following stimulation of adenylate cyclase activity.
Computer model simulation of the adenylate cyclase/PDE system by 
Reynolds [646] shows that variation in the activity of cAMP-PDE may be 
important in the regulation of cellular response to cAMP mediated 
hormones. Plasma membrane bound high affinity cAMP-PDE may be 
particularly important. For example, insulin activation of hormone 
sensitive plasma membrane bound high affinity cAMP-PDE would result in 
an increase by a factor of 2.6 in the concentration of glucagon 
required to produce an intracellular cAMP concentration of 1//M. Thus 
in the light of the discovery that serine/threonine phosphorylation of 
the insulin receptor by a cAMP dependent mechanism results in 
modification of receptor function (see section 1.3.8.(ii)a), plasma 
membrane bound PDE might be expected to be capable of influencing 
insulin receptor activity. Since such serine/threonine phosphorylation 
inhibits both insulin binding and receptor tyrosine kinase activity, 
this system might be imagined, under appropriate conditions, to form 
part of an indirect feed-forward mechanism antagonising the insulin 
stimulated loss of receptor function and therefore contributing to 
maintenance of "normal" receptor function, as shown in Figure 4.
Figure 4 Model for the Regulation of Insulin 
Receptor Function Mediated by 
cAMP-dependent Protein 
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Although low affinity cAMP-PDE activity would have little effect at low 
cAMP concentrations, at saturating hormone levels, stimulation of low 
affinity activity by Ca2+/calmodulin could considerably depress the 
maximal cAMP concentration achieved [646].
The presence of adenylate cyclase on intracellular membranes 
would reduce the cAMP concentration gradient predicted by Fell's basic 
model [212] but if adenylate cyclase and high affinity cAMP-PDE were 
associated with different intracellular membranes, as suggested by 
Westwood et al. [835], the local cAMP concentrations around these 
membranes would be quite different and concentration gradients would be 
accentuated [212]. Local variations in cAMP concentration of this kind 
might be destroyed by diffusion but the activity of soluble low 
affinity cAMP-PDE may prevent this by producing gradients away from 
each cAMP producing site and, therefore, allowing greater independence 
of one site from the effects of others. Similar effects might result 
from distribution of the different forms of PDE on different cellular 
membranes which would then, in effect, be acting on separate pools of 
cAMP as proposed by Russel et al. [669]. Since uncompartmented 
enzymes of this type would probably have only marginal effects when 
independently modulated, such a separation would provide support for 
the advantage of evolving different PDE forms within the same cell.
Mammary tissue is known to possess an intact, functional 
adenylate cyclase system responsive to modulation by various agonists 
(see section 1.1.) and has also been demonstrated to express various 
classes of PDE activity, including high affinity cAMP-PDE (see section
1.2.). As noted earlier (sections 1.2.2.(ii) and 1.2.4.), the potential 
importance of hormone dependent modulation of high affinity cAMP-PDE 
activity in the regulation of cellular metabolism is well recognised,
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particularly with respect to mechanisms of insulin action. It is, 
therefore, of great interest to determine whether the mammary enzyme is 
sensitive to hormonal regulation and, bearing in mind the reported 
rapid effects of insulin on mammary lipogenesis [656], an assessement 
of the ability of insulin to influence mammary high affinity cAMP-PDE 
activity is of particular significance. Since there is currently 
insufficient information available concerning the regulatory 
characteristics of this enzyme to allow comparison with the well 
characterised hormone dependence of analogous enzymes in adipose tissue 
and liver (see section 1.2.2.(ii)), the present study was initiated in 
order to establish whether, in common with high affinity cAMP-PDEs of 
these other tissues, the mammary enzyme is susceptible to such 
modulation, particularly in response to insulin.
1.3. Protein Phosphorylation
1.3.1. Glycogen Metabolism
The existence of proteins containing covalently bound phosphorus was 
established almost a century ago but it was not until the discovery in 
1956, by Krebs and Fischer [438] that the enzyme glycogen phosphorylase 
could be activated by conversion of the dephosphorylated 'b' form to 
the phosphorylated 'a' form, that interest in protein phosphorylation 
began to gather impetus. In the following ten years, two more enzymes, 
phosphorylase kinase [439] and glycogen synthase [229] were found to be 
regulated by reversible phosphorylation and after the discovery by 
Walsh et al. [817] in 1968 of a protein kinase whose activity is 
modulated by cAMP, research advanced rapidly, giving rise to 
the identification of some forty or more enzymes whose activities are 
regulated by phospho-dephosphorylation in vitro as well as inumerable
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non-enzymic phosphoproteins. Although the first proteins found to 
contain covalently bound phosphorus, phosvitin (from egg yolk) and 
casein (from milk) do not possess enzymic activity, it is those 
proteins which do possess such activity and exhibit modulation by 
reversible phosphorylation that have provoked the greatest interest, 
providing what has come to be accepted as the major mechanism mediating 
in the intracellular response of mammalian tissue to external 
physiological stimuli [114]. Early work in this field concentrated on 
the enzymes of glycogen metabolism and it is the regulatory enzymes of 
glycogen metabolism in mammalian skeletal muscle that now serve as a 
model for all other enzyme systems regulated by 
phospho-dephosphorylation.
The metabolic pathways controlled by the phosphorylation state 
of phosphorylase and glycogen synthase and the major factors governing 
their activities in skeletal muscle are summarised in Figures 5 and 6. 
The key enzyme in the control of glycogen metabolism, by virtue of its 
ability to control the activities of both phosphorylase and glycogen 
synthase, is phosphorylase kinase. The enzyme molecule is a tetramer 
of functional units, each consisting of four subunits and may be 
represented as (cx0y6)4. The catalytic activity appears to reside in 
the y-subunit [711] while phosphorylation of the 0-subunit by cAMP 
dependant protein kinase (cAMP-PrK) results in ~ 15-20 fold stimulation 
of that activity at saturating Ca2+ concentrations and ~ 15 fold 
reduction in Ka for Ca2+ of the Ca2+ binding 6-subunit [110, 115]. The 
a-subunit is also phosphorylated by cAMP-PrK, though less rapidly than 
the (3-subunit [113, 119] and with no apparent effect on the enzyme's 
activity [113, 119]. Each a and 0-subunit is phosphorylated on a single 
serine residue and activation of phosphorylase kinase correlates with 
the extent of phosphorylation of the 0-subunit [110, 868].
Figure 5 Role of Phospho-dephosphorylation 
in Muscle cell Glycogen Metabolism and its 
Modulation by Hormonal and Nervous Stimuli
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In the presence of saturating Ca2+, the dephosphorylated enzyme
binds and is strongly activated by calmodulin (originally termed the
6'-subunit since the 6-subunit is identical to calmodulin); however,
phosphorylated phosphorylase kinase shows little or no response to
calmodulin [112]. There is evidence that troponin C, a Ca2+ sensitive
protein associated with contractile apparatus function (as illustrated
in Figure 5) and closely related in structure and Ca2+ binding
properties to calmodulin, rather than calmodulin itself, might be the
important activator of phosphorylase kinase in vivo [112]. Since the
concentration of Ca2+ required for half maximal activation of
dephosphorylated phosphorylase kinase, either in the presence or
absence of calmodulin is approximately 20/jM. at physiological pH [112]
and the physiological range of Ca2 + concentrations is approximately
0.1//M to 10/jM [275a], the effect on enzyme activity mediated by either
2 +calmodulin or the 6-subunit, in response to changes in Ca 
concentration in vivo, should be relatively small. However, troponin C 
mediated activation has a half maximal activation concentration for 
Ca2+ of only 4/vM under conditions when phosphorylase kinase activity 
is directly proportional to the concentration of active troponin 
molecules (ie 1/10 saturating concentration of troponin) allowing, at 
1/uM Ca2+, expression of an activation of around 75% that observed at 
maximally stimulating Ca2+ concentrations (over 100//M) in the absence 
of troponin. The effect of this is a 75-fold activation of 
phosphorylase kinase at 1/;M Ca2+ (15 times greater activation than 
produced by 1/;M Ca2+ in the absence of troponin) over the activity at 
0.1/t/M Ca2+ and 250-fold activation at 3/vM Ca2+ (25 times greater 
activation than in the absence of troponin at 3juM. Ca2+).
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The Ca2+ sensitivity of phosphorylase kinase represents a means 
of synchronising increased production of ATP with events involving 
increased ATP hydrolysis. Since both muscle contraction and increased 
rate of ATP synthesis are initiated by Ca2+ acting as a 2nd messenger 
in the response to nervous stimulation, ATP supply and demand increase 
simultaneously, helping to maintain ATP levels. A comparison of the 
influence of troponin and phosphorylation on the response of 
dephosphorylated phosphorylase kinase to Ca2+ concentration is shown in 
Figure 7, illustrating clearly how the magnitude of increase in 
glycogen breakdown provoked by nervous stimulation is subject to 
considerable modification depending on the existing phosphorylation 
state of phosphorylase kinase. The increased response to changes in 
Ca2+ concentration conferred on phosphorylase kinase by cAMP-dependent 
phosphorylation may represent an important mechanism whereby the 
efficiency and performance of muscle might be enhanced as part of the 
"fight or flight" response to adrenaline (see Figure 8).
The effect of cAMP on glycogen metabolism is further magnified 
by its effect on inhibitor 1 which is active only after phosphorylation 
by cAMP-PrK on a specific threonine residue [6, 121, 562]. Active 
inhibitor 1 converts protein phosphatase 1 (PrP-1), the major enzyme 
responsible for dephosphorylation of the (3-subunit of phosphorylase 
kinase, glycogen phosphorylase and glycogen synthase in skeletal muscle 
[12] to its inactive form (Figure 6).
Glycogen synthase is phosphorylated on seven serine residues of 
which only three (sites la, lb and 2) show cAMP-dependence [116]. After 
exposure to adrenaline in vivo, phosphorylation of both the 
cAMP-dependent and three other sites termed 3a, 3b and 3c is increased, 
the latter three together accounting for half of that increase [591].
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The phosphorylation state of sites 3 is an important regulator of 
glycogen synthase activity and has a greater inhibitory effect than 
phosphorylation at other sites on the enzyme [122, 186]. However, the 
enzyme responsible for phosphorylation of sites 3a, 3b and 3c, glycogen 
synthase kinase 3 (GSK 3) is not activated by cAMP [122, 186] and the 
increase in phosphorylation must therefore be the consequence of a less 
obvious sequence of events. There are several possible explanations 
for these findings including a) phosphorylation and activation of GSK 
3, although there is as yet no evidence to support this [116], b) 
conformational change induced by phosphorylation at sites la, lb and 2 
allowing more rapid phosphorylation of sites 3 by GSK 3, c) reduction 
in dephosphorylation of sites 3 due to increased competition with sites 
la, lb and 2 or other cAMP-dependent phosphoproteins such as 
phosphorylase and phosphorylase kinase for PrP-1, d) reduction in 
dephosphorylation of sites 3 by PrP-1 due to conformational change 
induced in the synthase molecule by phosphorylation of sites la, lb and 
2, e) activation of inhibitor 1 by cAMP-PrK resulting in inhibition of 
PrP-1 and f) activation of GSK 3 resulting from events associated with 
ar-adrenergic stimulation. Consistent with a role for e) above is the 
observation that activation of inhibitor 1 (as described earlier) is 
increased markedly in response to adrenaline [404, 491] and occurs at a 
similar rate to phosphorylation of glycogen synthase and phosphorylase 
kinase in vitro [121].
In addition to cAMP-PrK, site 2 of glycogen synthase is also 
phosphorylated by phosphorylase kinase and glycogen synthase kinase 4 
(GSK 4). The former was first reported by Roach et al., in 1978 
[653a] and later, evidence was presented that phosphorylase kinase and 
glycogen synthase kinase 2 are in fact the same enzyme [186a]. The
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amino acid sequence in the region of site 2 is similar to that around 
the serine residue phosphorylated by phosphorylase kinase in glycogen 
phosphorylase [185a] and both of these phosphorylase kinase-catalysed 
phosphorylations proceed at similar rates in vitro [158a, 185a, 653a]. 
Glycogen synthase kinase 4 phosphorylates site 2 exclusively [122] and 
may be largely responsible for the phosphorylation of this site 
observed [591] under conditions (propranolol treatment) known to 
inactivate both cAMP-PrK and phosphorylase kinase.
Glycogen synthase kinase 5 phosphorylates the remaining 
phosphorylation site on glycogen synthase but does not affect the 
kinetics of the enzyme in vitro [116, 611] and under all conditions so 
far examined in vivo, site 5 remains fully phosphorylated [590, 591]. 
However, it has been reported that phosphorylation of site 5 is a 
prerequisite for phosphorylation of sites 3 by GSK 3 [611].
Although the regulation of phosphorylase, phosphorylase kinase 
and glycogen synthase activities is of most obvious relevance to liver 
and muscle cells, there is evidence that glycogen may also have a role 
to play in the provision of hexose phosphate for lactose, glycolytic 
and pentose phosphate pathways in mammary epithelial cells [187]. The 
potential contribution to overall mammary cell function made by enzymes 
of glycogen metabolism is, however, likely to be small compared with 
those involved in glucose metabolism and lactogenesis particularly 
lactose, lipid and cholesterol synthesis. In the non-ruminant, glucose 
is the major source of acetyl-CoA and NADH for both fatty acid and 
glycerol synthesis. Pyruvate derived from its passage down the 
glycolytic pathway enters the mitochondria where it feeds the TCA 
cycle. The citrate produced may then be exported to the cytosol where 
it is cleaved by ATP citrate lyase to form acetyl-CoA which feeds both
fatty acid and cholesterol synthesis. During lactation, glucose 
utilisation for fatty acid synthesis reaches phenomenal proportions and 
therefore flux through the glycolytic pathway must be increased 
proportionately, making its acute regulation a necessity in order to 
maintain the synthetic and energetic economy of the cell. The ability 
to suppress glucose utilisation by mammary gland in the short term is 
particularly important to the lactating animal during periods of food 
deprivation when an inability to control such utilisation would 
severely compromise its chances of survival.
Examples of regulatory enzymes whose activities are controlled 
by reversible phosphorylation may be found in, among others, the 
pathways of glucose oxidation and, of particular significance for 
mammary tissue, those of lipogenesis and cholesterogenesis. 
Glycolytic/gluconeogenic activity is influenced by the phosphorylation 
state of pyruvate kinase and 6 phosphofructo-2-kinase/fructose 2-6 
bisphosphatase (PFK 2/F2,6P2ase), while the rates of fatty acid 
synthesis and cholesterogenesis are governed by acetyl-CoA carboxylase 
and 3-hydroxy, 3-methyl glutaryl Co-enzyme A reductase (HMG-CoA 
reductase) respectively, two more enzymes whose activities are 
regulated by phospho-dephosphorylation. The characteristics and 
significance of these and other control mechanisms are summarised below 
under the relevant headings.
1.3.2. Glycolys i s/Gluconeogene sis
The first glycolytic enzyme recognised to display the characteristics 
of regulation by reversible phosphorylation was pyruvate kinase. There 
are at least three distinct mammalian pyruvate kinase isoenzymes of 
which only the L-form, found in hepatocytes, shows significant
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allosteric regulation or phosphorylation (for review see [191, 550]). 
Although allosteric activation of liver pyruvate kinase by free 
fructose 1,6-bisphosphate (Fl,6-P2) has been described as the most 
important rapid regulatory mechanism controlling pyruvate kinase 
activity [219, 790] it is also evident that its deactivation by 
phosphorylation may be an equally significant factor, particularly in 
the gluconeogenic response to glucagon. During glucagon stimulated 
gluconeogenesis, the phosphoenol pyruvate (PEP) to pyruvate 
concentration ratio is increased [201, 202] and since pyruvate kinase 
operates at sub-saturating concentrations of PEP in vivo, the increase 
in its substrate concentration would lead to enhanced pyruvate kinase 
activity if it were not subjected to control by other means. 
Deactivation of pyruvate kinase by cAMP-dependent phosphorylation would 
therefore provide a mechanism capable of preventing significant 
substrate cycling during glucagon stimulated gluconeogenesis. It has 
indeed been shown that L-type pyruvate kinase is phosphorylated on a 
specific serine residue by cAMP-PrK in vitro [484] and that the 
phosphorylated enzyme has an increased Km for PEP in the absence of 
Fl,6-P2, an increased Hill coefficient, increased sensitivity to 
inhibition by ATP or alanine and a decreased sensitivity to its major 
activator Fl,6-P2 [179, 483]. In addition, there is evidence that 
these inhibitory effects might be reinforced by a phosphorylation 
mediated increase in the sensitivity of pyruvate kinase to proteolytic 
degradation [191]. Pilkis et al. [624] have recently reported 
phosphorylation of pyruvate kinase by Ca2+/calmodulin dependent protein 
kinase at two sites, one of which is the cAMP-PrK site while the other 
is specific to Ca2+/camodulin-dependent protein kinase. As for 
cAMP-dependent phosphorylation, inactivation of pyruvate kinase induced
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by phosphorylation of the Ca2+/calmodulin specific site is 
characterised by a decrease in the affinity of the enzyme for PEP. If 
confirmed, this system will represent another major regulatory 
mechanism controlling hepatic glycolytic and gluconeogenic pathways, 
conferring on pyruvate kinase, as it does, sensitivity to Ca2+-linked 
hormone action. Phosphorylation of pyruvate kinase appears, therefore, 
to perform an important regulatory function in the liver. However, in 
non-gluconeogenic tissue such as muscle, where pyruvate carboxylase and 
PEP carboxykinase activities are negligible, a mechanism for regulation 
of pyruvate kinase activity, in response to glucagon, such as the one 
found in hepatocytes would be redundant so it is not surprising that 
the pyruvate kinase found in non-gluconeogenic tissues displays 
classical Michaelis-Menten kinetics (review [330]) and is not 
phosphorylated by cAMP-PrK (review [191]).
The mechanism of control of the other cAMP-dependent enzymes of 
the glycolytic and gluconeogenic pathways, 6-phosphofructo 1-kinase 
(PFK 1) and fructose 1,6-bisphosphatase (Fl,6-P2ase) respectively has, 
until recently, been uncertain since cAMP-dependent phosphorylation has 
been shown to have little or no effect on the activities of either 
enzyme from mammalian sources [97, 376, 622, 652] and yet PFK 1 is 
inhibited by glucagon treatment of hepatocytes [85, 97, 798]. In 1980, 
Hers and coworkers reported [798] the presence, in extracts from 
control livers, of a low molecular weight stimulator of PFK 1 that 
could restore the activity of PFK 1 derived from hepatocytes incubated 
with glucagon and went on [801] to identify the stimulator as fructose 
2,6-bisphosphate (F2,6-P2). As well as activating PFK 1 [309, 620,
788] F2,6-P2 also inhibits Fl,6-P2ase [309, 618, 619, 799] and 
increases the affinities of both enzymes for AMP [309]. Although AMP
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is a potent allosteric activator of PFK 1 and inhibitor of Fl,6-P2ase, 
its intracellular concentration does not vary with changes in rates of 
glycolysis/gluconeogenesis except during anoxia when its concentration 
rises [309, 622]. The increase in AMP levels observed under these 
conditions probably plays a significant part in the stimulation of 
glycolysis by anoxia but the role, if any, of F2,6-P2 in this response 
is questionable [332].
Fructose 2,6-bisphosphate production and degradation are 
governed by a pair of enzymes analagous to PFK 1 and Fl,6-P2ase. The 
relative activities of these two enzymes, termed 6-phosphofructo
2-kinase (PFK 2) and fructose 2,6-bisphosphatase (F2,6-P2ase) 
respectively, therefore determine the cellular concentrations of 
F2,6-P2 (see Figure 9). Despite sharing the same substrate, fructose 
6-phosphate, PFK 1 and PFK 2 represent separate, distinct proteins 
differing in a number of respects, both structurally and functionally. 
The same is true of Fl,6-P2ase and F2,6-P2ase and a summary of their 
respective differences may be found in the review by Pilkis et al. 
[622]. Both PFK 2 and F2,6-P2ase are specific for their respective 
substrates [181, 622, 798], are activated by inorganic phosphate [180, 
798] and display product inhibition [180, 616, 797]. PFK 2 is 
activated by PEP [798] and inhibited by a glycerophosphate [98], ADP 
[616] and citrate [798], in contrast to F2,6-P2ase which is activated 
by a glycerophosphate [797].
PFK 2 and F2,6-P2ase activities from both bovine [432] and rat 
[180] liver copurify through various chromatographic steps [182] to 
give a single protein of apparent molecular weight 100-110kDa.
SDS-disc gel electrophoresis of the purified protein reveals a single 
peptide band with a molecular weight of 55kDa [432, 622]. It would
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appear, therefore, that the native enzyme represents a dimer possessing 
both PFK 2 and F2,6-P2ase activities and should consequently be 
classified as a bifunctional enzyme [180, 622, 797]. Recent evidence 
suggests that the PFK 2 and F2,6-P2ase activities reside in separate, 
distinct catalytic sites but it is not known whether they are each 
confined to their own subunit or whether the subunits are identical, 
possessing catalytic sites for both reactions [184, 621, 623, 676].
The role of this apparently bifunctional enzyme in the biosynthesis of 
F2,6-P2 and the effects of its modulation by cAMP-dependent 
phosphorylation on the activities of PFK 1 and Pl,6-P2ase are 
summarised in Figure 9.
Phosphorylation of the PFK 2/F2,6-P2ase complex by cAMP-PrK in 
vitro occurs on serine residues at one site only per subunit [180, 183] 
with concomitant inhibition of PFK 2 and activation of F2,6-P2ase [180, 
182, 233, 796]. The same relative effects on enzyme activity are 
observed after administration of glucagon to hepatocytes leading to a 
concentration dependent decrease in F2,6-P2 concentration [180, 333, 
797]. It is interesting, however, that these effects occur at glucagon 
concentrations well below those required to inhibit pyruvate kinase and 
therefore at very much lower cAMP concentrations, raising the 
possibility that they may be induced by cAMP-independent mechanisms. 
However, it appears more likely that phosphorylation of this enzyme 
system is simply more sensitive to changes in cAMP concentration than 
that of pyruvate kinase since F2,6-P2ase is an excellent substrate for 
cAMP-PrK [622] and is more sensitive to the addition of exogenous cAMP 
than is pyruvate kinase [617]. Fructose 2,6-P2ase activation is 
particularly sensitive to glucagon and shares the same half maximally 
effective glucagon concentration as the decrease in F2,6-P2
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concentration. In comparison, inhibition of PFK 2 activity is closer 
in character to that of pyruvate kinase with a half maximally effective 
glucagon concentration intermediate between the latter and that of 
F2,6-P2ase activation [180]. The reciprocal changes in PFK 2 and 
F2,6-P2 ase activities in response to glucagon [180, 616. 797, 871] and 
cAMP [182, 233, 796] are both characterised by a reduction in the 
affinity of PFK 2 for its substrate (Fructose 6-phosphate) and an 
increase in the substrate (F2,6-P2) affinity of F2,6-P2ase, suggesting 
that the reduction in F2,6-P2 levels observed in response to glucagon 
is indeed mediated by cAMP-dependent phosphorylation [182, 622].
Two other hormones found to influence F2,6-P2 levels are 
adrenaline and insulin. Adrenaline lowers F2,6-P2 levels [617, 648, 
649] and although insulin alone has no effect, it is capable of 
increasing the concentration of either glucagon or cAMP required for 
half maximal reduction in F2,6-P2 levels [617]. Although many of the 
effects of insulin have been attributed to ill-defined cAMP-independent 
mechanisms, the indications are that its ability to lower intracellular 
cAMP concentrations is a major factor in its antagonism of glucagon or 
adrenaline provoked reduction in F2,6-P2 levels [617, 622] and 
consequent stimulated of gluconeogenesis [622]. The potential 
regulatory influences of hormonal modulation of F2,6-P2 levels are 
summarised in Figure 10.
1.3.3. 2-Oxoacid Dehydrogenase Complexes
The mitochondrial 2-oxoacid dehydrogenase activity of animal tissues is 
accounted for by three 2-oxoacid dehydrogenase complexes of which two, 
pyruvate dehydrogenase (PDH) and branched chain 2-oxoacid dehydrogenase 
(BCDH), are regulated by phospho-dephosphorylation [207, 477, 478].
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The third complex, 2-oxoglutarate dehydrogenase, an integral enzyme of 
the TCA cycle, is regulated allosterically by ADP, ATP, Ca2+ and H+ and 
displays product (NADH and Succinyl CoA) inhibition [236, 523] but is 
not, apparently, regulated by reversible phosphorylation [637]. PDH 
and BCDH complexes are both also inhibited by their products (acyl-CoA 
and NADH) [144, 237, 604, 636] and share a general structure consisting 
of multiples of three types of enzyme, a 2-oxoacid decarboxylase or 
dehydrogenase (E1), an acyl transferase (E ) and a lipoyl dehydrogenase 
(E3) [635, 637]. The E3 component is a dimer of subunit molecular 
weight 55kDa, common to both enzyme complexes and although the E2 
components of both also share a common subunit molecular weight of 52 
kDa [604, 635], the number of copies of E2 per complex may differ and 
the two subunits show distinct migration characteristics on SDS 
polyacrylamide gel electrophoresis [635]. E components contain 
multiple subunits of two types, a and 3. The a-subunits of PDH are of 
molecular weight 41kDa [635] and those of BCDH, 46kDa [604, 575], while 
their 0-subunit molecular weights are 36kDa [635] and 31-35kDa [604, 
635] respectively.
1.3.3.(i) Pyruvate Dehydrogenase
The PDH complex catalyses the irreversible conversion of pyruvate to 
acetyl-CoA, generating NADH and C02, the overall reaction being
represented by:-
Pyruvate + NAD+ + CoA > Acetyl—CoA + NADH + C02
By virtue of its position in relation to the supply of substrate for 
the TCA cycle in the mitochondrial matrix or, via cytosolic citrate, 
for fatty acid and sterol synthesis, PDH is an important regulator of 
net carbohydrate utilisation, particularly in tissues with
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insignificant gluconeogenic capacity such as muscle, brain, and mammary 
gland. The enzyme's activity is subject to control by the availability 
of oxidisable substrate, an important factor in the preferential 
oxidation of lipid fuels by muscle and liver during starvation [155].
In addition, insulin has been shown to increase PDH activity, 
stimulating fatty acid synthesis from glucose in tissues such as liver, 
adipose tissue (white and brown) and lactating mammary gland [15, 27, 
154, 156, 374, 522, 779].
An a-subunit of the PDH complex is phosphorylated on three 
serine residues by a kinase (PDH kinase) intrinsic to the complex [477, 
745, 746, 747], One particular site designated TAl in reference to its 
position in a tryptic peptide of the a-subunit, is phosphorylated much 
more rapidly than the other two [678, 679, 746, 869]. Greater than 98% 
of the observed inactivation of PDH accompanying phosphorylation of the 
a-subunit has been attributed to phosphorylation at this site [678], 
the proportion of inactive complex being linearly related to its 
occupancy [399, 677, 679, 869]. The predominance of
site TAl in the control of PDH activity has also been confirmed in vivo 
[680]; however, it appears that phosphorylation of the other two sites 
inhibits dephosphorylation and reactivation of the complex [399, 677, 
680] by the Mg2 + - and Ca2+-dependent PDH phosphatase [157, 478, 679]. 
The level of phosphorylation of sites 2 and 3, at a minimum in fed, 
normal rats, is maximal during starvation, leading to a three-fold 
reduction in the initial rate of reactivation of phosphorylated complex 
[680]. It has been suggested that this potentially hysteretic 
mechanism may be capable of inhibiting reactivation of phosphorylated 
PDH during starvation [635, 680]. The observation that the inhibitory 
action of site 2 and 3 occupancy on reactivation can not be
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demonstrated using PDH phosphatase purified to apparent homogeneity 
[763] is, as yet, unexplained but may suggest the existence, in less 
pure phosphatase preparations and mitochondria, of a factor expressing 
a permissive role in the inhibitory mechanism.
There is evidence that insulin-induced activation of PDH is 
achieved by an equal reduction in the level of phosphorylation of all 
three phosphorylation sites on the a-subunit [335] and appears to be a 
result of increased PDH phosphatase activity rather than inhibition of 
PDH kinase [156]. Activation of rat heart PDH in response to 
adrenaline is mediated by increases in intramitochondrial Ca2+ 
concentrations and presumably, therefore involves activation of PDH 
phosphatase [137, 524]. However, the same mechanism cannot, apparently 
be invoked to explain the activation of PDH in response to insulin 
since there is evidence to indicate that mitochondrial Ca2+ levels are
insensitive to insulin and that the activation of PDH provoked by
insulin in the presence of Mg2+ persists despite depletion of those
levels [515]. The finding that, in the presence of Mg2+, PDH
phosphatase activity is stimulated by polyamine [644] may therefore 
prove important in relation to elucidation of the mechanism(s) involved 
in this effect of insulin, bearing in mind the insulin-like effects of 
polyamines (see section 1.3.8.(i)c).
1.3.3.(ii) Branched Chain 2-0xoacid Dehydrogenase Complex 
Branched chain 2-oxoacid dehydrogenase (BCDH) catalyses the conversion 
of ketoacids derived from the branched chain amino acids (L-isomers of 
leucine, isoleucine and valine) to their acyl CoA counterparts, 
generating NADH and C02 as summarised below:
RCO.COOH + NAD+ + CoA > Acyl-CoA + NADH + C02
The branched chain amino acids are essential amino acids in man and the
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rat and this reaction represents the first irreversible step in their 
degradation. The activity of BCDH therefore determines the dietary 
requirement for these amino acids and abnormally low activity (as 
observed in Maple Syrup Urine Disease, an inborn error of human 
metabolism) can result in increases in plasma concentrations of 
branched chain amino acids of up to 70-fold, leading to severe brain 
damage [94, 185].
The existence of interconvertible forms of the enzyme was 
demonstrated in 1978 by Parker and Randle [594]. Strong evidence for 
the participation of phospho-dephosphorylation in this process followed 
soon after [336, 462, 574] and was confirmed by work involving BCDH and 
its kinase copurified to apparent homogeneity [207, 289, 575]. As with 
PDH, phosphorylation of the BCDH complex is confined to serine residues 
on the a-subunit of the E1 component [207, 463]. Phosphorylation has 
been observed on three tryptic peptides (designated T , T2 and T3) of 
the a-subunit, both in the purified enzyme [124a] and within intact 
mitochondria [124b]. However, these are derived from only two 
phosphorylation sites, of which only one (contained in the T peptide) 
is involved in the inactivation of the enzyme complex [867, 123a]. 
Inactivation correlates closely with phosphate incorporation into this 
site [124a] and the phosphorylated form is essentially inactive under 
all assay conditions [868a]. The BCDH kinase which, like PDH kinase is 
intrinsic to the enzyme complex [463, 575], apparently loses its 
ability to phosphorylate the complex once separated from it, since 
kinase activity, lost during purification, cannot be restored by 
recombining fractions [575, 637]. In the absence of its own kinase, 
purified BCDH has, however, been shown to be only minimally 
phosphorylated by both PDH kinase and cAMP-PrK with no resulting change
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in activity [604]. BCDH kinase activity is inhibited by the three 
physiological substrates of BCDH (4-methyl-2-oxopentanoate,
3-methyl-2-oxopentanoate and 3-methyl-2-oxobutyrate, the transamination 
products of leucine, isoleucine and valine respectively) but the 
concentrations required are high in relation to those likely to be 
encountered in vivo [637] implying that such a mechanism might not have 
any physiological significance. If, however, as proposed by Randle 
et al. [637], ADP can be shown to lower the concentration of BCDH 
substrate required for half maximal inhibition of BCDH kinase as has 
been demonstrated for pyruvate inhibition of PDH kinase [632], this 
system may prove to represent a significant factor in the in vivo 
regulation of BCDH activity. Reactivation of phosphorylated BCDH 
complex in mitochondria and rat heart is well documented [289, 594,
829] but a phosphatase with properties appropriate to an enzyme 
responsible for such a function has only recently been identified. One 
of the broad specificity, cytosolic, type 2 protein phosphatases (see 
section 1.3.9.(ii)) has been shown to be capable of performing this 
function in vitro, providing direct evidence for reactivation 
associated with dephosphorylation [289] but due to its cellular 
location it is unlikely to be the major BCDH phosphatase in vivo. Of 
greater interest, therefore, are the recent reports that certain 
partially purified preparations of ox-kidney complex contain BCDH 
phosphatase activity [637] and that mitochondria of the same tissue 
possess a BCDH complex-specific phosphatase [143, 644]. This enzyme, 
purified about 8000-fold from mitochondrial extracts [143] has an 
apparent molecular weight of approximately 460kDa and unlike PDH 
phosphatase, is active in the absence of divalent cations and shows no 
response to Ca2+ or polyamines but is stimulated by basic polypeptides
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and inhibited by nucleoside di and tri phosphates [143, 644]. A potent 
protein inhibitor of BCDH phosphatase with a molecular weight of 30kDa 
has also been purified from bovine kidney mitochondria and found to be 
half maximally effective at nanomolar concentrations [644, 142a].
A higher level of control, not found in the PDH system, is 
imposed on the BCDH complex by an activating factor identified in high 
speed supernatant extracts from liver and kidney [208, 637]. The 
activator does not affect the phosphorylation state of the complex but 
rapidly activates phosphorylated BCDH to levels comparable with those 
exhibited by the dephosphorylated form [208, 637]. Activation will 
only proceed in the presence of NAD+, CoA, TPP (Thiamine pyrophosphate) 
and 4-methyl-2-oxopentanoate (transaminated ketoleucine) in addition to 
the activator and phosphorylated BCDH complex. Neither PDH nor 
dephosphorylated BCDH complex activities are influenced by incubation 
with the activator and the other factors required for activation of the 
phosphorylated BCDH complex [637]. So far the BCDH activating factor, 
thought to be a protein of molecular weight approximately lOOkDa has 
not been detected in either heart or skeletal muscle mitochondria and 
its physiological significance has recently been called into question 
by Yeaman et al. [868a]. These authors have presented strong evidence 
that the protein activator is in fact free E1 component, presumably 
released from the enzyme complex during ultracentrifugation and is 
therefore unlikely to fulfil any regulatory role in vivo.
1.3.4. Lipid Metabolism
The two pathways responsible for lipid deposition and mobilisation, 
lipogenesis and lipolysis, are both subject to control by reversible 
phosphorylation of certain regulatory enzymes. The first and most 
important step of lipolysis, in terms of rate of lipid mobilisation, is
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catalysed by the phospho-dephospho enzyme hormone sensitive lipase 
(HSL) which catalyses the hydrolysis of l(3)-ester bonds in tri, di and 
mono acyl glycerols [228]. The first step in de novo synthesis of 
fatty acids from acetyl-CoA is catalysed by acetyl-CoA carboxylase and 
represents a major rate limiting step in the lipogenic pathway [529, 
553, 659]. Like hormone sensitive lipase, acetyl-CoA carboxylase 
activity is also regulated by reversible phosphorylation [78, 79, 282],
1.3.4.(i) Hormone Sensitive Lipase
In recent years it has become apparent that the HSL activity of adipose 
tissue and cholesterol ester hydrolase (CEH) activity of steroidogenic 
tissue such as corpus luteum and adrenal cortex may in fact be two 
characteristics of the same enzyme protein or at least represent 
isoenzymes [740]. In adipose tissue CEH activity copurifies with HSL 
[228, 614] and accounts for all the neutral CEH activity present in 
that tissue [228]. Since CEH and HSL activities in this purified 
enzyme preparation are also inhibited by diisopropylfluorophosphate to 
the same extent it seems likely that they are indeed properties of the 
same enzyme [228]. CEH purified from adrenal cortex cells has a 
molecular weight of 84kDa [125], identical to that calculated for 
adipose tissue HSL [228] and corpus luteum CEH [124]. A direct 
comparison of adipose tissue HSL and adrenal cortex CEH inspired by 
these compelling similarities demonstrated that the two enzymes are 
very similar or identical [126].
The primary function of mammary cell lipid metabolism is to 
supply lipid for lactogenesis, consequently, the rate of lipolysis is 
necessarily very low to prevent the prodigious waste of metabolic 
energy that would accompany any significant rate of lipogenic/lipolytic
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cycling. However, mammary tissue does store cholesterol as cholesterol 
ester and has been demonstrated to possess acyl-CoA : cholesterol 
acyl transferase (ACAT) [664], the enzyme responsible for synthesis of 
cholesterol ester from cholesterol, so it seems inconceivable that it 
should not also possess an enzyme with CEH activity to allow 
mobilization of such stores since 85-90% of bovine and rat milk 
cholesterol is unesterified [368, 642]. Assuming that CEH and HSL are 
indeed one and the same enzyme, then the indications are that mammary 
tissue does, at least, have the potential to express a certain 
lipolytic capacity but how or if this potential is suppressed are, at 
present, subjects for conjecture.
The role of this purportedly multifunctional lipase in mammary 
lipid metabolism is, at best, uncertain but its regulation, in adipose 
tissue, by hormone dependent phosphorylation represents an important 
example of the ability of such mechanisms to control the activity of 
major metabolic pathways. Lipolytic hormones were shown to increase 
glycogen phosphorylase activity in adipose tissue over twenty years ago 
[802] and when it was demonstrated, later, that adrenaline stimulated 
both lipolysis and intracellular accumulation of cAMP, the former also 
being achieved when dibutyryl cAMP was substituted for adrenaline [74], 
by analogy with liver phosphorylase it was inferred that HSL was 
subject to control by reversible phosphorylation. The discovery of 
cAMP-PrK in adipose tissue [128] and the demonstration that HSL in 
adipose homogenates is activated by cAMP and Mg-ATP [340, 341, 781] but 
blocked by cAMP-PrK inhibitor [130, 408] while activation of partially 
purified particulate HSL has been shown to be almost completely 
dependent of addition of exogenous cAMP-PrK [342, 343] are all 
consistent with the proposed model for activation of HSL by cAMP-
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dependent phosphorylation. Confirmation that this system operates in 
intact cells came from work showing activation of HSL in cell-extracts 
by cAMP and Mg-ATP before but not after preincubation of isolated fat 
pads [341, 342, 781] or adipocytes [405, 408, 614] with adrenaline. 
Subsequent treatment of adipocytes with insulin restores the ability of 
the isolated enzyme to be activated by cAMP and Mg-ATP. The 
involvement of protein phosphorylation in this mechanism was further 
demonstrated by studies on deactivation of the enzyme. Reversal of 
cAMP and Mg-ATP dependent activation was observed in adipose tissue 
preparations after dialysis to remove these factors [694], a process 
that was stimulated by Mg2+, inhibited by inorganic phosphate, could be 
mimicked by exogenous phosphatase from various sources [694] and was 
completely blocked by preparations of phosphatase inhibitor from either 
adipose tissue or skeletal muscle [695].
Because of the difficulties associated with obtaining sufficient 
quantities of purified HSL to enable studies to be made of the 
properties of the isolated enzyme [228, 740], absolute confirmation of 
the importance of HSL phosphorylation in its activation by cAMP-PrK has 
only been presented very recently [228, 739]. HSL is phosphorylated on 
a single serine residue per 84kDa subunit by cAMP-PrK and 
phosphorylation of this site is closely paralleled by the corresponding 
increase in HSL activity [739], the rate of its phosphorylation being 
comparable with that observed in intact fat cells after exposure to 
lipolytic hormones [37, 561]. Glycogen synthase kinase 4, partially 
purified from skeletal muscle is reported to phosphorylate a second 
site at a rate similar to that obtained with cAMP-PrK but occupancy of 
this site is not accompanied by an increase in HSL activity [740]. 
Cyclic GMP-dependent protein kinase appears to be capable of
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phosphorylating both sites and invoking a similar parallel increase in 
HSL activity to that observed for activation by cAMP-PrK [740].
Deactivation of HSL has been shown to be most effectively 
executed by protein phosphatase 2C (PrP2C) of skeletal muscle but 
phosphatases 1 (PrPl) and 2A (PrP2A) also show significant activity and 
it has been speculated that in adipose tissue the activities of all 
three towards HSL might not differ by more than a factor of three 
[740]. However, there is insufficient evidence to predict the major 
phosphatase(s) responsible for HSL deactivation in vivo with any 
degree of confidence.
Due to the hydrophobic nature of its substrate, characterisation 
of the kinetic parameters affected by phosphorylation of HSL is 
difficult and many different factors can influence the results 
obtained, as evidenced by the conflicting reports of the enzyme's 
behaviour in systems with various emulsified substrate compositions and 
ill-defined interface structure [406, 407, 693, 740].
Through work with isolated adipocytes equilibrated with 32 P. , it 
has been established that the lipolytic hormones noradrenaline [37, 38, 
740], ACTH [740] and glucagon [740] induce an increase in 
phosphorylation of HSL at the site phosphorylated by cAMP-PrK 
accompanied by a simultaneous increase in its activity, as evidenced by 
release of non-esterified fatty acid into the incubation medium. Both 
the activity and the degree of phosphorylation of HSL are rapidly 
returned to control levels by addition of the ^-adrenergic antagonist 
propranolol to noradrenaline stimulated adipocytes [740] and the 
increases in both induced by exposure to varying concentrations of 
noradrenaline follow the same response curve with a half-maximal 
noradrenaline concentration of 25nM [37]. Insulin treatment of cells
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previously exposed to noradrenaline restores the ability of the HSL 
activity in cellular extracts to be activated by cAMP-PrK [409] 
implying that insulin is able to reduce the level of HSL 
phosphorylation observed in response to noradrenaline. Further 
manipulations of the 32 P.-equilibrated adipocytes revealed that insulin 
does indeed reduce noradrenaline stimulated HSL phosphorylation with a 
concomitant fall in the enzyme's activity [37]. In the absence of 
lipolytic hormone, a "basal" phosphorylation is observed apparently at 
the site previously shown to be phosphorylated by GSK 4 but occupation 
of this site has no effect on HSL activity and is completely 
independent of insulin [37, 740].
The mechanism of action of insulin in this system is 
controversial but it has been asserted recently that the antilipolytic 
action of insulin may be entirely explained by its ability to reduce 
intracellular cAMP levels [852, 853]. Although this is an attractive 
explanation, bearing in mind the well established ability of insulin to 
activate high affinity cAMP-PDE in several tissues including adipose 
tissue (see section 1.2.2.(ii)) and the reported inhibition of 
adenylate cyclase in response to insulin (see section 1.1.) in 
adipose tissue [373], adipocyte homogenates [344], fat cell "ghosts" 
[308] and other preparations [452], the possibility that insulin action 
is mediated, at least in part, by a cAMP-independent mechanism, perhaps 
involving activation of specific phosphatases (see section 1.3.9.), 
cannot be discounted. An effect mediated by decreased cAMP levels 
would, however, be reinforced by the increase in PrPl activity 
resulting from reduced inhibition by the cAMP-dependent inhibitor 1 
(see sections 1.3.8.(i)a and 1.3.9.(i)) and may, therefore, be subject 
to sufficient amplification to obviate the need for a parallel, 
cAMP-independent mechanism.
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1.3.4.(ii) Acetyl-CoA Carboxylase
The demand for fatty acids for incorporation into milk fat by the 
lactating mammary gland cannot be met entirely from dietary lipid and 
in order to maintain the high rates of lactogenesis prevailing during 
lactation, the rate of de novo fatty acid synthesis must be capable of 
responding to bridge that deficit. The daily glucose uptake of 
lactating rat mammary gland is comparable with the whole body glucose 
turnover of a male rat and as much as 70% of that uptake is used for 
fatty acid synthesis. However, de novo synthesis makes large demands 
on metabolic energy and if the pathway were not strictly controlled, 
substantial energetic inefficiency would result. Both acetyl-CoA 
carboxylase and fatty acid synthase (FAS) are subject to control by 
changes in the rates of their synthesis and degradation, leading to 
changes in the absolute quantity of individual enzyme protein 
molecules, thus effecting long term regulation of fatty acid synthesis 
(for reviews see [51, 659]). In addition to these chronic 
modifications of the total lipid biosynthetic capacity of mammary 
tissue, characteristically most marked at the onset and cessation of 
lactation, acute control of flow through this pathway is also afforded 
by covalent modification of acetyl-CoA carboxylase [280, 415].
The active form of acetyl-CoA carboxylase, purified to apparent 
homogeneity from rat liver [354, 556a], bovine adipose tissue [548], 
rat mammary gland [2] and rabbit mammary gland [281, 507] shows the 
same linear polymeric structure with a molecular weight of about 107, 
irrespective of its source. The polymer isolated from rat liver and 
mammary gland and rabbit mammary gland appears to be an aggregation of 
identical subunits of molecular weight 230-250kDa [2, 68, 281, 497],
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each one possessing two active sites [280]. Separate, distinct 
catalytic sites are, therefore, assumed to account for the two partial 
reactions i) biotin carboxylation and ii) carboxyl transfer that have 
been demonstrated to constitute acetyl-CoA carboxylase activity [518]. 
Under specific conditions (eg high ionic strength at alkaline pH), the 
active polymer dissociates to give inactive "protomeric" components of 
molecular weight 410-560kDa which probably represent dimers of the 
230-250kDa subunits [284]. An early study of the biotin binding 
characteristics and substrate and allosteric binding site complement of 
each 230-250kDa subunit suggested that the minimal binding unit of 
acetyl-CoA carboxylase would consist of two such subunits and, 
therefore, that the dimeric "protomer" represented the basic unit of 
the enzyme [269]. However, more recent work in three separate 
laboratories has indicated that each subunit binds one molecule of 
biotin [2, 354, 760], suggesting that the basic unit of acetyl-CoA 
carboxylase may not in fact be the dimeric "protomer" but rather the 
230-250kDa subunit itself.
Whether the reversible transition between active polymeric and 
inactive protomeric forms operates in vivo is uncertain. Dissociation 
of the polymer may be induced in vitro by incubation of acetyl-CoA 
carboxylase with its substrates in the absence of its allosteric 
activator, citrate [270] suggesting that low cytosolic citrate 
concentrations may be capable of shifting the polymer/protomer 
equilibrium towards the inactive protomeric form. Indirect evidence 
that such an equilibrium might exist in intact cells has been generated 
by work with chicken liver cell monolayer cultures treated with 
digitonin to perforate the plasma membrane without disrupting the cell 
[533]. In such preparations leakage of acetyl-CoA carboxylase is much
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slower than that of other cytosolic enzymes such as LDH. Moreover, 
pretreatment of these cells with dibutyryl cAMP which should promote 
dissociation to the protomeric form by precipitating a reduction in 
cytoplasmic citrate concentrations [827], causes rapid leakage of 
acetyl-CoA carboxylase following digitonin treatment implying that a 
greater proportion of enzyme was indeed present in its protomeric form 
[533]. The mechanism by which citrate influences the protomer/polymer 
transition in vivo may be more complex than anticipated since 
phosphorylation both in vivo [251] and of partially purified acetyl-CoA 
carboxylase [470] leads to an increase in the proportion of the enzyme 
found in its inactive protomeric form and this phosphorylation is 
inhibited by high citrate concentrations [470]. At lower 
concentrations of citrate, phosphorylation is enhanced by cAMP [470] so 
the increase in protomeric/polymeric ratio observed after treatment of 
chicken liver cells with dibutyryl cAMP [533] may be the result of a 
combination of direct allosteric effects and both direct and indirect 
(via attenuation of inhibition) effects on extent of cAMP-dependent 
acetyl-CoA carboxylase phosphorylation.
Animal acetyl-CoA carboxylases are completely inactive in the 
absence of citrate or isocitrate. Activation by citrate is 
characterised by an increase in the V rather than a decrease in Ka max m
[268, 827] and involves both partial reactions [518]. Since citrate, 
an intermediate of the TCA cycle, transported from mitochondrial matrix 
to cytoplasm, forms the substrate for ATP citrate lyase, giving rise to 
the major source of cytoplasmic acetyl CoA, it may also be regarded as 
the basic precursor of all de novo fatty acid synthesis. The 
concentration of citrate required for half maximal activation of 
acetyl-CoA carboxylase in vitro is of the same order as the range of
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concentrations (0.2-2mM) estimated to prevail in the cytoplasm [706].
It has therefore been proposed that citrate activation of acetyl-CoA 
carboxylase represents a mechanism for feed forward control of fatty 
acid synthesis governed by the concentrations of TCA intermediates but 
there is no direct evidence to either confirm or discredit this 
suggestion [280]. A similar situation exists concerning the inhibition 
of acetyl-CoA carboxylase by palmityl-CoA and other fatty acyl-CoAs 
observed in vitro [52, 261, 573, 576] but the indications are that this 
mechanism is, at least potentially, a physiological one providing 
negative feedback control of acetyl-CoA carboxylase activity by what 
may be regarded as end products of fatty acid synthesis [261, 576].
The first direct evidence that acetyl-CoA carboxylase may be 
phosphorylated and that this event is accompanied by reduced enzyme 
activity was provided by Carlson and Kim [78] who demonstrated that 
time dependent activation of a partially purified acetyl-CoA 
carboxylase preparation could be blocked by the phosphatase inhibitor 
NaF and that inactivation required Mg-ATP and the presence of a 
supernatant protein fraction [78, 79, 465]. Several factors have since 
been proposed to account for the Mg-ATP dependent inactivation observed 
by these workers including a well documented inactivation initiated by 
slow carboxylation in the presence of Mg-ATP and traces of dissolved 
C02 [270, 276, 453] but this [470] and other proposals have either 
proved invalid or cannot be demonstrated to explain all of the observed 
effects. Using the same acetyl-CoA carboxylase preparation, Carlson 
and Kim have characterised more fully the change in kinetics associated 
with its phosphorylation. Under such conditions, dephosphorylated 
acetyl-CoA carboxylase expresses five-fold greater activity, even at 
saturating citrate concentrations, and displays a half-maximal
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concentration for activation by citrate an order of magnitude lower 
than that exhibited by the phosphorylated form [80]. Despite the early 
scepticism, regulation of acetyl-CoA carboxylase activity by reversible 
phosphorylation has been confirmed in isolated cells [69, 323, 849], 
tissue homogenates [528, 873] and the purified enzyme [282, 283, 551, 
777]. Because of the relative abundance of acetyl-CoA carboxylase in 
lactating mammary tissue [280] and the benefits associated with its 
apparently low intrinsic level of proteolytic activity [281], lactating 
rat and rabbit mammary gland have often been chosen as a source of 
acetyl-CoA carboxylase for studies involving the purified enzyme. The 
mammary gland enzyme can be phosphorylated by at least five different 
protein kinases; cAMP-PrK [103, 282, 283], acetyl-CoA carboxylase 
kinase 2 [551], Ca2+/calmodulin-dependent protein kinase [856] and 
casein kinases I and II [551]. Of these, at least two (cAMP-PrK and 
acetyl-CoA carboxylase kinase 2) have been shown to be capable of 
inactivating acetyl-CoA carboxylase [283, 551]. Both phosphorylate 
sites located on identical peptides and their dephosphorylation leads 
to complete reactivation of the enzyme [283, 286, 551]. Both this and 
the equivalent site in rat liver acetyl-CoA carboxylase are 
dephosphorylated by PrPl, PrP2A and PrP2C (see section 1.3.9.) [283, 
346, 347]. Phosphorylation of purified rat mammary acetyl-CoA 
carboxylase by cAMP-PrK decreases the Vmax of the enzyme two-fold 
and increases the concentration of citrate required for half-maximal 
activation two-fold [283], qualitatively similar, though less 
pronounced effects to those observed by Carlson and Kim for 
phosphorylation of partially purified rat liver enzyme [80]. In 
hepatocytes exposed to glucagon, increased phosphorylation of 
acetyl-CoA carboxylase at the cAMP-dependent site accompanies the
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decrease observed in activity of acetyl-CoA carboxylase purified 
rapidly by avidin-Sepharose chromatography and entirely accounts for 
the effect of the hormone on fatty acid synthesis in such preparations
[323]. This and comparable correlations between phosphorylation of 
acetyl-CoA carboxylase and decrease in activity of the purified enzyme, 
observed in adipocytes exposed to glucagon or adrenaline [322], provide 
strong evidence that phosphorylation of acetyl-CoA carboxylase by 
cAMP-PrK represents an important physiological mechanism for the 
control of fatty acid synthesis. Incubation of adipocytes with 
adrenaline has been shown to cause a decrease in V and an increasemax
in Ka for citrate of acetyl-CoA carboxylase in crude extracts [69] and 
purified enzyme [322] prepared from such cells. These changes are also 
very similar to those associated with phosphorylation of purified rat 
mammary acetyl-CoA carboxylase by cAMP-PrK [283]. Although an analogous 
glucagon induced decrease in acetyl-CoA carboxylase activity is also 
observed in hepatocytes, in this instance the major component of 
inactivation is a decrease in the enzyme's susceptibility to activation 
by citrate [323], the decrease in Vmax being less pronounced than that 
reported for similarly treated adipocytes [322]. Differences in basal 
phosphorylation site occupancies have been recruited to offer an 
explanation for this discrepancy [322]. Hepatocyte acetyl-CoA 
carboxylase displays a higher level of phosphate incorporation per 
subunit under basal conditions than its counterpart in adipose tissue 
[322, 323] and phosphorylation of acetyl-CoA carboxylase on a 
particular peptide (peptide 1) phosphorylated during exposure to 
glucagon in both hepatocytes and adipocytes is known to affect mainly 
the concentration of citrate required for activation of this enzyme 
[551]. However, this site is only one of a number of sites found to be
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phosphorylated in response to adrenaline and glucagon in adipocytes 
[322] and the proposal is that it is these extra sites that are 
responsible for the large decrease in Vmax characterising the adipocyte 
acetyl-CoA carboxylase response to these hormones [322]. The 
explanation for the lack of such an effect in hepatocytes being that 
the extra sites are phosphorylated even under basal conditions in liver 
cells thus accounting for the higher phosphate content per subunit, 
lower V and comparatively small change in V following hormone
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treatment. Whether phosphorylation of these other sites is also 
cAMP-dependent is not known but it has been emphasised that such 
modulation need not occur directly and might equally well be achieved 
via activation of protein phosphatase inhibitor proteins [322] (see 
section 1.3.9.(i)). Though plausible, this elegant explanation for the 
discrepancies between hormone induced acetyl-CoA carboxylase 
deactivation in adipocytes and hepatocytes does not appear consistent 
with the recent findings of Swenson and Porter [751] who report 
inactivation of hepatocyte acetyl-CoA carboxylase by glucagon involving 
a marked decrease in V (of the order observed in adrenaline treatedmax
adipocytes) accompanied by a percentage change in AQ for citrate of a 
similar magnitude reported for acetyl-CoA carboxylase in adrenaline 
treated adipocytes (though-absolute values were depressed in 
comparison). These authors point to the inclusion of protease 
inhibitors in their own incubations as the key to explaining the 
disparity between theirs and previous reports of glucagon dependent 
effects in hepatocytes [323, 849] and have shown how the observed 
phosphate incorporation and acetyl-CoA carboxylase activity can both be 
dramatically reduced by proteolytic activity, obscuring any changes 
resulting from exposure to glucagon. The role, if any, of
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phosphorylation at sites other than peptide 1 in response to glucagon 
or adrenaline remains, therefore, uncertain but the available evidence 
seems to suggest that under conditions where proteolytic activity is 
minimised, liver and fat cell acetyl-CoA carboxylase might respond to 
hormonal elevation of intracellular cAMP in a very similar manner.
Such studies have proved impossible in lactating mammary gland since 
both acetyl-CoA carboxylase activity and lipogenesis are apparently 
insensitive to glucagon in this tissue [656]; however, effects of 
insulin have been reported in all three cell types (liver [848], 
adipose tissue [65, 66, 874] and mammary gland [656]). Activation of 
the enzyme in liver and adipose tissue is accompanied by a slight 
increase in phosphorylation [66, 848, 850]. However, although exposure 
of rat adipose tissue to insulin results in a 2-3 fold increase in the 
acetyl-CoA carboxylase activity of crude tissue extracts [276, 466,
726] and activation is accompanied by an increase in the 
phosphorylation of a site distinct from those affected by exposure to 
adrenaline [66, 850], Witters et al. [850] have observed no effects of 
the increased phosphorylation on the activity of purified acetyl-CoA 
carboxylase. The effect of insulin on the degree of phosphorylation of 
mammary acetyl-CoA carboxylase freshly prepared from cellular extracts 
was, until recently, uncertain [286]. In common with work by Witters 
et al. in adipose tissue, Clegg et al. [102] have reported no effect on 
the acetyl-CoA carboxylase activity of purified enzyme from insulin 
treated mammary acini despite previous work demonstrating a dose 
dependent stimulation of lipogenesis by insulin in the same type of 
preparation [656]. While it is still accepted that there must be at 
least one other rate-limiting step in the pathway for fatty acid 
synthesis (as suggested by these findings), Munday and Hardie [552]
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have now demonstrated that manipulation of insulin levels in vivo has 
marked effects on the phosphorylation state and activity of this 
enzyme. In this study, refeeding rats starved previously for 24h 
resulted in a decrease in phosphate content of purified acetyl-CoA 
carboxylase and a concommitant activation (increase in Vmax and 
decrease in concentration of citrate required for half-maximal 
activation) of the enzyme to control (fed) levels. These effects were 
blocked completely by treatment of the starved rats with streptozotocin 
prior to refeeding, suggesting that the increase in plasma insulin that 
occurs on refeeding was responsible for the activation of the enzyme. 
Furthermore, this activation could also be achieved by treating acetyl- 
CoA carboxylase purified from the starved rats with protein 
phosphatase-2A in vitro, providing support for the involvement of 
enzyme phosphorylation in these regulatory processes.
In conclusion, it seems certain that phosphorylation/ 
dephosphorylation of acetyl-CoA carboxylase represents a major 
mechanism for acute regulation of fatty acid synthesis in both liver 
and adipose tissue though the significance of this regulatory mechanism 
for the control of fatty acid synthesis in mammary gland remains 
uncertain. The relevance of insulin effects on acetyl-CoA carboxylase 
phosphorylation in terms of regulation of its activity is 
controversial. The demonstration of a loss of activation during 
purification of the enzyme while the increased phosphorylation is 
preserved [850] tends to suggest that phospho/dephosphorylation is not 
an important factor in the control of adipocyte-acetyl-CoA carboxylase 
activity by insulin. However, the apparently insulin-dependent effects 
observed in vivo by Munday and Hardie [552] on both phosphorylation and
activity of acetyl-CoA carboxylase, provide strong evidence that, at 
least in mammary tissue, the phosphorylation state of this enzyme plays 
an important role in the regulation of its activity in response to 
hormonal stimuli.
1.3.5. HMG-CoA Reductase
Though not a quantitatively major component of milk, cholesterol is 
essential for the maintenance of fat droplet membrane structure [163] 
and considerable quantities (16mg/day) are secreted in rat milk [95]. 
The cholesterol requirements of mammary tissue for milk production may 
be met from two sources, i) circulating serum cholesterol, ii) 
cholesterol synthesis. The relative contributions of these two sources 
is controversial but sterol synthesis by mammary gland has been
demonstrated both in vivo [95] and in vitro [135, 627] and, more
recently it has been suggested that a major proportion of rabbit milk
sterol is supplied by mammary cholesterol synthesis [536] though 
Gibbons et al. [244] have calculated that cholesterol synthesised by 
the mammary gland provides a maximum of only 40% of the daily total 
secreted in milk. Whatever the actual proportion of milk cholesterol 
derived from its synthesis in mammary tissue, in order to meet the 
varying demands for cholesterol imposed on the tissue by diurnal 
variation in milk production, cholesterol synthesis must be amenable to 
short-term regulation. The third step in mammalian cholesterol 
synthesis from acetyl-CoA, conversion of HMG-CoA and NADPH to 
mevalonate, CoA and NADP, is catalysed by HMG (3-hydroxy, 
3-methylglutaryl)-coenzyme A reductase (HMG-CoA reductase). Generally 
believed to be the rate limiting enzyme in de novo biosynthesis of 
cholesterol [60, 162, 209] it can be safely assumed that under most
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circumstances the activity of HMG-CoA reductase will be an important 
determinant of the rate of cholesterol synthesis in the liver though 
exceptions include fasting [657] and dexamethasone treatment [634].
High HMG-CoA reductase activities have been observed in both rat [224] 
and rabbit [536] lactating mammary gland but the major site of sterol 
synthesis is the liver [786] and consequently it is the HMG-CoA 
reductase of the latter tissue which has been most extensively studied.
In mammalian cells, HMG-CoA reductase consists of a single 
90-100kDa glycosylated polypeptide [61, 92, 175, 279, 479, 786] though 
whether it exists as a monomer or an oligomer in vivo is not yet 
known. The enzyme is integrally associated with endoplasmic reticulum 
[61, 479] but its active site is exposed to the cytosol [608] and 
limited proteolysis releases a catalytically active soluble peptide of 
molecular weight 50-56kDa [398].
Early work on modulation of HMG-CoA reductase activity 
concentrated on mechanisms associated with long-term regulation 
involving changes in the amount of enzyme protein. Regulation of this 
kind results from manipulation of synthesis at both transcriptional 
[96, 480] and post-transcriptional [366, 419, 428] levels and variation 
in the rate of enzyme degradation [89, 209, 383, 708]. Mechanisms 
implicated in short term control of HMG-CoA reductase include the 
influences of membrane composition and fluidity [214, 540, 650, 709], 
thiols [165, 658], microtubules [807, 808] and cytosolic lipid 
inhibitors and their binding proteins [272, 467, 532] on the enzyme's 
catalytic activity but perhaps the most significant acute control 
mechanism, particularly with respect to hormonal effects, is provided 
by modulation of its phosphorylation state. The first indication that 
HMG-CoA reductase activity is susceptible to modulation by reversible
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phosphorylation came from work by Beg et al. [30] who reported that 
HMG-CoA reductase activity of washed rat liver microsomes was 
reduced dramatically by prior treatment with Mg-ATP and a fraction from 
rat liver cytosol. The degree of inactivation was time-dependent and 
the lost activity was restored by treatment with a second cytosolic 
fraction. The Mg-ATP dependent decrease in HMG-CoA reductase activity 
in the presence of cytosolic or endogenous microsomal factors has been 
confirmed in several laboratories [53, 62, 93, 348, 569, 579, 696] as 
has its reversal following treatment with a cytosolic factor [195, 337, 
348, 569, 579, 696]. Inactivation of the microsomally bound enzyme by 
incubation with [y-32P]ATP results in the formation of 32P-phosphoserine 
labelled HMG-CoA reductase [32, 249, 394, 395] and parallel 
inactivation and phosphorylation of purified HMG-CoA reductase has also 
been demonstrated using purified or partially purified HMG-CoA 
reductase kinases from rat liver microsomes [34, 213] and cytosol 
[292]. The latter kinase preparation exhibited a requirement for ADP, 
consistent with previous reports that inactivation of HMG CoA reductase 
by Mg-ATP was dependent on ADP [62, 659]. The inactivation produced is 
characterised by a decrease in the enzyme's V with no change in the
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Km values for either HMG-CoA or NADPH and appears to be provoked by 
phosphorylation of a single site [63, 213] though at least one other 
structurally distinct site has also been identified [220, 394]. No 
function has as yet been assigned to phosphorylation of this second or 
other sites but it has been suggested that such phosphorylations may 
control the susceptibility of the "primary" site to the action of 
kinases or phosphatases or may influence the rate at which HMG-CoA 
reductase is proteolytically degraded [398]. Activation of 32P 
labelled HMG-CoA reductase accompanied by concomitant release of 32 Pi
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from the enzyme has been observed during incubation with various 
purified phosphatase preparations [32, 63, 213, 250, 736]. However it 
has been estimated that PrP2C would represent the major HMG-CoA 
reductase phosphatase in liver, though by virtue of its cellular 
distribution (a significant proportion is associated with the 
microsomal fraction), PrPl may also be an important HMG-CoA reductase 
phosphatase [345].
The enzyme responsible for phosphorylation of HMG-CoA reductase, 
HMG-CoA reductase kinase is cytosolic and is itself, apparently, the 
substrate for another cytosolic protein kinase, termed reductase kinase 
kinase. Following the discovery by Ingebritsen et al. that the rate 
of inactivation of reductase kinase was reduced in incubations 
containing phosphate and completely blocked by 50mM NaF (both 
inhibitors of phosphatases, the latter being the more effective) [245, 
348, 351] but that kinase activity could not be restored by addition of 
these ions after inactivation [345, 348], it was proposed that 
regulation of HMG-CoA reductase is achieved via a bicyclic 
phosphorylation cascade as shown in Figure 11. Active reductase kinase 
is inactivated in the presence of a broad specificity phosphatase and 
can be reactivated by incubation with Mg-ATP and reductase kinase 
kinase [348, 351]. In addition, incubation of homogeneous reductase 
kinase with its kinase in the presence of [y~32P] ATP, Mg2+ results in 
incorporation of 32P into reductase kinase, while subsequent incubation 
with a purified protein phosphatase precipitates a 70% loss of 
reductase kinase associated 32P [33] further strengthening the proposal 
that HMG-CoA reductase kinase activity is regulated by reversible 
phosphorylation. Beg et al. [33] have purified HMG-CoA reductase 
kinase to apparent homogeneity and reported a molecular weight of
Figure 11 Bicyclic Phosphorylation Cascade 
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380kDa with a subunit weight of 58kDa suggesting that the native 
enzyme is a hexamer.
Despite reports that treatment of isolated rat hepatocytes with 
glucagon or cAMP markedly reduces HMG-CoA reductase activity [176, 246, 
307, 349, 592], it has been demonstrated that both reductase kinase and 
reductase kinase kinase are cAMP-independent protein kinases [31, 36, 
351] suggesting that the effects observed in intact cells may be due to 
phosphatase inhibition rather than activation of the kinases comprising 
the bicyclic phosphorylation system (Figure 11). Microsomal 
phosphatase 1 activity might then prove to be an important factor in 
regulation of HMG-CoA reductase since the PrPl inhibitor, inhibitor 1, 
is activated by cAMP ([212, 247, 274], see also sections 1.3.8.(i)a and 
1.3.9.(i)) though, as for HMG-CoA reductase itself, the major reductase 
kinase phosphatase is thought to be PrP2C [345]. Little is known about 
the factors governing the activities of reductase kinase and reductase 
kinase kinase but it has recently been reported that the latter is 
modulated in vivo by mevalonolactone [35]. It has also been discovered 
that reductase kinase is not the only protein kinase capable of 
phosphorylating and inactivating HMG-CoA reductase. Beg et al. [35] 
have described inactivation of both the native reductase (molecular 
weight lOOkDa) and its 53kDa soluble catalytic fraction by protein 
kinase C (see section 1.3.8.(i)b) and have established that this 
inactivation is accompanied by the incorporation of approximately 1 
mole phosphate per mole of native lOOkDa enzyme subunit.
Regulation of HMG-CoA reductase in intact animals is complicated 
and the activity expressed in vivo depends upon both the total amount 
of enzyme protein present and the state of phosphorylation of that 
enzyme population. Both parameters are under hormonal control (see
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reviews by Ingebritsen [345], Dugan and Porter [168] and Rodwell et_ 
al. [657]) and have been shown to vary in a diurnal cycle [173, 657]. 
Consequently, phosphorylation of HMG-CoA reductase is now accepted as a 
major regulator of cholesterol synthesis in vivo.
1.3.6. ATP Citrate Lyase
ATP citrate lyase catalyses the conversion of cytosolic citrate to 
acetyl-CoA and therefore governs the supply of substrate for de novo 
synthesis of both fatty acids and sterols but is not rate-limiting for 
either pathway. Although ATP citrate lyase is phosphorylated in intact 
cells and is one of a small number of identified proteins for which 
insulin increases the degree of phosphorylation [284], there is, as 
yet, no evidence that these events have any effect on its catalytic 
activity.
1.3.7. Non-Enzymic Targets for Protein Phosphorylation
1.3.7.(i) The Histones
The range of non-enzymic proteins known to be substrates for protein 
kinase activity is vast and expanding all the time but in general the 
possible significances of such phosphorylations are unclear and 
consequently, most have attracted only limited interest. Among the 
non-enzymic targets for protein phosphorylation, which include proteins 
of cytosolic, membrane, nuclear, ribosomal, contractile and 
cytoskeletal origin, one of the most extensively studied groups, the 
histones, particularly Hi and H3, show interesting correlations between 
degree of phosphorylation and stage of cell cycle. Histone Hi which 
appears to have an important influence on chromatin packing, 
particularly during mitosis [302, 378, 866] shows increased
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phosphorylation at up to six sites on serine and threonine residues 
during interphase and metaphase [380, 451, 459]. There is evidence 
that the phosphorylation of one of these sites in the C-terminal region 
of the molecule accompanies DNA synthesis and it has been suggested 
that this may have a role in distinguishing replicated DNA from 
unreplicated DNA and ensuring that each region of the chromosome is 
replicated only once per cell cycle [421]. Phosphorylation of Hi 
proceeds under the influence of at least three different protein 
kinases or groups of protein kinases, one of which was discovered to be 
cAMP-PrK [454, 505] and to predominantly phosphorylate only one of the 
N-terminal region serine residues (serine-37) [455]. Phosphorylation 
of the remaining sites is independent of cAMP and accounted for by 
another kinase specific to one particular, though different serine 
residue (serine-106 in the globular region) [455] and an enzyme or 
group of enzymes known as growth associated histone kinase (kinase-G), 
capable of phosphorylating multiple sites on Hi [285, 321] including 
the DNA synthesis dependent site [285]. Although the links between 
protein phosphorylation and control of cell division are, at best, 
tentative, it is such correlations (including that observed between 
ribosomal protein S6 phosphorylation and stimulation of protein 
synthesis [see below]) and the known significance of phosphorylations 
involving enzyme modulator proteins such as inhibitors 1 and 2 (see 
section 1.3.9.(i)) that provide the most promising indications of a 
role for phosphorylation of non-enzymic proteins in the control of 
cellular activities.
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1.3.7.(ii) Ribosomal Protein S6
Stimulation of ribosomal protein S6 phosphorylation on multiple sites 
has been observed following treatment of cells with a variety of 
hormones and growth factors including insulin [293/ 461, 560, 599, 713, 
768, 838], epidermal growth factor (EGF) [560, 600, 768], prostaglandin 
F2 a [768], platelet-derived growth factor [88, 565, 836] and insulin­
like growth factor [293]. The rapid activation of S6 phosphorylation 
observed in response to EGF in quiescent swiss mouse 3T3 cells has been 
shown to be accompanied by stimulation of protein synthesis, followed, 
12 hours later, by a surge in the rate of initiation of DNA synthesis, 
leading, ultimately, to cell division [765, 768]. The dose responses 
of S6 phosphorylation, protein synthesis and DNA synthesis for 
activation by EGF are closely related [768] and, together with the 
findings of other studies both in vivo and in vitro (see [572] and 
references therein), these observations provide evidence in support of 
the hypothesis that multiple phosphorylation of S6 is a prerequisite 
for the activation of protein synthesis accompanying initiation of cell 
division.
Phosphorylation of S6 has been reported to be catalysed by 
several protein kinases, including cAMP-dependent protein kinase [170, 
837, 839], a protease activated protein kinase [234], protein kinase C 
[605] and an S6 kinase whose activity is regulated by reversible 
phosphorylation [572]. The first three kinases have been shown, in 
vitro, to phosphorylate sites related to those phosphorylated in cells 
exposed to insulin [838, 839] or platelet derived growth factor [836] 
and treatment with phorbol ester (a potent activator of protein kinase 
C; see section 1.3.8.(i)b) is known to markedly stimulate S6 
phosphorylation in hepatoma cells [780] suggesting that these kinases
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may also be involved in S6 phosphorylation in vivo. The remaining S6 
kinase is interesting in that its activity appears to be dependent on 
tyrosine phosphorylation [572], raising the possibility that receptor 
associated tyrosine kinase might directly activate this S6 kinase; 
however, further work, presented in the same report, suggests a more 
indirect sequence of events leading to S6 phosphorylation. Besides 
phosphorylation of S6, phosphorylation-activated S6 kinase activity 
appears to be involved in down-regulation of EGF receptors [572] and 
may, therefore, represent an important link in the regulatory 
mechanisms governing both intracellular propagation of hormone or 
growth factor initiated stimuli and feedback control of cell-surface 
receptor activity.
1.3.8. Protein Kinases
Protein kinases catalyse the transfer of the y phosphoryl-group of ATP 
to serine, threonine or tyrosine residues of their polypeptide 
substrates. Phosphorylation of histidine and lysine residues of 
histones IV and I respectively has also been reported in nuclei of a 
carcinoma cell line [714] but the functional significance of these 
modifications is unclear and the phenomenon has received little 
attention.
Since many of the known protein kinases have broad and sometimes 
overlapping substrate specificities, it is often more convenient to 
classify these enzymes according to their specific regulatory effectors 
though some continue to be named with reference to the protein with 
which their activity was originally associated. This system enables 
protein kinases sharing the same mode of regulation or those with 
unknown regulatory properties to be distinguished from other members of
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the same general group. Examples of such enzymes include phosphorylase 
kinase (Ca2+/calmodulin-dependent), myosin light chain kinase 
(Ca2+/calmodulin-dependent), casein kinases 1 (unknown regulatory 
properties) and 2 (polyamine-dependent) and glycogen synthase kinases 
3, 4 and 5 (unknown regulatory properties). However, as the functions 
of enzymes named according to this system are more fully characterised, 
it becomes apparent that a number might equally well be described as 
kinases of proteins other than those suggested by their original 
nomenclature as evidenced by phosphorylase kinase (glycogen synthase 
kinase 2), casein kinase 2 (glycogen synthase kinase 5) and GSK 3 
(factor FA).
1.3.8.(i) Serine/Threonine Protein Kinases
The vast majority of phosphorylations so far identified are specific to 
serine or threonine and the enzymes which catalyse these reactions form 
the most extensively characterised group of protein kinases.
1.3.8.(i)a Cyclic Nucleotide-Dependent Protein Kinases 
cAMP-Dependent Protein Kinase
The most intensively studied of all protein kinases is cAMP-dependent 
protein kinase (cAMP-PrK) which appears to be ubiquitous among animal 
species and tissues [447, 456]. Modulation of cAMP-PrK activity 
provides the only known link between changes in intracellular cAMP 
concentrations and the metabolic consequences of such changes and 
therefore fulfils a key role in the cellular response to a number of 
hormones including glucagon, catecholamine and ACTH (see section 1.1.). 
Although cAMP-PrK is largely cytosolic in most tissues including muscle 
and liver [318], the brain contains approximately equal amounts of
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soluble and particulate enzyme [318, 499, 668, 787a] and endogenous 
enzyme has been detected in nuclear fractions of various tissues [556]. 
Soluble and particulate forms share virtually identical biochemical and 
immunological properties [486, 667, 668] suggesting that the same 
enzyme can exist in both environments but it remains possible that 
partitioning is determined by some minor, as yet undetected difference 
[556]. All mammalian cAMP-PrKs have catalytic (C) subunits with very 
similar physical and functional properties [563, 687, 879]. The 
tetrameric holoenzyme consists of two catalytic and two regulatory 
subunits (R2C2) arranged as a regulatory subunit dimer associated with 
two catalytic subunits [437, 588] and exists in two forms designated 
type I and type II on the basis of their order of elution, with 
increasing ionic strength, from DEAE cellulose columns [437,
729]. The two classes differ functionally in a number of respects but 
share the same substrate specificities [437, 663, 821]. The 
differences between type I and type II cAMP-PrKs appear to be wholly 
attributable to differences in the R-subunits of each [317, 879] which 
have molecular weights of 49kDa and 52-55kDa respectively [556], There 
is immunological evidence to suggest that the R-subunits of muscle and 
brain type II cAMP-PrK also differ structurally [197, 215, 668]. 
Furthermore, type II cAMP-PrKs in these two tissues give rise to 
specific, distinct tryptic peptide maps [291, 727] and appear to 
interact differently with the C-subunits [290]. No such tissue 
differences have been reported for type I cAMP-PrK [556], Subunits of 
type II cAMP-PrK (R^-subunits) are autophosphorylated on one serine 
residue per subunit when incubated with Mg-ATP resulting in an 
increased responsiveness of the kinase to activation by cAMP [82, 196, 
317, 639]. The autophosphorylation site of bovine heart RIX is serine
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95 in the primary sequence and although further phosphorylation 
has been observed on serines 74 and 76 by casein kinase 2 (also 
sometimes termed GSK-5) [82, 303] and on serine residues at positions 
44 and 47 by glycogen synthase kinase 3 [303], no significant function 
has been assigned to occupation of the sites phosphorylated by either 
of the latter two kinases [82]. Both autophosphorylation and casein 
kinase 2 sites are phosphorylated iui vivo [82, 638, 688] and there is 
evidence that the level of in vivo autophosphorylation is sensitive to 
cAMP levels, implying that phosphorylation/dephosphorylation may be an 
important physiological regulator of PrK activity [688]. Unlike RXI, 
the R-subunit of type I cAMP-PrK (Rj) does not undergo 
autophosphorylation in vitro [317, 824] but does bind Mg-ATP with high 
affinity [275, 317] and can be phosphorylated on two sites per subunit 
by cGMP-dependent protein kinase, one of which is homologous with that 
autophosphorylated in RII [242, 243, 295]. Phosphorylation of Rx does 
also occur in vivo though not, apparently, at the site showing homology 
with the Rjj autophosphorylation site [243, 728, 730]. Changes in the 
phosphorylation state of RIZ in response to steroid hormones have been 
proposed to have a possible mechanistic role in some of the actions of 
these hormones [481, 482] thus extending the regulatory potential of 
cAMP-PrK and allowing modulation of the action of agents that influence 
cellular cAMP levels by steroid hormones. None of the R^  
phosphorylations have been reported to be associated with changes in 
either cAMP binding or catalytic activity of type I cAMP-PrK.
Both types of R-subunit consist of two proteolytically resistant 
domains connected by a proteolytically sensitive "hinge" region [131, 
628, 831], The major domain, accounting for about 2/3 of the subunit
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structure contains the cAMP binding sites [628] and the second
proteolytically stable region, comprising a further 1/4 of the
R-subunit appears to be involved in R-R interaction in the regulatory 
subunit dimer [630]. The remaining "hinge" region contains the 
autophosphorylation site of type II cAMP-PrK and its homologous 
(cGMP-PrK dependent) phosphorylation site in type I cAMP-PrK [629]. 
Several lines of evidence suggest that this region plays a critical 
role in interaction with the C-subunit [131, 241, 266, 630, 759]. Each 
R-subunit possesses two cAMP binding sites [70] distinguishable by 
differences in dissociation rates of bound cAMP and in relative 
affinities for analogues of cAMP [400, 640, 641]. Although both cAMP 
binding sites of purified R-subunit apparently have equal affinities 
for cAMP [640] it is bound preferentially to one of the two in the
holoenzyme [437, 71, 367] but the precise stoichiometry of cAMP binding
required to achieve full activation is uncertain. Despite reports that 
occupation of only two of the four cAMP binding sites present in the 
R-subunit dimer is sufficient to elicit full activation of the protein 
kinase [129, 437, 641], there is evidence to suggest that the remaining 
two binding sites also contribute to the activation process [129, 577, 
655].
The cAMP-PrKs are inhibited by a soluble heat stable protein 
found in many tissues but most extensively studies in rabbit skeletal 
muscle [816]. Widely known as the Walsh inhibitor after the team 
responsible for its discovery, cAMP-PrK inhibitor binds to the 
C-subunit of cAMP-PrK and is competitive with respect to protein 
substrates for the kinase [149]. In common with all other cAMP-PrK 
inhibitor proteins, the Walsh inhibitor is acidic, a property which has 
been suggested to be significant in relation to binding to the highly
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basic C-subunit [729]. The physiological function of this inhibitor is 
uncertain since even in skeletal muscle where it is relatively 
abundant, the concentration of inhibitor protein is such that only 1/5 
of the cellular cAMP-PrK could be blocked [815]. At such levels the 
inhibitor might nullify the effects of low concentrations of cAMP [28] 
but could not be a significant factor at high cAMP concentrations 
[437]. Whether the reported variations in inhibitor concentration 
under different physiological conditions [132, 445, 815] would be 
capable of making an effective contribution to the regulation of cAMP 
mediated events is therefore debatable but the purified protein is 
nevertheless a valuable tool for distinguishing the actions of cAMP-PrK 
from those of other protein kinases.
cGMP-Dependent Protein Kinase
Unlike cAMP-PrK which is present in similar concentrations in most 
mammalian tissues [318, 444, 822, 823], cGMP-PrK is unevenly 
distributed with relatively high concentrations being found in lung, 
heart, smooth muscle and intestine [83, 147, 476, 819, 820]. cGMP-PrK 
appears to be predominantly cytosolic in most tissues [446] and the 
purified enzyme of bovine lung [148, 252, 255, 474] and heart [217] 
consists of a dimer of identical 74-81kDa subunits containing two 
cGMP binding sites within a region referred to as the cGMP-binding 
domain [319, 320, 498] and a catalytic domain [556]. Binding of cGMP 
activates the enzyme by inducing a conformational change which exposes 
the catalytic domain [251, 475], Although cAMP is also capable of 
activating the enzyme, much higher concentrations are necessary to 
achieve activation than are required for cGMP induced activation [319]. 
Autophosphorylation of purified cGMP-PrK is stimulated by either cGMP
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or cAMP [148, 222, 251, 319, 320, 475]. The latter is reported to be 
more effective in this respect [222, 251, 319] though cGMP stimulates 
autophosphorylation at lower concentrations than those required for 
stimulation by cAMP [319] and cAMP stimulated autophosphorylation is 
inhibited by cGMP [251, 319, 475]. Originally no change in the 
activity of cGMP-PrK was observed following its autophosphorylation 
[222, 475] but recently autophosphorylation has been shown to be 
accompanied by an increase in the phosphotransfer Vmax of the enzyme 
[319, 320] and over 10-fold decrease in the concentration of cAMP 
required for its activation [319]. The concentrations of cAMP required 
to achieve full (4mol phosphate per mol subunit) autophosphorylation 
in vitro are above the normal physiological range but the enzyme is 
known to be phosphorylated to a certain extent in vivo [319] so it 
remains at least possible that this modification is a significant 
modulator of cGMP-PrK activity in vivo [319].
Relatively few physiological substrates have been identified for 
this kinase [556] but in vitro, it shows a similar substrate 
specificity, with respect to histones and synthetic peptides, to that 
displayed by cAMP-PrK [218, 255, 256, 257]. Although little is 
therefore known about the regulatory significance of cGMP-PrK in vivo 
the wealth of evidence supporting an important role for cGMP in 
neuronal function (see [556] and references therein) suggests that 
cGMP-PrK activity may, at least in nervous tissue, represent an 
important factor in the control of cellular metabolism.
1.3.8.(i)b Calcium-Dependent Protein Kinases
In contrast to the cyclic nucleotide-dependent protein kinases which 
have been characterised primarily in muscle and liver, much of the work
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on calcium dependent protein kinases has been carried out on enzymes 
from brain [556].
Calcium/Calmodulin-Dependent Protein Kinase
Unlike the cAMP-PrKs the Ca2+/calmodulin-dependent protein kinases 
(CC-PrKs) have distinctly different catalytic subunits with different 
substrate specificities but are all activated by a calmodulin-mediated 
Ca2+-dependent mechanism and therefore may be considered to share 
identical regulatory subunits [436]. Ca2+/calmodulin-dependent 
activation, originally described for phosphorylase kinase (see section 
1.3.1) and myosin light chain kinase of muscle [140, 624a, 810, 860] 
has also been observed for liver glycogen synthase kinase [436] and two 
brain synaptosomal membrane kinases termed CC-PrKs I and II [685, 686]. 
Both phosphorylase kinase [582, 753] and myosin light chain kinase 
[139a, 296] have also been identified in brain. Myosin kinase 
(molecular weight 130kDa) has been partially purified from this 
tissue and found to be a highly specific enzyme which preferentially 
phosphorylates smooth muscle myosin light chain [296, 556]. Myosin 
light chain kinase activity has been shown to be Ca2"'’/calmodulin- 
dependent in several other tissues besides smooth muscle and brain 
[295a, 818, 870] and phosphorylation of the smooth muscle enzyme by 
cAMP-PrK has been reported to be accompanied by a decrease in its 
activity [1], Although not as yet purified from brain, the 
phosphorylase kinase identified in this tissue appears to be similar to 
the skeletal muscle enzyme and is activated both by Ca2+ and by 
phosphorylation by cAMP-PrK [753] but only partially cross-reacts with 
antibody raised against skeletal muscle phosphorylase kinase indicating
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that the two forms are distinct iso-enzymes [753]. CC-PrKI appears to 
have a limited substrate specificity with highest activity expressed 
towards the neuronal proteins synapsin I and protein III [556]. Of 
these, synapsin I is reported to be the better substrate. CC-PrKI and 
cAMP-PrK share similar Km values for phosphorylation of both substrates 
and the two kinases have been shown to phosphorylate the same site(s) 
on protein III [556]. Although there is little evidence that CC-PrKI 
is an effective protein kinase in tissues other than brain, the enzyme 
does display some activity against smooth muscle light chain and there 
are indications that physiological substrates in addition to synapsin I 
and protein III may exist in both neuronal and non-neuronal mammalian 
tissues [556]. CC-PrKI activity is predominantly cytosolic and has 
been observed in several tissues including spleen, heart, adrenal gland 
and skeletal muscle though specific activities in these tissues range 
from less than 1/20 (skeletal muscle) to around 1/4 (spleen) of the 
value obtained for brain [397, 556]. Molecular weights of 37kDa, 39kDa 
and 42kDa calculated for polypeptides separated by SDS PAGE of CC-PrKI 
purified to apparent homogeneity [367, 556]. In contrast, a single 
symmetrical peak of CC-PrKI activity with a molecular weight of 49kDa 
was obtained by gel filtration suggesting that the enzyme protein is a 
monomer. It is not known whether the three lower molecular weight 
forms which also each display kinase activity are proteolytic products 
derived from a higher molecular weight native enzyme or represent 
iso-enzymes of CC-PrKI [367]. In the presence of Ca2+, CC-PrKI binds 
calmodulin and is autophosphorylated on threonine residues though at a 
lower rate than that displayed by the enzyme for phosphorylation of 
synapsin I [556]. In common with CC-PrK I from bovine brain, CC-PrK II 
of rat brain demonstrates greatest activity with synapsin I as
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substrate [40, 526, 527] though phosphorylation occurs preferentially 
at a site distinct from that phosphorylated by CC-PrKI [556]. CC-PrKII 
is reported to have a relatively broad substrate specificity unlike the 
other Ca2+/calmodulin-dependent protein kinases, phosphorylase kinase, 
myosin light chain kinase and CC-PrKI. Good substrates include 
synapsin I, MAP 2, glycogen synthase, smooth muscle light chain [40, 
230, 526, 527, 684, 862], tau protein [684, 861], tyrosine hydroxylase, 
tryptophan hydroxylase [809, 855, 863], myelin basic protein [230,
258], ribosomal protein S6 [262] and Ca2+/calmodulin-sensitive cyclic 
nucleotide PDE [231] of which all but glycogen synthase, myosin light 
chain and ribosomal protein S6 are predominantly neuronal. CC-PrKI 
purified to apparent homogeneity from rat forebrain has a native 
molecular weight of 55-56kDa composed of 50kDa and 58/60kDa subunits in 
the ratio 3:1 [40, 526] all of which are autophosphorylated in a 
Ca2 +/calmodulin-dependent manner, bind calmodulin in the presence of 
Ca2+ and are labelled by the photoaffinity label 8-N3-ATP [40, 526,
556] suggesting that protein kinase activity is associated with all 
three subunits. As with all other Ca2+/calmodulin-dependent protein 
kinases, CC-PrKII is activated by calmodulin in the presence of Ca2+, 
probably in a similar manner to that described for Ca2+/calmodulin 
activation of Ca2+/calmodulin-sensitive PDE (see section 1.2.1.(i)). 
Although autophosphorylation of the enzyme inhibits its activity [556] 
and has been reported to increase its affinity for calmodulin [703], 
CC-PrKII does not appear to be phosphorylated by other protein kinases 
[556], CC-PrKII is present in very high concentrations in both soluble 
and particulate fractions of brain [40, 526] and it appears that the 
subcellular distribution is subject to modification by exposure of 
certain neurons to seratonin [672]. It has also been suggested that
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autophosphorylation may regulate subcellular distribution [40]. The 
CC-PrKII of rat forebrain and cerebellum share similar purification 
characteristics, physical properties and substrate specificities [525, 
526, 537] and are composed of identical (by peptide mapping) subunits 
though the ratio of 50kDa to 58/60kDa subunits comprising the native 
enzymes differ markedly [525, 526, 537]. Rabbit skeletal muscle 
glycogen synthase kinase which is composed of a polypeptide doublet of 
molecular weight 58/60kDa also displays a number of properties in 
common with the CC-PrKII of brain including substrate specificity, 
peptide maps, physical properties and immunological properties [527, 
556]. Other tissues found to contain kinases with similar substrate 
specificities, native molecular weights and autophosphorylation 
characteristics to CC-PrKII are rabbit liver [3, 598], rat pancreas 
[262], bovine heart [584], turkey erythrocytes [586], Aplysia nervous 
system [160] and Torpedo electric organ [587]. In view of the 
apparently widespread tissue and species distribution of CC-PrKII 
isoenzymes, it seems likely that further substrates will be found and 
this kinase may prove to be an important mediator in a number of 
cellular responses to changing Ca2+ concentrations. There is some 
evidence that CC-PrKII phosphorylates synapsin I in intact nerve cells 
[559, 783] but strong correlations between kinase-dependent 
phosphorylation and associated in vivo events of the kind described 
for cAMP-PrK have not yet been reported for either CC-PrKI or Cc-PrKII 
and the physiological significance of their activities must, therefore, 
remain uncertain.
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Calcium/Phospholipid-Dependent Protein Kinase (Protein Kinase C)
First purified from cerebellum as a cyclic nucleotide-independent 
protein kinase that could be activated by Ca2+-dependent protease 
[353, 754], the holoenzyme was subsequently found to be activated by 
Ca2+, diacylglycerol and various membrane phospholipids [377, 420,
755, 756], The enzyme from brain is a monomer of molecular weight 
80-87kDa and is thought to consist of a hydrophilic catalytically 
active domain and a hydrophobic domain which is involved in the 
activation of the enzyme [413]. Protein kinase C (PrKC) is widespread 
throughout the phyla of the animal kingdom from anelids to higher 
chordates including mammals [444] and shows very similar physical, 
kinetic and catalytic properties in a variety of tissues [444, 539].
In most rat tissues including liver, adipose tissue, heart and skeletal 
muscle, specific activities of cAMP-PrK and PrKC measured under similar 
conditions are approximately equal but in several tissues (platelets, 
brain, lymphocyte and granulocytes) PrKC activity far exceeds that of 
cAMP-PrK [444, 539]. PrKC activity is highest in spleen with 
comparable activities in cerebral cortex and cerebellum [444], while 
activities in other non-neuronal tissues such as liver, skeletal muscle 
and adipose tissue vary between 1/10 and 1/200 of these values [444, 
539]. The proportion of total cellular enzyme activity found to be 
membrane associated in non-nervous tissue ranges from approximately 2% 
in muscle and platelets to between 22% and 39% in liver, kidney, heart 
and spleen [391, 413, 444]. However, particulate PrKC activity in 
brain consistently accounts for a higher proportion of total activity 
(45-64%) than in any of the non-nervous tissues studies [391, 413,
444]. The two forms are biochemically indistinguishable [413] and the 
significance of the tissue specific distributions is not yet known.
84
Besides a number of uncharacterised protein substrates [393,
846, 857, 858, 859], the broad substrate specificity of PrKC 
encompasses proteins of both predominantly neuronal and non-neuronal 
origin including EGF receptor [106], somatomedin C receptor [361], 
insulin receptor [139, 361, 757], |3 adrenergic receptor [396, 705], 
nicotinic ACH receptor [334], eukaryotic initiation factor 2 (eIF-2) 
[683], smooth muscle myosin light chain [188, 564], troponin T [392], 
glycogen synthase [4, 654], ribosomal protein S6 [471], vinculin [834], 
tyrosine hydroxylase [8], GABA-modulin [847], myelin basic protein 
[787, 846], MAP-2 [811, 812], the B-50 protein [10] and histones 1, 2 
and 3 [755].
Activation of PrKC in vivo [433, 434, 529, 710] or by micromolar 
concentrations of Ca2+ in vitro [413, 595] is accompanied by 
redistribution of the enzyme from cytosol to membrane fractions and is 
dependent on the presence of certain membrane phospholipids [115, 420, 
539]. Experiments with purified phospholipid have shown that both the 
concentration of Ca2+ required for activation of PrKC and the degree of 
activation achieved at a given Ca2+ concentration depend upon the 
nature of the phospholipid present, phosphatidyl serine and 
phosphatidyl inositol being the two most effective [377, 420, 755]. In 
the presence of diacylglycerol, the Ka for Ca2+ is reduced by an order 
of magnitude (from between 1 and 10 x 10”5M to between 1 and 8 x 10”6M) 
[420, 544, 756] and the affinity of the enzyme for phospholipid is also 
increased [420, 544] so that in the presence of both diacylglycerol and 
phosphatidyl serine, PrKC is fully active at Ca2+ concentrations in the 
10-7M range [377, 413]. Diacylglycerols possessing at least one 
unsaturated fatty acid are the most effective PrKC activators and those 
with unsaturated fatty acyl moieties esterified at position 1 or 2 are
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equally active [544]; however, monoacylglycerols and triacylglycerols 
are both ineffective [420, 544, 756]. Activation of PrKC, studied 
using purified enzyme and reconstituted vesicles containing 
phosphatidyl serine and diacylglycerol, appears to be a complicated 
process involving the simultaneous intraction of Ca2+, a hydrophobic 
domain of the enzyme molecule and the phospholipid vesicle surface 
[413, 556]. This conclusion is based on the observation that 
association with membranes does not in itself guarantee activation of 
PrKC [413, 543] and that Ca2+ binds to phosphatidyl serine vesicles 
[178, 589] but not, apparently, directly to the enzyme itself [556]. 
There is indirect evidence to suggest that interaction of Ca2+ with 
certain membrane phospholipids is necessary to create a molecular 
configuration capable of interacting in a specific manner with the 
hydrophobic domain of PrKC and as a result, activating the enzyme.
Tumor-promoting phorbol esters such as TPA (12-0-tetradecanoyl 
phorbol 13-acetate or 4|3-phorbol 12-myristate 13-acetate) act as a 
substitute for diacylglycerol and activate PrKC directly both in vitro 
and in vivo [84] though related non-tumor promoting phorbol esters are 
unable to activate the kinase [84]. There is evidence that this 
relationship is not coincidental since some, if not all, of the tumor 
promoting actions of these agents are known to be mediated by PrKC 
[414, 568]. The number of phorbol ester receptors in the brain roughly 
matches the amount of PrKC present in this tissue and the two entities 
are now considered to be one and the same [414]. A kinetic study of 
phorbol ester-stimulated activation suggests that activation of one 
PrKC molecule results from interaction with one molecule of phorbol 
ester [414]. This does not necessarily imply that the effect of 
phorbol ester is a direct consequence of ligand-ligand interaction but
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may instead involve modification of the phospholipid microenvironment 
to create the configuration necessary for formation of a fully active 
enzyme/Ca2+/phospholipid complex [414, 568]. Because phorbol ester 
substitutes for diacylglycerol in this activation process the 
possibility is raised that "normal physiological" activation of PrKC by 
diacyl glycerol may involve a similar stoichiometry [568]. A number of 
drugs inhibit the activity of PrKC but none are specific and several, 
including trifluoperazine, fluphenazine and W-7 also inhibit 
Ca2+/calmodulin dependent protein kinase [568]. These inhibitors 
interact with phospholipid and inhibit PrKC activation in a competitive 
manner [568].
Identification of the role of diacylglycerol in PrKC activation 
and work relating to polyphosphoinositide metabolism in thrombin- 
stimulated platelets have led to the construction of a model for 
regulation of cellular responses to hormonal stimulation involving 
activation of PrKC [46, 115, 568] (Figure 12). It is envisaged that 
stimulation of polyphopshoinositide turnover by hormones such as 
thrombin, vasopressin, angiotensin II and adrenergic agonists [45, 
47, 136, 416, 417, 418, 534, 535, 767, 778] leads to the generation of 
increased cellular concentrations of both inositol 1,4,5 triphosphate 
and diacylglycerol (mostly 1-stearyl, 2-arachidonyl diacylglycerol
[324]) by the action of phospholipase C on phosphatidyl inositol 4,5 
diphosphate. Since inositol 1,4,5 triphosphate stimulates the release 
of Ca2+ from intracellular stores [25, 46, 72, 198, 199, 200, 372,
741], two potential second messengers are generated in response to a 
single hormonal stimulus. The increases in Ca2+ concentration 
accompanying such hormonal stimulation are probably physiologically 
irrelevant in relation to PrKC activation since diacylglycerol reduces
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the Ca2+ concentration required for full activation to a level low 
enough to allow activation of the kinase even at basal intracellular 
Ca2+ concentrations [568], However, the increased Ca2+ would lead to 
activation of the Ca2+/calmodulin-dependent protein kinases while 
increases in diacylglycerol would also result in an increase in 
prostaglandin synthesis via arachidonic acid which would, in turn, 
activate cGMP-PrK (Figure 12) [46, 568].
The possibility is emerging that PrKC activation provoked by 
increased phosphoinositide turnover may be involved in the mechanism(s) 
of action of insulin. Evidence in support of this role is afforded by 
the observation that phospholipase C, the enzyme responsible for 
production of diacylglycerol (see Figure 12), is activated following 
insulin-treatment of fat cells [427], a finding which is consistent 
with previous reports that insulin stimulates phosphoinositide turnover 
[205]. Furthermore, both phorbol ester and phospholipase C have been 
shown to elicit various metabolic effects similar to those produced by 
insulin [325, 427]. Together these observations provide quite 
compelling though circumstantial evidence for an important role for 
PrKC in insulin action and it now appears that this kinase may also be 
capable of modulating adenylate cyclase activity [364, 389]. The 
latter effect of PrKC is reported to involve suppression of Gi function 
resulting from PrKC catalysed phosphorylation of its a-subunit [389] 
(see section 1.1.). As discussed earlier, this system provides a 
mechanism for modulation of the action of adenylate cyclase-linked 
hormones by hormones whose primary action involves manipulation of 
phosphoinositide metabolism and thus has the potential to allow 
considerable hormonal interaction leading to greater flexibility of 
response to various combinations of hormonal stimuli.
1.3.8.(i)c Polyamine-Dependent Protein Kinase
The two major classes of cell surface receptor found in most tissues 
are receptors related to cellular cAMP levels and those which induce 
rapid polyphosphoinositide turnover and Ca2+ mobilisation [568]. 
However, not all of the diverse effects of hormones such as insulin, 
glucocorticoids, progesterone and prolactin can be adequately explained 
by these mechanisms alone. The discovery of polyamine-stimulated 
protein kinase has therefore provoked a great deal of interest since 
cellular levels of the polyamines are known to be influenced by a large 
number of hormones [20, 301, 441, 546, 578, 752, 843], are increased 
dramatically during the early phase of cell growth [578, 752, 843] and 
are high (up to millimolar) in non-proliferating tissues actively 
engaged in protein synthesis, such as lactating mammary gland, 
pancreas and prostate gland [578, 752, 843] (see also section
1.3.9.(i)).
Polyamines are aliphatic polycations found in all living cells. 
Through ionic interactions and H-bonding they can complex with nucleic 
acids, proteins and phospholipids while their aliphatic character 
suggests a capacity to interact with hydrophobic environments such as 
those of membranes [441]. The three major naturally occurring 
polyamines are putrescine, spermine and spermidine (for structures see 
Figure 13) and all three are synthesised by nucleated eukaryotic cells 
but prokaryotes are apparently unable to synthesise spermine [752,
843]. Prokaryotes generally contain higher concentrations of 
putrescine than spermidine but eukaryotes contain little putrescine and 
relatively higher concentrations of spermidine and spermine [441]. The 
major biosynthetic pathway leading to polyamine formation in mammalian
89
cells involves direct decarboxylation of L-ornithine by ornithine 
decarboxylase (ODC) to produce putrescine which is then converted to 
spermidine and spermine by successive donations of an aminopropyl group 
from decarboxylated S-adenosyl methionine (SAM) catalysed by spermidine 
synthase and spermine synthase respectively (Figure 13). ODC is 
generally recognised as the major rate-limiting enzyme of the pathway 
[76, 441, 733, 752] but provision of decarboxylated SAM by SAM 
decarboxylase may also limit synthetic rates [733].
Polyamine has been found to inhibit both cAMP-PrK [316, 339,
554] and PrKC [846] and abolish the cGMP sensitivity of cGMP-PrK [825] 
but crude cyclic nucleotide-independent protein kinase preparations 
containing casein kinases are activated by these polycations [554] and 
at least 2 polyamine-dependent protein kinases have now been identified 
[104]. The best defined of these is casein kinase G (casein kinase 2) 
while the other, polyamine-dependent ODC kinase, has so far only been 
described in detail in nuclei of the slime mould Physarum polycephalum 
[441, 442] and therefore will not be discussed at length in this 
report.
Casein kinase G (Casein Kinase 2)
Originally termed casein kinases 1 and 2 with reference to their order 
of elution from ion exchange columns during purification, the two 
enzymes from bovine adrenal cortex were renamed casein kinases A and G 
respectively when they were found to differ in their phosphate source 
requirements [107]. Casein kinase A (CKA) is only active with ATP as a 
phosphoryl donor but casein kinase G (CKG) will catalyse the transfer 
of phosphate from either ATP (Km 8//M) or GTP (Km 18^M) [107]. Both 
kinses are insensitive to cyclic nucleotides and Ca2+/calmodulin and,
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therefore, had been designated messenger-independent enzymes until 
Cochet et al. [107] discovered that CKG activity could be stimulated 
5-10 fold by millimolar concentrations of polyamine in vitro.
CKG purified from bovine adrenal cortex [108] exhibits an 
apparent molecular weight of 140kDa upon gel filtration and appears 
to be composed of two types of subunit designated a (molecular weight 
38kDa) and 3 (molecular weight 27kDa) in an |32 holoenzyme 
conformation [104]. Catalytic activity resides in the a-subunit but 
its expression is limited in the absence of 3-subunit. Although the 3 
component undergoes autophosphorylation [104], the effects, if any, of 
this modification on enzyme function have not been determined.
Spermine appears to bind to the a-subunit and activation of the 
purified enzyme is characterised by a five fold increase in V withc max
no change in Km . However, the extent of activation depends on the 
nature and concentration of the substrate and is sensitive to Mg2+ 
concentrations [104]. The polyamine effect is maximal at Mg2+ 
concentrations below 5mM and is lost progressively at higher 
concentrations but in the absence of magnesium no polyamine stimulation 
of CKG activity is observed at all whereas Mg2+ strongly activates the
enzyme in the absence of polyamine [104]. A heat-stable selective
inhibitor of CKG has been isolated from various bovine tissues [369]
and demonstrated to be ineffective against either CKA or cAMP-PrK. The
inhibitor, termed casein kinase G inhibitor (CKG I) is competitive with 
casein and its inhibitory effect is antagonised in a dose-dependent 
manner by low (< O.lmM) concentrations of polyamine [370], At 
millimolar concentrations of spermine CKG I induced inhibition 
equivalent to that observed in crude adrenocortical cytosols 
(approximately 50-60%) is completely abolished and direct activation of
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CKG proceeds resulting in a further increase in kinase activity [104, 
370]. On the basis of velocity sedimentation characteristics of CKG in 
the presence and absence of its modulators and work with radioactively 
labelled polyamines, Job et al. [370] have constructed a model for the 
interactions between CKG, CKG I and polyamines (Figure 14) which, if 
shown to operate in vivo, would represent a means of extending the 
range of concentrations over which polyamine could effectively modulate 
CKG activity. The active moiety of CKG I resembles heparan sulphate 
[613] and, in fact, micromolar concentrations of heparin mimic CKG I 
inhibition of CKG in vitro [210].
Casein kinases A and G have been described as ubiquitous in 
mammalian tissues [104, 298] and CKG is reported to be similar to a 
number of enzymes described by several laboratories [104] including 
casein kinase 2 from reticulocytes [297], calf thymus [141] and 
skeletal muscle [331], nuclear casein kinase Nil [660, 661, 775], liver 
casein kinase TS [531] and a skeletal muscle glycogen synthase kinase 
termed GSK PC 0.7 [158] or GSK 5 [122]. Among the endogenous 
substrates identified for CKG in vitro are glycogen synthase of both 
muscle and liver [122, 530, 558], calsequestrin, troponin T and protein 
phosphatase inhibitor 1 [530], protein synthesis initiation factor 
eIF-2 [15,9 653], acetyl-CoA carboxylase [122] and RII of cAMP-PrK. 
However, the activities of enzymes such as glycogen synthase and 
cAMP-PrK are apparently unaffected by CKG mediated phosphorylation 
[122, 671] and although phosphorylation of eIF-2 has been reported to 
result in a slight stimulation of eIF-2-dependent met-tRNA binding to 
the 40s ribosomal subunit, no physiological significance has been 
assigned to this effect [159]. Because of the well established link 
between cellular polyamine levels and protein synthesis/cell growth
Figure 14
CKG = Casein Kinase G
CKGI = Casein Kinase G Inhibitor
Figure 14 Casein Kinase G Inhibitor-Mediated Modulation of
Polyamine-Dependent Stimulation of Casein Kinase G
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[578, 752, 843], polyamine-dependent phosphorylation of nuclear 
proteins has attracted a great deal of attention. Although purified 
cytosolic CKG has been shown to phosphorylate both RNA polymerase II 
[141, 142] and high mobility group (HMG) chromosomal proteins [825] in 
vitro, the polymerase activity remains unchanged by such modification 
and the significance of the HMG phosphorylaton in vivo (known to occur 
at the same site as that phosphorylated in vitro by CKG [825]) is 
uncertain. However, phosphorylation of polymerase II by a purified 
nuclear kinase very similar to CKG [104, 435] is accompanied by an 
increase in its activity. A homologous kinase, nuclear casein kinase 
Nil phosphorylates RNA polymerase I [167] and II [435, 737] in vitro 
with a concomitant increase in their respective activities and the 
phosphorylation and activation of polymerase II has been shown to be 
stimulated by millimolar concentrations of spermine [355]. Indirect 
evidence for the involvement of CKG in the regulation of nuclear 
activity and RNA metabolism is provided by the observations that the 
enzyme is 5-fold more active in hepatoma than in normal liver nuclei 
[660, 661] and CKG has been found to be associated with m-RNP particles 
in reticulocyte extracts [653].
Recent work by Cochet et al. directed towards characterisation 
of a 50-55kDa protein found to undergo polyamine-stimulated 
phosphorylation in adrenal cortex cytosols [104], has led to the 
suggestion that ODC is itself a substrate for CKG activity [104]. If 
confirmed, these observations would provide an interesting parallel to 
the work of Kuehn and coworkers who have identified and characterised 
a polyamine stimulated nuclear kinase from the slime mould Physarum 
polycephalum (for review see [441]). Simply termed polyamine- 
dependent protein kinase, this enzyme displays some properties,
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including ability to utilise ATP or GTP, insensitivity to cyclic 
nucleotides and susceptibility to autophosphorylation, in common with 
CKG but unlike the latter kinase, P. polycephalum polyamine-dependent 
protein kinase phosphorylates tyrosine residues only, appears to have a 
more restricted substrate protein specificity and is absolutely 
dependent on polyamine for its activity [441]. The slime mould enzyme 
is tightly bound to its proposed in vivo substrate, ODC and 
phosphorylation of this substrate by polyamine-dependent protein kinase 
results in a decrease in ODC activity towards ornithine but perhaps 
also a stimulation of its selective activation of rRNA transcription 
[104]. Such properties provide a mechanism for negative feedback on 
polyamine synthesis and may prove to be an important characteristic 
of polyamine metabolism in mammalian tissues also. Whether the 
polyamine-stimulated increase in ODC phosphorylation observed in 
adrenal cortex cytosols can be attributed to CKG or is an indication 
that an enzyme analogous to the polyamine dependent protein kinase of 
P. polycephalum is also present in this tissue is uncertain but there 
is some preliminary evidence to suggest that a kinase similar to the 
slime mould enzyme is indeed present in mammalian tissues [16],
1.3.8.(ii) Tyrosine Protein Kinases
Protein phosphorylation on tyrosine residues is rare compared with that 
on serine or threonine but the kinases responsible for tyrosine 
phosphorylation may prove to be equally important in the conctrol of 
cellular events since a major group of this type of kinase is composed 
of activities associated with hormone and growth factor receptors. 
Published evidence of soluble tyrosine kinase activity is rare, 
however, nuclear topoisomerase has recently been described as a
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substrate for cytosolic tyrosine kinase in liver [782]. Although 
several oncogene-related tyrosine kinases have been described, their 
counterparts in normal cells have not as yet been identified and the 
significance, if any, of their action is unknown [436].
1.3.8.(ii)a Receptor-Associated Tyrosine Kinase Activity 
The first demonstration of receptor-associated kinase acitivity was 
described for the EGF receptor system ([123, for reviews of EGF 
receptor and other tyrosine kinases see [338, 692]) and subsequent work 
has revealed that receptors for platelet derived growth factor (PDGF) 
[177, 566], insulin [387] and insulin-like growth factor (IGF 1) [360] 
also possess tyrosine kinase activity [139, 338, 436]. These 
discoveries have stimulated research directed at elucidating the 
molecular mechanisms of signal transduction related to the biological 
actions of these receptors and particularly the insulin receptor for 
which the mechanism coupling hormone binding to cellular response 
remains elusive.
The Insulin Receptor
Stimulation of insulin receptor phosphorylation by insulin has been 
demonstrated in several cell types [288, 386, 388, 795]. In intact 
cells this phosphorylation occurs on tyrosine, serine and threonine 
residues of the receptor |3-subunit [388, 757] but autophosphorylation 
of solubilised insulin receptor is solely or predominantly confined to 
(3-subunit tyrosine residues [387]. The 2-3 fold stimulation of insulin 
receptor phosphorylation by insulin observed in intact cells may in 
fact be an underestimate of the potential in vivo effect since the 
interference caused by phosphatase activity can not be ignored due to
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the difficulty of ensuring its elimination during receptor preparation 
[139]. Autophosphorylation of insulin receptors purified to varying 
degrees, up to near homogeneity, proceeds rapidly in the presence of 
[y-32P]ATP [19, 50, 384, 385, 603, 872, 875] and has been demonstrated 
with solubilised receptors from many different cell types including 
human placenta [19, 384, 603, 872], rat hepatocytes [795], 3T3-L1 
adipocytes [603], cultured human lymphocytes [666] and human 
erythrocytes [271]. The presence of either Mn2+ or Co2+ is required in 
order to observe insulin receptor autophosphorylation, Co2+ being much 
less effective in supporting kinase activity than Mn2+, unlike EGF 
receptor autophosphorylation which is supported equally well by Mg2+, 
Co2+ or Mn2+ [19, 875]. It has been suggested that the concentration 
of Mn2+ necessary to permit optimal receptor phosphorylation indicates 
that, in addition to forming a complex with ATP, Mn2+ also acts as a 
receptor cofactor [139]. The marked activation of insulin receptor 
autophosphorylation by insulin is achieved by an increase in the 
apparent V of the kinase reaction rather than a decrease in its Kmax m
for ATP [840]. Under optimal conditions insulin receptor 
autophosphorylation is very rapid and, like EGF receptor 
autophosphorylation can be readily observed at 0°C [139, 840]. Because 
the rate of autophosphorylation is independent of receptor 
concentration [702, 840] it must proceed via an intramolecular 
mechanism and it appears that the tetrameric holoreceptor (see Figure 
15) is the most active kinase configuration since dissociation of the 
receptor into a£ dimers induced by DTT or N-ethyl maleimide results in 
inhibition of insulin stimulated autophosphorylation [702], At DTT 
concentrations below that required to produce dissociation, kinase 
activity is stimulated markedly [702] leading to detectable a-subunit
Figure 15. The Insulin Receptor; Subunit Structure 
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phosphorylation [139]. It has therefore been suggested that a reduced 
sulphydryl group at or near the kinase active site is required for 
maximal activity [702]. Tyrosine phosphorylation of the insulin 
receptor 0-subunit leads to stimulation of receptor tyrosine kinase 
activity [662, 877] and abolition of its sensitivity to modulation by 
insulin [662]. Dephosphorylation of specific tyrosine residues in a 
single tryptic peptide of the 0-subunit has been observed to be 
accompanied by inactivation of the receptor tyrosine kinase [872] and 
phosphorylation of similar sites by src kinase has also been shown to 
activate the insulin receptor tyrosine kinase [139].
The solubilised receptor catalyses the phosphorylation of a 
number of exogenous proteins including angiotensin II, tubulin, casein, 
histone H2B and a synthetic peptide mimicking the tyrosine 
phosphorylation site of Rous sarcoma virus transforming protein kinase 
[384, 724]. It has been reported that the src and EGF receptor protein 
kinases have a similar substrate specificity to that of insulin 
receptor kinase [724]. Despite the variety of exogenous insulin 
receptor kinase substrates in vitro, no endogenous proteins other than 
the receptor itself have been found to be rapidly tyrosine- 
phosphorylated in response to insulin in intact cells [139]. Although 
the importance of receptor tyrosine kinase activity to insulin receptor 
function is still a subject for debate, there is some evidence to 
suggest that it does not play a major role in signal transduction.
This is provided by the observation that anti-insulin receptor 
immunoglobulin preparations mimic the biological actions of insulin 
without activating the receptor kinase [707, 876].
An affinity-purified and affinity-labelled receptor protein of 
molecular weight 45-50kDa, isolated from rat liver [358, 359] and
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adipocytes [516] has been identified on electrophoretic gels and found 
to be derived from the insulin receptor complex. This species was 
later demonstrated to be a proteolytic fragment of the native 90kDa
0-subunit [517]. The 0-subunit is extremely sensitive to proteolytic 
cleavage by an endogenous lysosomal protease released during cellular 
disruption [139, 517]. This specific and selective proteolytic 
processing has been claimed to occur with remarkable uniformity and 
precision and is described as ubiquitous among all tissues studied 
[517]. While the detailed structure of the 45-50kDa 0-subunit fragment 
(0X) is not known, insulin receptors containing this, rather than a 
whole 0-subunit, display characteristics of insulin binding and 
dose-response with respect to glucose oxidation identical to intact 
native receptor populations, suggesting that the 0X fragment retains 
most, if not all its functional integrity. It would therefore seem 
reasonable to assume that the 0X fragment contains both its 
serine/threonine phosphorylation site and an intact tyrosine kinase 
and tyrosine autophosphorylation site.
Recently it has been discovered that insulin receptor affinity 
is reduced by 50% in response to 0-adrenergic stimulation [139, 601] or 
exposure to tumor promoting phorbol esters [273, 361, 757]. The
0-adrenergic effect is mimicked by incubation with agents such as 
methylxanthines which elevate cAMP levels and is accompanied by 
phosphorylation of the insulin receptor or a receptor modulating 
protein [601]. Insulin binding is inhibited at physiological 
concentrations of catecholamine [601] and insulin-stimulated tyrosine 
autophosphorylation is decreased in insulin receptors extracted from 
isolated adipocytes treated with the 0 agonist, isoproterenol [139]. 
Although no change in non-insulin stimulated autophosphorylation is
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engendered by isoproterenol treatment, insulin stimulation of receptor 
autophosphorylation is blocked completely, even at insulin 
concentrations high enough to saturate the receptors [139]. Phorbol 
esters stimulate phosphorylation of the insulin receptor 3-subunit on 
serine and threonine residues, presumably by activation of PrKC (see 
section 1.3.8.(i)b) and inhibit the ability of insulin to enhance 
3-subunit tyrosine phosphorylation [139, 757]. Since 3-adrenergic 
effects on insulin binding and 3-subunit autophosphorylation parallel 
the phorbol ester mediated effects it is tempting to conclude that 
raised cAMP levels also result in 3-subunit phosphorylation on 
serine and threonine residues. However, this being so, it does not 
appear to be achieved by the direct action of cAMP-PrK because the 
insulin receptor is a very poor substrate for this kinase in vitro 
[139]. Nevertheless in view of the fact that insulin-stimulated 
serine and threonine phosphorylation of the insulin receptor 3"Subunit 
in vivo [386, 757] occurs under conditions known to provoke 
down-regulation of insulin receptors [239, 514, 725] it has been 
speculated that such modifications are important general regulators of 
the tyrosine kinase and hormone binding characteristics of the insulin 
receptor system though the phosphorylation sites favoured by the 
insulin-mediated and the phorbol ester-dependent effects appear to 
differ [757]. The proposed interactions between tyrosine and 
serine/threonine phosphorylation are summarised in Figure 15 and the 
projected effects of such a system on receptor affinity are illustrated 
in Figure 16. Very similar interactions between serine/threonine 
phosphorylation and receptor affinity/tyrosine kinase activity have 
been reported recently for the EGF receptor [166 ], suggesting that such 
regulatory mechanisms may be common to many receptor types.
Figure 16
Since the negative feedback control of serine/threonine phosphorylation 
is governed by intracellular insulin effects, at low insulin 
concentrations, the effect on receptor affinity will be minimal. 
Affinity therefore rises with increasing insulin concentration.
However, the resulting increase in magnitude of insulin effects 
stimulates serine/threonine phosphorylation leading to increased 
inhibition of tyrosine phosphorylation and, consequently, reduced 
receptor affinity. Serine/threonine phosphorylation may also act as a 
"signal" for internalisation.
* The recent suggestion that depletion of cellular ATP levels
precipitates a loss in insulin receptor affinity [371] is consistent 
with the proposal that tyrosine phosphorylation induces an increase 
in receptor affinity since phosphotyrosine turnover is very rapid and 
would therefore be extremely sensitive to kinase inhibition resulting 
from restrictions in ATP supply.
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Models for the regulation of insulin receptor binding activity 
have been proposed based on interpretations of experimental results 
suggesting either the existence of multiple receptor affinities [164, 
277, 401, 581] or a negatively cooperative response to insulin binding 
[151, 152]. While neither mechanism is accepted universally, it is 
possible to construct models with characteristics incorporating both 
mechanisms which also suggest important roles for tyrosine and 
serine/threonine phosphorylation of the insulin receptor. An example 
of such a model, represented in Figure 16 also allows for expression of 
effects mediated by receptor internalisation. The response to insulin 
predicted by this model is characterised by an initial increase in 
receptor affinity with increasing insulin concentration followed by a 
concentration-dependent decrease in affinity at higher insulin 
concentrations. Such a response, at physiological insulin 
concentrations, has been reported recently by Marsh et al. [513] and 
represents an elegant mechanism for modulating insulin action. At low 
insulin concentrations, receptor affinity is increased, resulting in 
enhanced insulin binding and, therefore, cellular response but 
overstimulation is prevented by a reversal of this effect as the 
maximally effective insulin concentration is exceeded [513].
1.3.8.(ii)b Potential Regulatory Roles of Tyrosine Kinases 
A number of other tyrosine kinase activities in normal cells have been 
reported recently [171, 750, 854] but the nature of both the kinases 
themselves and their substrate proteins are unknown. One of these, 
termed p75 on the basis of the molecular weight of an endogenous 
substrate, is a soluble 70kDa cytoplasmic enzyme purified from rat 
liver [854], while several other proteins have been reported to be
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tyrosine phosphorylated in membrane preparations from lymphoid cells 
[171, 750]. Phosphates on tyrosine residues turnover rapidly and, 
therefore, tyrosine phosphorylation potentially represents a highly 
sensitive control system [338]. The role of tyrosine phosphatases in 
such regulatory mechanisms is obviously, therefore, of equal importance 
to that of the tyrosine kinases but to date little information has been 
accumulated in this area. Whether tyrosine phosphorylation will prove 
to be as important in the mediation of cellular regulation as is 
indicated by its association with cell surface receptors remains to be 
seen but even if signal transduction is found to be independent of this 
activity, tyrosine phosphorylation may still be important in the 
modulation of hormone action by virtue of its ability to regulate 
hormone binding.
While the physiological role of tyrosine phosphorylation remains 
obscure, there is evidence to support a second, potentially more 
physiologically significant function of tyrosine kinases which might 
provide a valuable insight into the molecular mechanism(s) involved in 
propagation of intracellular signals following hormone or growth factor 
receptor occupation. The oncogene tyrosine kinase p68v-ros of avian 
sarcoma virus UR2 will phosphorylate itself and exogenous protein 
substrates on tyrosine residues [21, 211] but also catalyses the 
phosphorylation of phosphatidyl inositol (ptd.ins.) in vitro to give 
phosphatidyl inositol 4 phosphate (Ptd Ins 4P) [496]. Evidence that 
the latter property of p68v_ros is also expressed in vivo is provided 
by the observation that transformation of chicken embryo fibroblasts by 
UR2 is accompanied by an increase in phosphoinositide turnover [496].
In contrast, cAMP-PrK is not capable of catalysing phosphoinositol 
phosphorylation, suggesting that this property may perhaps be unique to
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p68v-ros and other tyrosine kinases. These observations raise the 
possibility that the primary function of tyrosine kinase activities 
associated with insulin and various growth factor receptors is not in 
fact expressed through phosphorylation of proteins on tyrosine residues 
but may instead be related to the ability of such kinases to 
phosphorylate ptd.ins. Speculation of this kind is extremely 
attractive in that it provides an explanation for the observation that 
insulin increases phosphoinositide turnover [205] and therefore 
suggests a direct link between insulin binding (known to activate the 
insulin receptor tyrosine kinase [see earlier]) and activation of 
protein kinase C (see section 1.3.8.(i)b). The regulatory potential of 
a system capable of modifying phosphoinositide turnover is now well 
recognised (see reviews [45, 205] and also section 1.3.8.(i)b) and the 
proposed link between tyrosine kinase activity and ptd.ins. 
phosphorylation may therefore have far reaching implications, 
particularly in the elucidation of mechanisms of action for growth 
factors and insulin.
1.3.8.(iii) Modulator-Independent Protein Kinases
Many protein kinases have been described for which no regulatory agents 
or effectors have so far been identified. While this does not 
necessarily mean that these enzymes or the reactions they catalyse are 
not subject to regulation, their physiological regulatory significance 
is not immediately obvious and therefore has not attracted as much 
general interest as the kinases described above whose activities are 
modulated in a specific manner by factors known or thought to be 
important in vivo. The phosphorylations catalysed by several of the 
members of this diverse group of protein kinases appear to have little
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or no effect on the properties of their designated protein substrates 
but this may simply reflect an inability to identify their 
physiologically important substrates. Examples of kinases whose 
regulatory potential was not recognised until some time after their 
discovery include casein kinase 2 (CKG, see section 1.3.8.(i)c) and 
glycogen synthase kinase 3 (phosphatase 1 activating factor, FA, see 
section 1.3.9.(i)). Although no effectors of the latter have yet been 
identified, the discovery that CKG activity is subject to modulation by 
polyamines has, necessarily, led to its reclassification. Bearing this 
in mind, it seems likely that other protein kinases, at present 
classified as modulator-independent will, in time, be recognised either 
as members of one of the established groups of effector-dependent 
kinases or examples of novel regulatory systems in their own right. 
However, since the primary object of the work described herein was to 
survey the contributions made by the major groups of regulatory protein 
kinases, particularly cAMP-PrK, to the phosphorylation of endogenous 
mammary proteins, a review of the numerous ill-defined kinases 
classified under the general heading of modulator-independent will not 
be presented in this report.
1.3.9. Protein Phosphatases
A comprehensive study of the protein phosphatase activities 
involved in regulation of the major pathways of intermediary metabolism 
has been undertaken by Ingebritsen and coworkers [346, 347, 352, 596, 
735, 810] who have established that all of the activities directed 
against serine/threonine phosphate can be explained by only four 
enzymes with the exceptions of PDH and BCDH dephosphorylations which 
are governed by the activity of distinct mitochondrial phosphatases
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[143, 314, 631, 644, 645]. The classification of these four enzymes is 
summarised in Table 1. The phosphatases which, with the exception of 
protein phosphatases 1 (PrP-1) and 2A (PrP-2A), are almost exclusively 
cytosolic [352], are divided into two classes on the basis of their 
subunit specificity with regard to dephosphorylation of phosphorylase 
kinase and sensitivity to inhibition by two thermostable proteins 
termed inhibitor 1 (1-1) and inhibitor 2 (1-2). Type 1 protein 
phosphatases (FrP-1) dephosphorylate the 3 subunit of phosphorylase 
kinase [11, 734] and are potently inhibited by the two thermostable 
inhibitor proteins [111, 120, 330, 562, 734] whereas Type 2 protein 
phosphatases (PrP-2) preferentially dephosphorylate the a subunit of 
phosphorylase kinase [11] and are insensitive to both 1-1 and 1-2 [120, 
562].
1.3.9.(i) Type 1 Protein Phosphatases
Protein phosphatase 1 has a very broad substrate specificity and 
is the major glycogen phosphorylase, phosphorylase kinase and glycogen 
synthase phosphatase in skeletal muscle in vitro [352]. While it is 
also the major glycogen synthase phosphatase in liver, it accounts for 
only 20-50% of glycogen phosphorylase and phosphorylase kinase 
phosphatase activity in this tissue in vitro [352]. Extrapolation of 
these results to the situation likely to prevail in intact liver cells 
is complicated by the observation that PrP-1 activity is inhibited 
strongly in less dilute tissue extracts suggesting the presence, in 
these preparations, of a macromolecular phosphatase inhibitor [352]. 
Whether this implies that liver PrP-1 activity would be even lower in 
vivo or that the inhibitory effects are artefacts of the in vitro 
system is unknown since the nature of the factors involved has not been
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determined. However, there is good circumstantial evidence to indicate 
that 1-1 and 1-2 are not responsible for this inhibition since 1-1 is 
essentially inactive under the conditions of assay used, the 
concentration of 1-2 is equally high in skeletal muscle preparations 
where no such effects are observed and the activity of liver PrP-2A, 
one of the inhibitor-insensitive type 2 phosphatases (see section
1.3.9.(ii)) also shows extract concentration dependent loss of activity 
[352]. Protein phosphatase 1 is active in the absence of divalent 
cations and although dephosphorylation of certain substrate proteins by 
this enzyme exhibits Mn2+ dependence the requirement for Mn2+ appears 
to be a characteristic specific to these substrates alone and not a 
general property of the phosphatase itself [352].
Both 1-1 and 1-2 are equally effective inhibitors of type 1 PrP 
but 1-1 is only active in this respect after phosphorylation by 
cAMP-PrK [121, 330, 562] on a threonine residue located 35 residues 
from the N-terminus of the protein [6]. Dephosphorylation of 1-1 by 
PrP-1 is not inhibited by 1-1 [115, 562] but is one of the Mn2+- 
dependent reactions and its significance in vivo is therefore uncertain 
since physiological Mn2 + concentrations may not be sufficient to allow 
1-1 inactivation by this mechanism [352]. Inhibition of phosphatase 
activity occurs at nanomolar 1-1 concentrations in vitro and since its 
concentration in vivo (1.8/yM) is higher than that calculated for PrP-1 
[224], 1-1 is potentially a very effective regulator of phosphatase 
activity in intact cells. Adrenaline induces a marked increase in 
in vivo 1-1 phosphorylation [223, 225, 404] and insulin is able to 
antagonise 1-1 phosphorylation at low concentrations of ^-adrenergic 
agonists [225, 226] suggesting that regulation of phosphatase activity 
by 1-1 may be an important determinant of the cellular response to
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hormonal stimuli. Recently it has been reported that dephosphorylation 
of glycogen synthase sites 3 by PrP-1 is stimulated 2.5 fold by 
spermine [117] which, in view of the known insulin like effects of 
polyamines (see section 1.3.8.(i)c), might suggest an involvement of 
PrP-1 in insulin induced activation of glycogen synthase.
At least two species of PrP-1 have been identified in rabbit 
skeletal muscle. Both the parent molecules, termed PrP-lj. and PrP-lQ 
and the free 37kDa catalytic (Fc)-subunit, common to both enzymes, 
have recently been purified to homogeneity [117]. Though not as yet 
confirmed, the major form of PrP-1 in skeletal muscle is reported to be 
PrP-1 which consists of the 37kDa F -subunit associated with a 105kDa
G C
(G)-subunit in a 1:1 molar ratio [117]. The G-subunit binds to 
glycogen and the glycogen bound enzyme predominantes over free PrP-lQ . 
Phosphorylation of the G-subunit, an excellent substrate for cAMP-PrK, 
increases the susceptibility of PrP-lG to inactivation by 1-1. Since 
1-1 is itself activated by cAMP-dependent phosphorylation, this sytem 
represents a means of increasing the sensitivity of PrP-lQ to cAMP- 
dependent inhibition. Before the relative contributions of PrP-lI and 
PrP-lG to total PrP-1 activity had been described, a great deal of 
interest centred on the properties of Mg-ATP dependent PrP, now known 
as PrP-lj, which displays the characteristics of a type 1 phosphatase 
only after activation involving inhibitor 2 and a protein kinase termed 
Fa (Figures 6 and 17). Although the activity of this phosphatase is 
now thought to be of secondary importance, quantitatively, in skeletal 
muscle [117], its subcellular distribution and mode of activation may 
endow PrP-lj with regulatory significance out of proportion to its 
relatively minor contribution to total PrP-1 activity. In addition, 
the situation in skeletal muscle may not be duplicated in other tissues
Figure 17. Activation and inhibition of Protein 
Phosphatase 1^ mediated by inhibitor 2.
INACTIVE
COMPLEX
1-2
INACTIVE PA
Mg-ATP
1-21-2 FcFc
A
Mg-ATP
Slow
Isomerisation
Fc 1-2
INACTIVE
Legend*
F Catalytic Subunit of Protein Phosphatase 1Tc j.
F. Activating factor.
(Glycogen Synthase Kinase III).
1-2 Inhibitor 2
P Phosphate.
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where PrP-lI might be relatively abundant in comparison and therefore 
of obvious importance to the control of cellular protein 
phosphorylation. The activation/deactivation of PrP-1 , as summarised 
in Figure 17 is complicated by the influence of 1-2 which is now 
recognised as a regulatory subunit of the PrP-lx complex [117, 375,
805, 865] as shown in Figure 16. The catalytic subunit (Fc ) of PrP-ll, 
inactive in the presence or absence of its regulatory subunit (1-2), 
may be activated by Mn2+ or Co2+ ions when free of inhibitor 2 [805] or 
by Mg-ATP and activator protein (F ) when bound to 1-2 in a specific 
manner [12, 115, 805]. During activation of the native PrP-lI complex 
(Fc + 1-2), 1-2 becomes phosphorylated, inducing a conformational 
change in the catalytic subunit, leading to its activation [24, 305, 
375, 805]. Dephosphorylation of bound 1-2 results in inactivation of 
the enzyme complex but does not cause a concomitant reversion of Fc to 
its inactive conformation, demonstrating that dephosphorylated 1-2 
prevents expression of catalytic subunit function [805]. If released 
from its regulatory protein at this point, Fc displays full activity 
and remains active indefinitely, in contrast to Fc remaining bound to
1-2 which slowly reverts to the inactive conformation of the native 
enzyme complex [375, 805]. The site of 1-2 binding to Fc is highly 
specific. The site that confers Mg-ATP dependence on PrP-lx appears 
to be masked on the isolated inactive catalytic subunit since 1-2 
binding to free inactive Fc produces a complex incapable of activation 
by Mg-ATP and F . However, a reconstituted I-2/active Fc complex 
exhibits the same properties as the native complex in that the active 
catalytic subunit reverts to its inactive conformation and may be 
reactivated by Mg-ATP and FA [805]. Active native PrP-1 appears to 
be susceptible to inhibition by a second 1-2 molecule which behaves in
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the same manner as 1-2 bound to isolated inactive Fc, suggesting that 
there might be a second 1-2 binding site on the Fc-subunit rather than 
that the second 1-2 molecule merely replaces the phosphorylated 1-2 in 
the active native phosphatase complex [375, 805]. The activator 
protein FA exhibits protein kinase activity and is, in fact, thought to 
be glycogen synthase kinase 3 (GSK 3) [122, 792], surprising since it 
must therefore be involved in both the phosphorylation of glycogen 
synthase and activation of a phosphatase capable of dephosphorylating 
the same enzyme. GSK 3 should, then, have the potential to modulate 
glycogen synthase activity in a similar, if less direct manner to that 
demonstrated by 1-2 in the regulation of PrP-lx activity. However, 
since PrP-lx is no longer thought to be the major PrP-1 in skeletal 
muscle [117], of equal or greater importance as a determinant of the 
phosphorylation state of glycogen synthase, may be the activity of 
PrP-1 .G
1.3.9.(ii) Type 2 Protein Phosphatases
The type 2 protein phosphatases (PrP-2) are divided into three 
categories, namely protein phosphatases 2A, 2B and 2C of which two 
(PrP-2A and PrP-2C) have broad substrate specificities similar to 
PrP-1, while PrP-2B displays a much higher degree of substrate 
specificity [347]. Besides catalysing the dephosphorylation of 
phosphorylase kinase at different sites, the major difference between 
the substrate specificities of PrP-1 and PrP-2A is that PrP-2A displays 
much higher myosin light chain phosphatase and ATP-citrate lyase 
phosphatase activities [347]. PrP-2C also has a broad substrate 
specificity but can be distinguished from PrP-2A by its dependence on 
Mg2+, its extremely low phosphorylase phosphatase and histone Hi
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phosphatase activities, its slow dephosphorylation of glycogen synthase 
sites 3 relative to site 2 and its extremely high HMG CoA reductase 
kinase phosphatase activity [347]. PrP-2B is a Ca2'''/calmodulin- 
dependent enzyme and the only three proteins so far identified as 
effective substrates are the a-subunit of phosphorylase kinase, 
inhibitor 1 and myosin light chain. Due to its dependence on 
Ca2+/calmodulin for activation, PrP-2B is specifically inhibited by the 
calmodulin inhibitor trifluoperazine [347, 735].
Enzymes classified as PrP-2A are further subdivided into three 
groups on the basis of their subunit structure. Designated PrP-2AQ, 
PrP-2AL and PrP-2A2 they share a common 36kDa catalytic (C)-subunit 
[117, 346, 348, 352, 596, 735] and one other subunit of molecular 
weight 60kDa termed the A-subunit [117]. However, while PrP-2A2 is 
simply a hetero dimer of A and C, PrP-2AQ and PrP-2A1 each possess an 
additional subunit, termed the Bf (54kDa) and B (55kDa) subunit 
respectively. The B-subunits are distinct and PrP-2AQ and PrP-2Al , are 
both tetramers, each incorporating two C-subunits to give subunit 
compositions of AB'C2 and ABC2 respectively [117]. Dissociation of the 
C-subunit from the native enzymes considerably enhances its activity 
and all three PrP-2As can also be activated by a mechanism involving 
interaction with basic proteins which does not induce dissociation of 
the C-subunit but the physiological significance of this phenomenon is 
unknown [117].
Dephosphorylation of various substrates for protein phosphatases 
1 and 2 is stimulated by 2mM spermine [117, 785] but the degree of 
stimulation is dependent both on the specific form of protein 
phosphatase and on the substrate towards which activity is directed 
[785]. PrP-2A activity is among those stimulated by spermine, the
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greatest effects being observed with glycogen synthase phosphorylated 
at sites 3. Dephosphorylation of these sites by PrP-2AQ and PrP-2A1 is 
stimulated 8-15 fold by spermine with a half-maximal activating 
concentration of 0.2mM and an optimal concentration of l-2mM [117].
This and the similar, though less dramatic effect of spermine on PrP-1 
are intriguing since insulin has been shown to reduce the steady state 
phosphorylation of glycogen synthase sites 3 in vivo [118] and 
polyamines are known to mimic certain insulin effects in isolated cells 
in a non-additive manner with respect to insulin [485]. In contrast, 
the activities of protein phosphatases 1, 2AQ, 2 and 2A. towards 
glycogen phosphorylase are all inhibited markedly by spermine [758].
Besides its possible importance in insulin-stimulated glycogen 
synthase sites 3 dephosphorylation PrP-2A may also be the only 
effective 1-1 phosphatase if PrP-1 is unable to perform this function 
in vivo (see section 1.3.9. (i)) and therefore PrP-2A activation, 
leading to antagonism of cAMP-dependent 1-1 activation would be an 
important modulator of PrP-1 activity. Thus PrP-2A activation might 
stimulate increased dephosphorylation of glycogen synthase sites 3 by 
both direct and indirect (via decreased PrP-1 inhibition) mechanisms.
Protein phosphatase 2B (PrP-2B) appears to be composed of two 
subunits, termed A (approximately 60kDa) and B (approximately 15kDa) 
in a molar ratio of 1:1 [116, 348]. This structure is very similar to 
that of calcineurin which is a major calmodulin binding protein of 
neural tissue and is composed of A and B subunits of molecular weights 
61kDa and 15kDa respectively [422]. Several lines of evidence 
suggest that these two calmodulin binding proteins might indeed be the 
same [735]. The B-subunit of PrP-2B binds Ca2+ and is therefore likely 
to be responsible for the Ca2+ sensitivity of this enzyme in the
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absence of calmodulin while the A-subunit interacts with calmodulin and 
is likely to be the catalytic subunit [422, 735]. Determination of the 
primary structure of B-subunit has revealed similarities with 
calmodulin and troponin C, particularly in the region of its four Ca2+ 
binding sites which probably accounts for the sensitivity of PrP-2B to 
inhibition by trifluoperazine in the absence of calmodulin [116]. 
Because of its dependence on micromolar Ca2+, it has been suggested 
that PrP-2B would only be active in cells whose Ca2+ levels had been 
elevated above resting levels [735]. Since PrP-2B is an extremely 
effective 1-1 phosphatase in the presence of Ca2+, it might play an 
important part in the regulation of PrP-1 activity by agents (neuronal 
or hormonal) that affect intracellular Ca2+ concentrations [735]. 
However, it is recognised that the most important physiological 
substrates of PrP-2B may not yet have been identified, particularly if 
the possible identity with calcineurin is confirmed [735].
Protein phosphatase 2C (PrP-2C) is a monomeric enzyme with a 
molecular weight of 40-48kDa [314, 645, 810] and, in common with PrPs 1 
and 2A has been shown to be capable of in vitro dephosphorylation of 
mammary gland acetyl-CoA carboxylase phosphorylated either in vivo 
[347] or by cAMP-PrK jm vitro [283]. However, PrP-2C activity may be 
of greater significance in the control of HMG-CoA reductase of which it 
is easily the major phosphatase in vitro [347]. Whether this is also 
the case in vivo is uncertain since 20% of liver PrP-1 activity is 
associated with the microsomal fraction and HMG-CoA reductase is a 
microsomal membrane bound enzyme [259, 352, 480, 657]. Thus, despite 
its low HMG-CoA reductase phosphatase activity in vitro compared with 
PrP-2C, PrP-1 may, nevertheless, be an important regulator of HMG-CoA 
reductase phosphorylation in vivo by virtue of close association with 
this substrate [352].
Ill
1.3.10. Protein Phosphorylation in Mammary Tissue
A most interesting feature of many of the enzymes involved in protein 
phospho-dephosphorylation is their apparent ubiquity and broad, often 
overlapping substrate specificities. This is evident for both kinases 
and phosphatases which represent the effectors of a highly complicated 
system allowing integrated regulation of diverse cellular processes in 
response to both neural and hormonal stimuli. Probably one of the most 
important and doubtlessly, the most extensively characterised of the 
multifunctional protein kinases is cAMP-PrK which appears to be common 
to all mammalian tissues. The activity of this enzyme is determined in 
vivo by intracellular cAMP concentrations and, as discussed in section 
1.1., these are subject to both hormonal and neural regulation. The 
mechanisms of action of cAMP mediated hormones such as glucagon and 
^-adrenergic agonists are well characterised (see section 1.1.) but 
the mode of action of insulin, a hormone known to antagonise a number 
of cAMP-mediated events, is uncertain. This facet of insulin action 
is, in many cases, assumed to be a reflection of its ability to either 
depress prevailing intracellular cAMP concentrations or antagonise the 
increase normally accompanying ^-adrenergic or other hormonal 
stimulation [617, 622]. There is good evidence that this effect of 
insulin may be mediated by hormone sensitive cAMP-PDE in adipose tissue 
and liver and stimulation of high affinity cAMP-PDE by insulin is 
reported here in mammary acini. However, the importance of 
modulation of cAMP concentrations in the regulation of mammary cell 
metabolism is brought into question by the observation that agents 
known to raise intracellular cAMP concentrations in mammary cells do 
not affect the steady-state phosphorylation of proteins labelled with
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32P in intact cells [100, 103] (see also section 3.2.). Furthermore, 
mammary acini have been found to lack glucagon receptors [656], raising 
the question of whether the intracellular mechanisms necessary for 
metabolic response to cAMP are in fact competent in mammary tissue or 
whether despite the potential ability of insulin and other agents such 
as ^-adrenergic agonists (see section 1.1.) to regulate cAMP levels in 
these cells, the cAMP-PrK system is absent or defective. The major aim 
of the phosphorylation work described herein was to address this 
problem by investigating the response of protein phosphorylation 
observed in various sub-cellular fractions in vitro to cAMP. However, 
a survey of the contributions of the other major multifunctional 
protein kinases of particular interest in mammary gland, namely 
Ca2+/calmodulin-dependent protein kinase, protein kinase C and 
polyamine dependent protein kinase to protein phosphorylation in vitro 
was also undertaken. Work similar in nature to that involved in 
achieving the first of these objectives was undertaken in 1972 by 
Majumder and Turkington [500] who described induction of cytosolic 
cAMP-PrK synthesis in response to insulin and/or prolactin in mouse 
mammary stem cells. However, although a number of plasma membrane and 
ribosomal proteins were demonstrated to be substrates for this kinases, 
no attempt was made either to investigate the phosphorylation of 
cytosolic or other membrane fraction proteins by these kinases or to 
determine the molecular weights or any other characteristics of those 
substrates which had been identified. Unlike the situation in liver, 
adipose tissue, brain and muscle, protein phosphorylation in mammary 
tissue has received little attention and the only mammary enzyme 
demonstrated, directly, to be regulated by reversible 
phosphorylation is acetyl-CoA carboxylase (see section 1.3.4.(ii))
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although there is good circumstantial evidence that mammary PDH is 
similarly regulated [26] and work is also in progress at present to 
characterise the regulatory properties of mammary gland HMG-CoA 
reductase [715, 716], an enzyme whose activity has been shown to be 
regulated by phosphorylation in other tissues (see section 1.3.5.).
The activity of an unspecified, quercitin-inhibited, cAMP-independent 
protein kinase purified from rat mammary tissue cytosols [698, 699] 
correlates with tissue proliferation during the normal physiological 
cycle of mammary gland development in pregnancy and lactation [698] and 
is high in DMBA-induced mammary tumors, falling to insignificantly low 
levels in regressing tumors [699]. In contrast, while cAMP-dependent 
protein kinase activity measured in the same rat mammary cytosols [698] 
is markedly elevated over virgin levels by mid-pregnancy, it remains at 
approximately the same level throughout the remainder of pregnancy and 
lactation and does not, therefore, correlate with tissue proliferation 
which continues to rise up to the end of lactation [698].
Recent reports [472, 700] by the authors of this work identifies an 
association between membranal tyrosine kinase activity, shown to have 
quercitin inhibition characteristics similar to those of the previously 
described cAMP-independent, quercitin-inhibited protein kinase of 
mammary and uterine tissue [698, 699, 701], and DMBA-induced rat 
mammary tumor growth. Protein kinase C activity in mouse mammary gland 
has been shown to vary inversely with mammary differentiation [86] and 
although total enzyme activity (measured under optimal Ca2+ and 
phospholipid conditions) does not correlate with tissue proliferation 
during the reproductive cycle, it has been suggested that a correlation 
may exist in vivo where physiological conditions might play a major 
role in the regulation of its activity [86]. In common with the
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cAMP-independent protein kinase of rat mammary gland, mammary PrKC is 
inhibited by quercitin and may represent the same enzyme.
Ca2+/calmodulin-dependent protein kinase activity has also been 
identified recently in a particulate fraction isolated from rat mammary 
acini [56]. The enzyme appears to be associated with a lOOOkDa 
particle composed largely of protein with a small lipid component and 
containing an endogenous protein substrate of molecular weight 53.6kDa 
[56].
While the work described above provides an indication that 
protein phosphorylation may be of equal importance to the control of 
metabolic function in mammary cells as it is in many other tissues, the 
profile of protein kinase activities potentially capable of 
contributing to such regulatory mechanisms has not been determined and 
a comparison with the distribution of the various well characterised 
effector-dependent protein kinases described in other tissues has, 
therefore, previously been impossible.
1.4. The Mammary Gland
Displaying remarkable synthetic capabilities, the mammary gland places 
enormous demands on maternal nutrition and is, therefore, necessarily 
subject to comprehensive regulatory controls. The nature of these 
regulatory mechanisms (both long and short term) is, in many instances, 
understood only poorly and has been the focus of numerous research 
projects, including the work described in this thesis. A brief 
introduction to the gland and its physiology is presented below.
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1.4.1. Structure
The mammary gland is composed of a complex system of secretory 
alveoli, each connected to a network of ducts leading, ultimately, to a 
common chamber (cistern) beneath the nipple. The secretory alveoli are 
organised into discrete lobules, separated by connective tissue; during 
lactation they are composed primarily of secretory (glandular) 
epithelial cells (g in Figure 18). These are, however, associated 
closely with several other cell-types, identified as myoepithelial, 
blood capillary and fibroblast-like cells (M, be and f, respectively, 
in Figure 18). In non-digested tissue, the surface of the alveoli is 
covered densely by collagenous fibres; a number of fat cells (F in 
Figure 19 [la]) are also evident in the inter-lobular connective 
tissue. The intricate mesh-work of large collagenous fibres and finer 
reticulate fibres conceals completely the alveoli (Figure 19 [16]).
Removal of inter-lobular connective tissue by an enzyme-HCl 
method (see 554a) reveals the surface of the alveoli (Figures 18 and 
20) which are roughly spherical and have diameters of approximately 
40-50/vm. As noted above, each alveolus is composed predominantly of 
secretory epithelial cells but up to four to six myoepithelial cells 
may stretch across its surface (see Figure 20) and several of the 
fibroblast-like cells may also be observed interspersed across the 
lobule (Figure 18).
Digestion of mammary tissue by the method described in Materials 
and Methods (section 2.2.2.) effects degradation of connective tissue 
and results in release of individual alveoli from the lobular matrix. 
The alveoli retain a degree of structural integrity and are isolated 
complete with remnants of their associated collecting duct. The 
sack-like structures (acini) so produced therefore contain a number of
Figure 18
g glandular epithelial cells 
M myoepithelial cells 
be blood capillaries 
f fibroblast-like cells
Figure 18. Scanning electron micrograph showing 
surface view of a lactating mammary 
gland in which almost all extracellular 
connective tissues have been removed 
with enzyme-HCl digestion.
Figure 19
la. A number of fat cells (F) and a dense covering of 
collagenous and reticular fibres almost conceal 
the terminal portions t*) of the gland.
lb. A higher magnification micrograph of the area 
enclosed by a rectangle in la, showing the 
organisation of collagenous (C) and reticular 
fibres that enclose the terminal portion.
Figure 19. Scanning electron micrograph of an
untreated portion of a lactating mammary 
gland, torn into lobules.
Figure 20
M myoepithelial cells 
be blood capillary
Large arrow indicates crossing-over of two 
myoepithelial cells
Small arrows show the boundaries of the glandular 
cells
Figure 20. Scanning electron micrograph showing the 
terminal portions of a lactating mammary 
gland.
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different cell types including myoepithelial, capillary and duct cells 
but are composed predominantly of secretory epithelial cells. Fat 
cells present in the interlobular connective tissue (see Figure 19 
[la]) are not sedimented by the centrifugal procedure used for 
harvesting of acini and are therefore removed during washing. Only 
secretory epithelial cells are involved directly in milk synthesis and 
it is therefore the metabolic regulation of these cells alone that is 
of interest in this study. Since acini prepared from lactating mammary 
gland are rich in this cell type, are easily manipulated in suspension, 
are responsive to hormonal stimulation and have been shown to be 
capable of maintaining linear rates of fatty acid synthesis for 
incubation periods in excess of one hour, this preparation provides an 
excellent system for the study of mammary gland metabolism and its 
regulation. Procedures are available for isolation of secretory 
epithelial cells from the other cell types residing in mammary acini 
but using such techniques, yields an insufficient quantity of these 
cells to allow studies of the kind conducted here and such preparations 
do not therefore offer a realistic alternative to the acinus 
preparation described above. Although the possible contribution of 
cell-types other than secretory epithelial to the results obtained 
using acinar preparations should not be ignored, in practice, this 
contribution is unlikely to be significant and will not therefore be 
considered in discussion of experimental findings.
1.4.2. Physiology
The onset of lactogenesis has been shown, in a variety of species, 
to be dependent on a rise in serum prolactin concentration and 
a fall in serum progesterone, with glucocorticoids appearing to play a
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permissive role [21b, 442a]. Results obtained from various in vitro 
and in vivo studies suggest that prolactin, cortisol and insulin are 
all important in the induction of mammary enzyme synthesis at this time 
[21a, 21b, 276a, 778b] and insulin, glucocorticoids and prolactin have 
been shown to act synergistically to stimulate production of milk 
constituents in cultured mammary explants of mid-pregnant rats and mice 
[778a].
The hormonal environment required to maintain lactogenesis 
appears to vary between species. Both prolactin and insulin are known 
to be necessary for the maintenance of normal lactation and there is 
evidence that hormones such as thyroxine, growth hormone and 
corticosteroids may also be involved in the regulation of lactation 
(134a). Prolactin is known to act at the level of transcription but 
there is also evidence that this hormone may play at least a limited 
role in acute regulation of mammary function [la, 213a, 529, 654b] 
but, as indicated by studies on mammary function during starvation/ 
re-feeding (see below), insulin seems to be a more important hormone in 
this respect.
Milk production by the lactating mammary gland creates a 
considerable drain on available nutrients and various changes in 
maternal physiology are required to accommodate these demands. Both 
the mammary gland itself and other organs, such as liver and alimentary 
tract, become hypertrophied and are served by an increased blood supply 
[89a, 135a, 211a, 270a, 716b] which is supported by an increase in 
cardiac output of up to two-fold [89a]. At peak lactation, food intake 
may be two to three-fold higher than in the unmated animal [136a, 211a, 
443a, 581a] and yet is usually accompanied by a net depletion of 
adipose tissue reserves [46a, 425a, 708a, 730a]. Adipose tissue lipid
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reserves are mobilised to help meet the increased demands for 
precursors for milk lipid biosynthesis. All these changes are required 
in order to support the development of the mammary gland as the major 
site of biosynthetic activity during lactation.
In fed lactating rats, the main substrates utilised by the 
mammary gland are glucose, amino acids and triacylglycerol fatty acids 
(supplied by plasma VLDL and chylomicra). Plasma glucose has been 
shown to be the precursor for lactose synthesis [842a] and also for a 
large proportion of milk lipid [22a, 442b, 577a]. The rates of 
lipogenesis and lactose synthesis in the mammary gland are both very 
sensitive to the metabolic status of the animal and vary diurnally, 
depending on food intake [82a, 553a]. However, while the rate of 
lipogenesis at peak lactation parallels hepatic lipogenesis (maximum 
observed just before maximum food intake [553a]), suggesting a 
relationship with circulating insulin and/or glucagon levels, food 
withdrawal and insulin supplementation experiments have shown that the 
rate of lactose synthesis does not coincide with changes in circulating 
insulin concentrations [82a]. The rate of lactose synthesis does, 
nonetheless, correlate closely with food intake, implying that although 
lipogenesis and lactose synthesis are both governed by nutritional 
status, only lipogenesis shows any signs of being regulated directly by 
insulin. Indeed, the evidence suggests that, should such a 
relationship exist between circulating insulin and lipogenic rates, it 
is not a simple one, since plasma insulin concentrations show little 
diurnal variation during peak lactation (553a).
In the rat, uptake of 2-deoxyglucose by the mammary gland, 
measured in vivo, is inhibited 90% by 16h starvation and is restored to 
normal levels by lh refeeding [776]. This close relationship between
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maternal nutrition and glucose uptake by the mammary gland has been 
confirmed recently in a study of arteriovenous glucose differences 
across the mammary gland of fed, starved and re-fed lactating rats 
[582a]. In this study, after 18h starvation, glucose uptake had fallen 
to 8% of fed values but recovered substantially within 15 min of 
re-feeding and had returned to fed levels lh after re-feeding.
Approximately 20% and 50%, respectively, of glucose uptake by 
the mammary gland is accounted for by lactose synthesis and fatty acid 
synthesis and in 15-18h starved rats, conversion of glucose to lactose 
and fatty acids is decreased to 3% and 1%, respectively, of fed values 
[73]. Synthesis of these milk solids is therefore shut down almost 
completely by 15-18h starvation and this is accompanied by a comparable 
fall in glucose uptake. The rapid resumption, on refeeding, of mammary 
activity, as indicated by recovery of glucose uptake (see above), does 
not appear to correlate well with concurrent changes in plasma insulin 
concentration [582a]. Although plasma insulin concentration also 
increases rapidly on re-feeding, the highly elevated levels attained do 
not persist. It therefore appears that the rapid peak in insulin 
concentration may be the signal required for resumption of mammary 
activity on re-feeding but that once stimulated, low insulin 
concentrations are sufficient to maintain this level of activity 
[532a,582a]. The ability to maintain elevated glucose uptake despite 
low plasma insulin concentrations is consistent with the need, during 
lactation, to direct glucose and fatty acids away from other 
extrahepatic tissues and towards the mammary gland [843a]. However, 
these observations imply that shortly after refeeding, the mammary 
gland acquires some independence of circulating insulin. Whether this 
is achieved through enhanced sensitivity to the hormone or through
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by-passing of insulin-dependent controls is unknown (see Zammit [872a] 
for discussion).
Besides glucose, the other major substrate of dietary origin for 
milk production in the rat is long-chain fatty acid. Following 
re-esterification in the intestinal epithelium, dietary fatty acid is 
transported in the blood as triacylglycerol within chylomicra. However, 
before it can be taken up by other cells, the lipoprotein 
triacylglycerol must be hydrolysed to produce free fatty acids and 
glycerol. The majority of the fatty acid enters the cell but the 
glycerol produced is carried away in the circulation, to be metabolised 
by the liver and kidneys. This generalisation may not apply to mammary 
tissue since there is evidence that glycerol also may be taken up by 
these cells. Circulating lipoprotein triacylglycerol is hydrolysed by 
lipoprotein lipase on the endothelial surface of capillaries supplying 
the tissue. The activity of the mammary enzyme increases during 
lactation in contrast to that of adipose tissue which decreases around 
parturition and remains low throughout lactation [877a],
Another important source of fatty acids for mammary lipogenesis 
is plasma VLDL produced by the liver either by de novo synthesis or 
from plasma non-esterified fatty acids (NEFA) generated by lipolysis in 
adipose tissue. During lactation, lipogenesis (from circulating 
glucose) in adipose tissue is decreased considerably [216, 654a, 716a] 
and is accompanied by an increase in lipolysis [716c]. As a result, 
less glucose and, due to decreased lipoprotein lipase activity, less 
triacylglycerol fatty acid, are removed from the circulation by adipose 
tissue. Meanwhile, the elevated rate of adipose tissue lipolysis leads 
to increased release of NEFA into the bloodstream. Hence, during 
lactation, the mammary gland becomes the predominant site of fatty acid 
utilisation.
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Circulating lipoprotein and NEFA are particularly important to 
the mammary gland during the post-absorptive period of digestion when 
utilisation of glucose by peripheral tissues is decreased. At this 
time, fatty acids from the diet (only available after a delay of 
several hours due to the characteristics of digestion and absorption of 
dietary lipid) and NEFA from adipose tissue (following conversion to 
hepatic VLDL) supplement the supply of fatty acids required for milk 
synthesis.
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2. MATERIALS AND METHODS
2.1. Treatment of Animals
Wistar rats were fed pasteurised breeding diet (see section 2.9.1.) 
and water ad libitum, and housed at constant temperature (21°C) 
in a 12-hour light/dark regime (lights on, 08.00h). Males were used 
at 2-3 months of age and females were mated at this age. The number of 
pups per mother was adjusted to 8 within 24hr after birth. These rats 
were used 9-12 days post-partum.
Where appropriate, diabetes was induced in rats by 
intraperitoneal administration of streptozotocin (150mg/kg)r 24hr 
prior to their use. The severity of diabetes was assessed by 
determination of blood glucose, as described previously [43] and rats 
were designated 'diabetic' when blood glucose concentrations exceeded 
25mM. Rats deprived of food 24hr prior to use are referred to, in 
the text, as 24hr starved animals.
2.2. Preparation of Adipocytes and Mammary Acini
Rats were anaesthetised by intraperitoneal injection of a solution, 
in normal saline, of pentobarbitone (60mg/kg body weight) at 
09.30h. Female rats were allowed to continue to be suckled by their 
young for the 10-15min period following injection, during which deep 
anaesthesia was being established. Male rats were simply returned to 
their cage for this period. All subsequent procedures were carried out 
in a warm room at 37°C.
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2.2.1. Adipocytes
Male rats were used as the source of adipose tissue for all 
experiments. The epididymal fat pads were removed and adipocytes 
prepared from these by collagenase digestion, as described previously 
[216]. Adipocyte size and number were determined as in [804] except 
that dry weight of cells was taken as an approximation to cellular 
lipid content.
2.2.2. Acini
The inguinal/abdominal mammary glands were dissected rapidly and acini 
prepared by a modification [656] of the collagenase digestion procedure 
developed for adipocytes [216] as described below.
Excised mammary glands were minced, using scissors, in 
oxygenated (02/C02, 95%/5%) Krebs-Henseleit [440] bicarbonate-buffered 
saline, pH 7.4 (composition as stated in [440] except that the Ca2+ 
concentration was 1.25mM i.e. half that recommended by Krebs and 
Henseleit), containing 5mM glucose and transferred to a PTFE square to 
be chopped finely with razor blades. The resulting finely-divided 
tissue was rinsed twice in five volumes of the same buffered-saline 
before being resuspended in 30ml of digestion medium (buffered-saline, 
containing 2% (w/v) fatty acid-free bovine serum albumin, 5% (w/v) 
dialysed [against distilled water] Ficoll and 0.1% (w/v) collagenase). 
This suspension was placed in a 250ml plastic conical flask and 
incubated at 37°C in a vigorously shaking (180 strokes/min) waterbath 
for 60 min. The flask was gassed continuously with 02/C02 (95%/5%). On 
completion of this incubation, the digested tissue was strained through 
a nylon mesh (approximately 0.15mm mesh size) which retained undigested 
tissue. The suspension of acini that passed through the nylon mesh was
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then washed three times (in the buffered saline described above, 
containing 2% (w/v) dialysed Ficoll). Harvesting of acini, following 
each wash, was achieved by light centrifugation (400 x g for 15 sec) 
which also accomplished separation of the acini from adipocytes and 
cell-fragments. Finally, the acini were resuspended in 6.5ml of 
incubation medium (the buffered-saline described above containing 2% 
(w/v) Ficoll and 4% (w/v) fatty acid-free bovine serum albumin).
Mammary acini in suspension have a tendancy to clump together, forming 
large agglomerates that are difficult to handle and display reduced 
response to hormonal challenge (as judged by lipogenic response to 
insulin). This clumping is ameliorated by addition of Ficoll, hence 
the inclusion of 2% (w/v) Ficoll in all media used for suspension of 
acini. The cellular integrity of acini prepared by the above procedure 
was verified by measurement of lactate dehydrogenase leakage as 
described by Christie et al. [93a] for a similar mammary cell 
preparation.
2.3. Incubation of Adipocytes and Acini
2.3.1. Phosphodiesterase Work
Aliquots (0.5ml) of adipocytes (suspended in the Krebs-Henseleit 
[440] bicarbonate-buffered saline described above, containing 5mM 
glucose, 4% (w/v) dialyzed, essentially fatty acid-free bovine serum 
albumin) or acini (suspended in a medium of similar composition to the 
adipocyte suspension medium but with the addition of 2% (w/v) dialyzed 
Ficoll) were dispensed into 25ml polycarbonate conical flasks 
containing 2ml appropriate incubation medium (identical composition to 
cell suspension medium) with or without hormones or other effectors, as 
indicated in the text. The flasks were gassed with an 02/C02 mixture
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(95%/5%), stoppered and secured in a shaking waterbath at 37°C. 
Incubation continued for 60min (unless otherwise stated) from time of 
addition of cells. The incubating flasks contained either 
approximately 105cells/ml (adipocytes) or approximately 35-50mg (wet 
weight) of acini/ml. Incubation was terminated by homogenisation of the 
entire contents of each flask in individual glass-glass 
Potter-Elvehjem-type homogenisers for 45s at 0°C, either by hand 
(adipocytes) or with a motor-driven pestle (lOOOrpm). The resulting 
homogenates were either used directly (adipocytes or acini) for assays 
or (acini only) subjected to centrifugation at 178,000xg for 2 min at 
4°C in a Beckman Airfuge to sediment a crude particulate fraction which 
was then resuspended to the original homogenate volume in 40mM Tris HCl 
(pH 8.0) containing 4.3mM 2-mercaptoethanol. In some experiments, the 
crude acinus particulate fraction suspension was incubated in the 
presence or absence of an inhibitor cocktail described in section
3.1.2.(ii), before assay for PDE activity. In a given experiment, each 
experimental condition (control, plus insulin etc.) was represented by 
duplicate flasks and each experiment was performed using a different 
preparation of adipocytes or acini as appropriate.
2.3.2. Protein Phosphorylation in Intact Acini
Acini were incubated, as described above, in phosphate deficient 
Krebs-Henseleit bicarbonate-buffered saline (composition as above 
except that the phosphate concentration was 0.24mM i.e. 1/5 that 
recommended by Krebs and Henseleit) containing 5mM glucose, 4% (w/v) 
dialyzed essentially fatty acid-free bovine serum albumin, 2% (w/v) 
Ficoll and carrier-free [32P] P. (40-65/vCi/ml) for lhr in order to 
establish steady-state labelling of phosphoproteins, as described, in
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adipocytes, by Brownsey et al. [194]. At this point, hormones or other 
effectors (as indicated in the text) were added and incubation 
continued for a further 15min. On completion of the incubation period, 
the acini were harvested rapidly by centrifugation at 800xg for 15s.
The supernatant was discarded and the acini pellets homogenised 
immediately in ice cold buffer (pH 7.4; 25ml per g wet weight of acini) 
containing 20mM Tris-HCl, 250mM sucrose, lOOmM KF, 2mM EDTA, 2mM EGTA, 
7.5raM glutathione (reduced), 2mM PMSF, 50^ /g/ml each of leupeptin, 
pepstatin and antipain. Homogenisation was for 30s at 20,000rpm using 
the PTA 10S probe of a Polytron. The homogenate was either treated 
immediately with an equal volume of ice cold 20% (w/v) TCA or used in 
the preparation of a high speed supernatant fraction, as described 
below. After not less than lOmin on ice, the TCA precipitated protein 
was collected by centrifugation at 7500xg for 5min. The supernatant 
was discarded and the pellet was washed with ice-cold 90% (v/v) acetone 
in H20. The precipitated protein pellet was reisolated by 
centrifugation as before, drained and allowed to dry before being 
disaggregated in boiling Tris-H3P04 (42.6mM) buffer, pH 6.7, containing 
1% (w/v) SDS, 15% (v/v) glycerol and 2% (v/v) 2-mercaptoethanol.
Samples of this preparation were loaded directly onto SDS 
polyacrylamide gels and subjected to electrophoresis.
Preparation of High Speed Supernatant from 32P-labelled Acini 
The homogenate of 32P-labelled acini, prepared as described above, was 
centrifuged at 8000xg (av) for lOmin at 4°C. After discarding the 
pellet, the supernatant was filtered through a plug of glass wool and 
centrifuged further at 105,000xg (av) for 45min at 4°C. The 
resulting high speed supernatant fraction was diluted with the
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disaggregation buffer described above and subjected to SDS 
polyacrylamide gel electrophoresis.
2.4. Incubation of Crude Acinus Membrane Fractions 
Acini, prepared as described above, were suspended in ice-cold 
buffer (3mM imidazole, pH 7.4) containing 250mM sucrose and homogenised 
under the conditions described above. The homogenate was subjected to 
centrifugation at 75xg (750rpm in an MSE bench centrifuge) for 5min at 
4°C and the supernatant frozen (liquid N2) in 1ml aliquots for storage 
at -80°C.
On the day of experiment, one aliquot was thawed and centrifuged 
at 22,500xg for lOmin at 4°C. The supernatant was aspirated and 
discarded and, unless otherwise indicated, the pellet was resuspended 
immediately in 1.6ml ice cold membrane incubation buffer containing 
20mM Tris-HCl, 5mM MgCl2 and 100/vM CaCl2, pH 7.4 to give a membrane 
protein concentration of approximately 1.2mg/ml. Membrane incubations 
were initiated by addition of 200/yl of this membrane suspension to a 
further 300/vl of incubation buffer with or without appropriate 
additions as indicated in the text. Following vortex mixing, the 
incubation tubes were incubated for 5min at 30°C (unless stated 
otherwise). At the end of the incubation period, the tubes were cooled 
to 0°C and subjected to centrifugation, once again for lOmin at 22500xg 
at 4°C. The supernatant was aspirated and, where appropriate, 
retained (see below) while the pellets were washed x 3 with ImM KHC03 
before being resuspended in lOO/ul PDE assay buffer. A 1:8 dilution of 
this membrane suspension was used directly for assay of PDE activity.
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2.4.1. Desalting of Membrane Incubation Supernatants 
Incubation supernatants (approximately 0.5ml) were diluted with 1ml 
incubation buffer containing dialyzed, essentially fatty acid free 
bovine serum albumin to a final concentration of lmg/ml and added to 
Centricon 10 microconcentrator devices. These were centrifuged at 
5000xg for 2hr at 4°C, achieving approximately 50-fold concentration. 
Fresh incubation buffer (2ml) was added to the concentrate (dead-stop 
volume) and centrifugation repeated. The final concentrate 
(approximately 30//1) was collected in weighed cups by centrifugation 
of the microconcentrators in an inverted position for 2min at lOOOxg 
at 4°C and adjusted (by weight) to a volume of 500/yl. These samples 
were assayed directly for PDE activity.
2.5. Sub-Cellular Fractionation of Mammary Acini 
Acini, prepared as described above, were washed twice by repeated 
centrifugal harvesting and resuspension in homogenisation buffer 
(lOmM Tris-HCl, 250mM sucrose and 0.1M KCl, pH 7.4) and finally 
homogenised in 2.5 x the compact acini volume of the same buffer for 
lmin at 10400rpm using the PTA 20N probe of a Polytron. The homogenate 
was centrifuged at 75xg for 5min at 4°C and the resulting supernatant 
subjected to further centrifugation at lOOOxg for lOmin at 4°C. The 
lOOOxg supernatant was decanted and the pellet (Px) washed once with 
homogenisation buffer before being held on ice pending further 
processing. The lOOOxg supernatant was centrifuged at 3000xg for lOmin 
at 4°C, the supernatant decanted and the pellet (P2) washed once in 
homogenisation buffer before storage on ice. Finally, the 3000xg 
supernatant was subjected to centrifugation at 105000xg for 45min at 
4°C, the resulting supernatant (Sn) was decanted and both this and the
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pellet (P3) (rinsed with homogenisation buffer) were stored on ice.
All the membrane fractions were then resuspended in homogenisation 
buffer and, together with Sn, were adjusted to a protein concentration 
of lOmg/ml as determined by the dye binding method in [55]. Membrane 
fractions P1, P2 and P3 are referred to, in the text, as the 'nuclear', 
'mitochondrial' and 'microsomal' fractions, respectively, while Sn is 
termed the 'cytosolic' fraction.
2.6. Incubation of Subcellular Fractions to Determine Protein 
Phosphorylation
Samples of subcellular fractions, prepared as described above, 
were incubated in a buffer containing 25mM (5-glycerophosphate lOmM 
MgCl2, ImM DTT, 2mM EGTA (unless indicated otherwise) and 60.6/;M 
[y—32P] ATP (final radioactive concentration 500/vCi/ml), pH 7.4, at a 
final protein concentration of lmg/ml, in the presence or absence of 
additions as indicated in the text. Incubations, in a final volume of 
55//1, were initiated by addition of the ATP to tubes containing the 
remaining incubation constituents and terminated after 30s (unless 
otherwise stated) at 37°C by addition of 100/yl ice cold TCA (20% w/v). 
The precipitated protein was then isolated, washed and disaggregated, 
as described earlier, in preparation for SDS polyacrylamide gel 
electrophoresis.
Control incubations in which the TCA was added prior to addition 
of mammary cell fractions showed no evidence of protein 
phosphorylation, regardless of whether other additions such as Ca2+ 
(10//M), calmodulin (5/vg/mg protein) or cAMP (1/vM) (see later) were 
present or absent. In autoradiograms derived from such incubations, 
the regions corresponding to electrophoretic separations of proteins
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contained in the mammary cell fractions were completely clear, 
indicating that, unlike neighbouring strongly exposed tracks (derived 
from incubations performed in the normal way i.e. TCA added to 
terminate the incubation), protein-associated radioactivity was not 
significantly greater than background. Consequently, no correction was 
necessary of the figures for 32P-incorporation determined, as 
described in section 2.7., by liquid scintillation counting of excised 
sections of dried electrophoretic gels.
2.7. SDS Gel Electrophoresis, Autoradiography and Liquid Scintillation 
Counting of 32P-Labelled Gel Slices 
Proteins contained in samples taken from disaggregated incubation 
contents (from either intact cell or subcellular fraction 
incubations) were resolved by one dimensional SDS polyacrylamide gel 
electrophoresis as described in [450]. Gels were stained with 
Coomassie brilliant blue, destained, and dried onto Whatman No. 1 
filter paper in preparation for autoradiography. Typically, 
autoradiographs were exposed for 10-14hr in intensifying screens at 
-80°C. Major phosphoprotein bands in dried gels were identified by 
reference to the autoradiograph and the 32P content of slices of gel 
containing such bands was determined by liquid scintillation counting 
in toluene-based scintillation fluid. In various control experiments, 
the efficiency of 32P-counting was the same whether protein-bound 32P 
was deposited on filters, dried and counted as above or dispersed 
uniformly throughout the bulk phase using either dioxane-based 
aqueous-compatible scintillator cocktail (for example, Packard 
Scintillator 299) or 1ml of tissue solubiliser (for example, commercial 
quaternary amine-based solubilisers such as 'NCS' or 'PCS') plus 10ml
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of toluene scintillator. Furthermore, no difference was noted in the 
count registered for an excised segment of dried electrophoretic gel 
whether counted as described above, simply by immersion in toluene 
scintillator or counted after hydration and dissolution in 0.2ml 30% 
(v/v) (approximately "100 volumes") H202 at 50°C overnight, followed by 
incorporation into 10ml toluene scintillator by the addition of 1ml 
NCS.
2.8. Enzyme Assays
2.8.1. Cyclic AMP Phosphodiesterase (EC 3.1.4.17)
Suitable dilutions of unfractionated adipocyte or acinus homogenates or 
of acinus particulate fractions were assayed in duplicate for cAMP-PDE 
activity at 0.2/vM (adipocytes) or 1//M (acini) cAMP using the two-step 
procedure in [771]. In addition to sample and tritiated substrate 
(approximately 200,000cpm/assay), the assay mix (final volume 0.4ml) 
contained lOmM Tris-HCl, l.lmM 2-mercaptoethanol and 12mM MgCl2, pH
8.0. The primary reaction was initiated by addition of sample and the 
mix was incubated for lOmin at 30°C. Termination of this reaction was 
achieved by immersing the assay tubes in liquid N2 for 5s and 
immediately thereafter, transferring them to a boiling water bath for 
45s. After cooling, on ice, the second incubation commenced on 
addition of 100/yl of a lmg/ml solution of snake venom rich in 
5'nucleotidase activity, and continued for lOmin at 30°C. On 
completion of this incubation period, the assay tubes were returned to 
ice and labelled product was subsequently separated from substrate on 
small columns (7mm diam. x 10mm) of Dowex 1 x 8 -  400 anion exchange 
resin, allowing quantitation of product by liquid scintillation 
counting. One unit of enzyme activity is that which generates l^ wmol 
product/min under the defined conditions of assay.
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2.8.2. Marker Enzymes
5' Nucleotidase (EC 3.1.3.5.) was assayed at 37°C as in [99], Lactate 
dehydrogenase (EC 1.1.1.27) activity was measured using a standard 
spectrophotometric assay [42]. Cytochrome-C oxidase (EC 1.9.3.1) was 
assayed as described by Brown et al. [59].
2.9. Materials
2.9.1. Animals
Rats were supplied by A. Tuck and Son, Rayleigh, Essex and were fed 
pasteurised breeding diet 41B produced by Oxoid, Basingstoke,
Hampshire, England.
2.9.2. Radiochemicals
[8-3H] Adenosine 3',5' cyclic monophosphate, [y-32P] Adenosine 5' 
Triphosphate and [3 2 P] Pi were obtained from Amersham International 
PLC, Aylesbury, Buckinghamshire, England.
2.9.3. Chemicals and Equipment
The following were all purchased from Sigma Chemical Co. Ltd., Poole, 
Dorset, England: pentobarbital, bovine serum albumin (fraction V, 
essentially fatty acid-free), Ficoll type 400, tris (hydroxymethyl) 
aminomethane ('Trizma' base), ^-glycerophosphate, imidazole, 
cycloheximide, 3-isobutyl-l-methyl xanthine, isoproterenol, protein 
kinase inhibitor type II (Walsh inhibitor), Soya bean trypsin inhibitor 
(type 1-S), e-amino-n-caproic acid, benzamidine hydrochloride, phenyl 
methyl sulphonyl fluoride, leupeptin, pepstatin, glutathione (reduced 
form), adenosine, adenosine 5'-monophosphate, adenosine 3'5'-cyclic
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monophosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate, 
guanosine 5'-triphosphate, N6, 2'-0-dibutyryl adenosine 3'5'-cyclic 
monophosphate, protamine sulphate, dithiothreitol, riboflavin, 
40-phorbol, 12(3-myristate, 13a-acetate, Dowex 1 X 8-400 (chloride 
form), cytochrome-C (type III), glycogen phosphorylase (EC 2.4.1.1), 
0-galactosidase (EC 3.2.1.23), catalase (EC 1.11.1.6), ovalbumin,
Triton X—100, Ophiophagus hannah (King Cobra) venom and coomassie 
brilliant blue R. Collagenase was obtained from Worthington (CLS III, 
Lot. no. 415130) or Boehringer (from Clostridium histolyticum), Lewes, 
East Sussex, England.
Adenosine 5'-0-(3-thiotriphosphate) (ATPyS), nicotinamide adenine 
dinucleotide (reduced form) and pyruvate were also obtained from 
Boehringer. Insulin (porcine, 23.6u/mg) was a generous gift from the 
Boots Co. Ltd., Nottingham, Nottinghamshire, England. The Bradford dye 
reagent for protein determination was supplied by Bio-Rad, Watford, 
Hertfordshire, England. Calmodulin was a kind gift from Professor P. 
Cohen, Department of Biochemistry, Dundee, Scotland. Kodak X-Omatic 
cassette intensifying screens, X-Qmat RP X-ray film and processing 
chemicals were from Kodak, Hemel Hempstead, Hertfordshire, England. 
Scintillator 299 was from United Technologies, Packard, Caversham, 
Berkshire, England and Forskolin was supplied by Calbiochem-Behring 
Diagnostics, La Jolla, California, USA. All other chemicals were of 
'AnalaR' purity from BDH Ltd., Poole, Dorset, England. Centricon 10 
microconcentrators were obtained from Amicon Ltd., Stonehouse, 
Gloucestershire, England.
The suitability of different batches of commercial collagenase 
for use in the preparation of mammary acini was assessed as follows: A 
sample of each batch available was used to prepare acini as described
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in Section 2.2.2. The quality of the acini produced was then assessed 
by determination of the period of linearity of lipogenic rates and the 
degree of stimulation of these rates by insulin (as described by Robson 
et al. [656]). Those batches producing acini capable of demonstrating 
adequate linearity of lipogenic rates (i.e. linear for at least lhr) 
and greatest response to insulin were chosen for future experiments. If 
an insulin response of consistently less than 140% of control was 
attained with acini prepared using a particular batch of collagenase, 
this batch was not used further.
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3. RESULTS
3.1. High Affinity cAMP-Phosphodiesterase
3.1.1. Adipocytes
Adipocytes prepared and incubated as described in sections 2.2. 
and 2.3. were found to contain high affinity cAMP-PDE activity 
that could be stimulated by exposure of the cells to insulin.
Cyclic AMP-PDE activity measured at 0.2/M  cAMP in whole cell 
homogenates derived from control incubations was 64.8 ±
14.0pmol/min/106 cells (mean ± SE of 11 observations) and the mean 
stimulation observed in response to insulin (ImU/ml) was 146 ±9.3% 
(also mean ± SE of 11 observations) with respect to control 
incubations. Insulin stimulated activity was significantly greater 
than controls (P < 0.0005) as determined by Student's t-test for paired 
observations.
Thompson and Appleman [770] have calculated a Km of 
approximately 40yt/M for low affinity cAMP-PDE activity of adipose tissue 
but a figure as low as 15^M has also been reported [506]. However, at 
the concentration of cAMP used for assay of PDE activity (0.2/yM), even 
assuming a Km of 15//M, the low affinity enzyme should be operating at 
only a fraction of its maximum rate whereas, with a Km of 0.2-0.3/yM 
[506,770,878] the activity of high affinity cAMP-PDE will be 
approaching half-maximal. Unfortunately, despite expressing only a 
fraction of its potential activity, even at 0.1/yM cAMP, the low 
affinity enzyme shows significant activity [770] and the possibility 
that the calculated increase in high affinity activity in response to 
insulin may, therefore, have been observed against a substantial 
background of low affinity activity cannot be ignored.
136
3.1.2. Mammary Acini
3.1.2.(i) Insulin Response
Two kinetically distinguishable cAMP-PDE activities with Km values of 
21.6//M and 1.3//M have been identified recently in rat mammary 
tissue [549]. Heterogeneity of mammary PDE activity had previously 
been described by Pizarro et al. [615] and Sapag-Hagar and Greenbaum 
[681], the latter reporting Km values of 6//M and 70//M for the two 
cAMP-PDE activities identified. The chromatographic separation of 
these enzyme activities performed in the most recent study [549] 
demonstrates that at a substrate concentration of 1//M, high affinity 
cAMP-PDE is the only enzyme expressing significant activity. Since 
PDE activity measured at a cAMP concentration of 1//M therefore 
reflects the activity of high affinity cAMP-PDE essentially free of 
interfering activities, it was this concentration rather than the 
0.2/yM employed for assay of adipose tissue high affinity cAMP-PDE 
that was chosen for the assay of the mammary enzyme. In view of the 
higher Km value ascribed to mammary high affinity cAMP-PDE as 
compared with its counterpart in adipose tissue, the higher substrate 
concentration is obviously preferable in that it allows expression of 
greater catalytic activity. Phosphodiesterase activity measured at 
this concentration of cAMP was higher in a crude particulate fraction 
prepared as described earlier (secion 2.3.) from homogenates of acini 
incubated in the presence of insulin than in the same fraction of 
control acini homogenates derived from incubations in the absence of 
insulin (Table 2) but, in contrast to the behaviour of adipocyte high 
affinity cAMP-PDE, no such insulin-stimulated increase was observed
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in unfractionated cellular homogenates. The insulin concentration 
used (1.68mU/ml) is that which has been shown to elicit a maximal 
lipogenic response in mammary acini incubated under identical 
conditions to those employed in this study [656].
Since incubations were of 60min duration, it was conceivable 
that the observed activation in response to insulin was merely an 
expression of generalised stimulation of protein synthesis known to 
be induced by insulin in several cell-types including adipocytes 
[670]. However, the failure of cycloheximide, an inhibitor of 
protein synthesis, to suppress the insulin-induced stimulation of PDE 
activity (Table 2) and the observation that this stimulation was 
evident even after an incubation period of just 15min (Table 3), 
demonstrate that such a mechanism was not responsible for the effects 
on PDE activity observed following the longer (60min) incubations. 
Interestingly, not only did cycloheximide fail to prevent insulin 
stimulation of PDE activity but its inclusion in incubations also 
led to the expression of an insulin-induced activation which, in 
contrast to incubation in its absence, was detectable even in 
unfractionated homogenate (Table 2). These observations remained 
essentially unchanged whether activities were expressed on a 'per 
incubation', 'per mg protein' or 'per unit of 5'nucleotidase 
activity' basis. Determination of a meaningful value for protein 
concentration in unfractionated homogenates was confounded by the 
high concentration of BSA present in these samples as a consequence 
of homogensation in incubation medium containing 4% (w/v) (40mg/ml) 
BSA. However, satisfactory protein determinations were possible 
using washed particulate fractions and expression of particulate 
cAMP-PDE activity was therefore possible on a 'per mg protein' basis.
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3.1.2.(ii) Storage Effects
During storage at 0-4°C, particulate fraction high affinity cAMP-PDE 
underwent spontaneous activation. After 1^ hours the activity 
expressed by particulate fractions derived from control incubations 
was approximately 1^-fold greater than that measured in the same 
samples at time 0 whether results were calculated 'per ml homogenate' 
or 'per unit 5'nucleotidase' (Table 4). During this time, insulin 
activation became attenuated both in terms of absolute values and, 
consequently also when expressed as a percentage of control activity 
(Table 4). Proteolytic activation of membrane bound high affinity 
cAMP-PDE is well documented in adipose tissue [502, 742, 841] but the 
activation observed here was only partially blocked by homogensation 
and storage in an inhibitor cocktail containing, in final 
concentrations, 2mM PMSF, O.lmg/ml leupeptin, pepstatin, antipain and 
trypsin inhibitor, 20mM e amino caproate, ImM benzamidine HCl, 2mM 
EDTA, 5mM EGTA and 50mM KF (after 1% hr at 0-4°C, control high 
affinity cAMP-PDE activity was 132% its value at time 0 [mean of 2 
experiments]). However, the percentage activation observed in 
response to insulin (145-150% control values, mean of 2 experiments) 
was preserved entirely under such conditions.
3.1.2.(iii) Effect of Physiological State on Insulin Activation 
The results obtained from a single experiment comparing the 
insulin-induced activation displayed by high affinity cAMP-PDE of 
acini prepared from mammary tissue of a normal mid- lactating rat 
with that observed in mammary acini derived from 24hr starved or 
diabetic rats in mid lactation (Table 5) indicated that changes in
Table 4 Effect of storage at 0-4°C on control and insulin-stimulated
high affinity cAMP-PDE activity
Particulate 
high affinity cAMP-PDE activity
Incubation
Additions
None
Insulin
None
Insulin
Insulin 
Activation 
(insulin 
-control)
Insulin 
Activation 
(% control)
Storage 
time (hr)
0
0
1.5
1.5
0
1.5 
0
1.5
/yU/mi n/ml 
homogenate
146.4±30.0
198.1±43.5
220.5147.1
255.6156.0
51.7115.3
34.9120.1
134.817.3
116.0115.0
/vU/min/mU 
5'-nucl.
0.25410.020
0.35810.056
0.38310.032
0.46210.075
0.10310.040
0.07910.060
139.7116.4
120.5116.4
Acini were incubated as described in Materials and Methods (section
2.3.1.) for 15 min, in the presence or absence of insulin 
(1.68mU/ml). Particulate fractions, prepared as described in the 
text, were assayed for PDE activity immediately and then again after 
storage on ice at 0-4°C as indicated. Values given are means 1 SE of 
three separate experiments.
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physiological state may have a marked effect on the magnitude of this 
particular response to insulin. However, tentative conclusions of 
this kind must be treated with considerable caution since the data on 
which they are based are derived from only one experiment and so 
may be subject to quite large errors.
In the experiment, activation of high affinity cAMP-PDE was 
evident even in the unfractionated homogenate, a phenomenon normally 
observed only in acini incubated in the presence of cycloheximide 
(Table 2). The differences between these results and previous ones, 
most likely to account for this discrepancy, are that while the high 
affinity cAMP-PDE activity expressed by control particulate fraction 
was broadly consistent with previous values, the activation observed 
in response to insulin was much greater and total cellular activity, 
represented by the value for unfractionated homogenate, was 
considerably lower than observed before, so that increases in the 
activity of insulin sensitive PDE were seen against a much reduced 
background activity. Since the procedures employed for preparation 
of samples and measurement of PDE activity were identical to those 
used previously, these inconsistencies are not easily explained but 
may arise, at least in part, from differences in the profile of 
enzyme activities exhibited by the collagenase preparations used for 
tissue digestion in the two separate experimental series. The 
properties of commercial collagenase, particularly, with respect to 
efficiency of digestion of mammary tissue are known to be highly 
variable and considerable differences are encountered both between 
the same product obtained from different suppliers and between 
individual batches of the same manufacturer's product. As described 
in section 2.9.3., the effect of such differences was minimised by
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screening each batch. However, the screening process involved 
monitoring the linearity and insulin sensitivity/responsiveness of 
only one metabolic pathway (lipogenesis). Hence, it is possible 
that, despite appearing comparable on this basis, the different 
batches of collagenase did in fact differ in their effect on the 
insulin dependence of the acinus cAMP-PDE system.
Both diabetes and 24hr starvation had marked effects on 
control high affinity cAMP-PDE activity. Twenty-four hr starvation 
resulted in a 40% reduction in unfractionated homogenate activity and 
31% reduction in activity associated with the particulate fraction, 
while the diabetic animal displayed 45% and 54% reductions 
respectively. The insulin-induced activation of high affinity 
cAMP-PDE assayed in both unfractionated homogenate and particulate 
fraction was greater in starved or diabetic rats than in control 
animals when expressed as a percentage but only the unfractionated 
homogenate derived from diabetic rat mammary acini showed an increase 
in the absolute amount of activation (Table 5).
3.1.3. Membrane Incubations
Addition of insulin (1.68mU/ml or 3.36mU/ml) to membrane incubations 
performed as described in Materials and Methods had no effect on the 
high affinity cAMP-PDE activity expressed by membranes incubated with 
ATP (3mM) or ATP (3mM) and cAMP (lOO^M) in the presence or absence of 
NaCl (9mM) or KF (60mM) whether conducted at pH 7.4 or pH 4.6 (mean 
activity of insulin-treated membranes expressed as a percentage of 
appropriate controls was 102 ±3%).
During the course of this series of experiments, it was 
noticed that KF, a potent inhibitor of protein phosphatase activity,
Table 5 Effect of physiological status on insulin stimulation of
high affinity cAMP-PDE activity in rat mammary acini
Physiological
State
Incubation High affinity cAMP-PDE
Additions activity (/yU/ml homogenate)
Unfractionated Particulate 
homogenate (ufh) fraction (pf)
Insulin 
stimulation 
(% control;
ufh. pf.
Normal None
Insulin
218.6
293.8
74.5
123.6
134 166
24hr starved None
Insulin
130.1
203.5
51.3
89.5
156 174
Diabetic None
Insulin
119.5
212.8
34.2
69.2
178 203
Acini, prepared from untreated, 24hr starved or diabetic 
(streptozotocin induced) rats, were incubated (as described in 
section 2.3.1) for 60 min, in the presence or absence of insulin 
(1.68 mU/ml). Values given are means of duplicate incubations from 
single experiments.
Table 6 Effect of KF, ATP and EDTA on high affinity cAMP-PDE
activity in a crude membrane fraction from rat mammary acini
Incubation
Additions
None
KF (lOOmM)
KF (lOOmM) + ATP (5mM)
KF (lOOmM) + EDTA (5mM) 
ATP (3mM)
EDTA (5mM)
Number of 
Experiments
14
14
5
3
2
1
High affinity cAMP 
PDE activity 
(/jU/mg protein)
23.911.1
45.612.2*
23.413.7 
31.015.5
20.3
32.7
2 +
Samples of mammary acinus particulate fraction were prepared, 
incubated in the presence or absence of additions (final incubation 
concentrations as indicated; all incubations also contained 5mM Mg 
and 100//M Ca2+) and assayed for high affinity cAMP-PDE activity as 
described in section 2.4. Values given represent means 1 SE (where 
appropriate). Statistically significant differences were determined 
using Student's t-test for paired observations. An asterisk denotes 
value greater than control (no additions) at PC0.0005.
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was capable of enhancing markedly the high affinity cAMP-PDE activity 
expressed by membranes isolated from control incubations but not 
those derived from incubations performed in the presence of ATP 
(Table 6). In this and the following series of experiments, the high 
affinity cAMP-PDE activities measured in control incubations were 
several-fold lower than those recorded in particulate fractions 
isolated from acinus incubations (Tables 2 and 3). This discrepancy 
is likely to have arisen as a consequence of the difference in 
procedures employed for preparation of the two particulate fractions, 
the major contributory factors being differences in homogenisation 
and centrifugation conditions (see sections 2.3.1. and 2.4.). In 
contrast, another significant difference in methodologies, storage of 
homogenate in liquid N2 (as described in Section 2.4.), has no 
discernable effect on high affinity cAMP-PDE activity observed in 
membrane fraction incubations and can probably therefore be 
eliminated from the list of possible contributory factor. That the 
KF-induced increase was also dependent on divalent cation was 
demonstrated by the discovery that addition of EDTA to incubations 
abolished the ability of KF to elevate PDE activity measured in the 
membrane fraction. Although both ATP and EDTA were equally effective 
inhibitors of the KF-stimulated increase in particulate high affinity 
cAMP-PDE activity if added prior to KF, when added to incubations 
already treated with KF, only EDTA was able to return activity 
expressed by the membrane fraction to approximately control levels 
(Table 7). This suggests that the mechanisms of action of ATP and 
EDTA are distinct, an inferrence that is supported by the observation 
that marked reduction in particulate high affinity cAMP-PDE activity 
occurs at ATP concentrations below lmM (Figure 22). Since the
Table 7 Effect of delayed addition of ATP or EDTA on KF-induced
enhancement of high affinity cAMP-PDE activity in a crude 
membrane fraction from rat mammary acini
High affinity 
cAMP-PDE activity
Incubation Additions (/yU/mg protein)
Time 0 5min 10 min
None None None 23.04
None lOOmM KF None 37.16
lOmM EDTA lOOmM KF None 23.31
None lOOmM KF lOmM EDTA 26.96
5mM ATP lOOmM KF None 22.09
None lOOmM KF 5mM ATP 33.83
Samples of particulate fraction were incubated, as described in
Materials and Methods (section 2.4) for a total of 15 min and were
treated, during this time, with KF and/or ATP or EDTA in the 
sequences indicated. Values given are means of duplicate incubations 
from a single experiment only.
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concentration of Mg2+ added exogenously was 5mM in all incubations, 
chelation of Mg2+ by ATP, at a maximum concentration of only ImM, is 
unlikely to have depressed free Mg2+ concentrations sufficiently to 
have had a significant effect on particulate cAMP-PDE activity.
The effect observed with KF was not reproduced in incubations 
exposed to an equal concentration of KCl but, under the same 
conditions, NaF was capable of mimicking at least partially the 
action of KF (Table 8). The concentration dependence of particulate 
PDE activity enhancement by KF was of a markedly biphasic nature with 
a maximally effective KF concentration of between 30 and lOOmM 
(Figure 21), however, the precipitous decline in activity observed at 
concentrations above 300mM is probably partially artifactual, 
reflecting inhibition of the PDE assay by KF not removed during the 
membrane wash procedure. Potassium fluoride in the PDE assay at a 
concentration of 5mM in the first incubation of the two-step 
procedure (see section 2.8.1.) resulted in a 28% decrease in the 
measured activity of high affinity cAMP-PDE in control membranes, 
rising to 35% at lOmM and 76% at lOOmM (all figures represent means 
of 2 experiments). At KF concentrations below 5mM, interference 
with the PDE assay was undetectable and, therefore, at most membrane 
incubation concentrations, including the standard lOOmM, the 
concentration of KF to which PDE assays were themselves exposed as a 
result of incomplete removal during the wash procedure would probably 
have been insignificant in terms of inhibition of the assay but at 
higher concentrations, carry-over of KF might well have been 
sufficient to interfere with the assay and give rise to an 
exaggerated fall in the measured PDE activity.
Table 8 Effect of KF, NaF and KCl on high affinity cAMP-PDE activity 
associated with a crude membrane fraction from rat mammary 
acini
Incubation
Additions
Number of 
Experiments
Particulate high affinity cAMP-PDE 
activity (% control value)
None 8 100
KF 6 148.6±6.7+t
NaF 6 118.4±5.9*+
KCl 2 95.3±18.2
Samples of particulate fraction were incubated, as described in 
Materials and Methods (section 2.4) in the presence or absence of KF, 
NaF or KCl, all at a final concentration of lOOmM. Values given are 
means ( ±'SE) of the number of experiments indicated. Statistically 
significant differences (calculated from PDE activities expressed in 
U/mg protein) were determined using Student's t-test for paired 
observations. An asterisk denotes a value less than the 'plus KF' 
sample at PC0.005. Daggers denote values greater than control at 
P<0.01 (t) or PC0.005 (ft).
Figure 21
Samples of mammary acinar membranes were incubated, as described in 
section 2.4, in the presence of increasing concentrations of KF. 
Points represent figures from one experiment only or mean of two 
experiments (*) except the point for PDE activity at lOOmM KF (**) 
which represents the mean of four experiments. The latter served as 
reference by which all other data were standardised.
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The increase in particulate PDE activity provoked by KF was 
dependent on the presence of divalent cation in the incubation medium 
but an accurate assessment of the relative importance of each of the 
three physiologically important metal ions investigated here is 
confounded by the high variability of data arising from incubations 
in the presence of BAPTA and, to a lesser extent, EDTA (Table 9). 
However, it appears that approximately physiological concentrations 
of either Ca2+ or Mg2 + but not Mn2 + were capable of supporting the 
effect of KF on these membrane preparations, as evidenced by the 
activity observed in incubations containing BAPTA (a potent chelator 
of divalent cations with particularly high affinity for Mn2+), 
supplemented with excess Ca2+ or Mg2 + as appropriate. Qualitatively 
identical results were obtained in an experiment where EDTA was 
substituted for BAPTA (1,2-bis (2-aminophenoxy)ethane-NNN'N'-tetra- 
acetic acid). In this same experiment, while, once again, Mn2 +
(lmM) on its own showed no evidence of an ability to facilitate 
the KF effect, its inclusion in incubations already containing 
Ca2+ and Mg2+ resulted in an enhanced increase in particulate 
PDE activity following KF treatment (increase in the presence 
of Mg2 + and Ca2+ alone was 156% but in the presence of Mg2+, Ca2+ 
and Mn2+, this rose to 216%).
Effective antagonism of the increase in particulate PDE 
activity normally associated with KF treatment was achieved by the 
inclusion of ATP, ADP, GTP or pyrophosphate (all at a final 
concentration of 5mM) in the incubation buffer. However, the 
non-hydrolysable analogue of ATP, ATPyS was not as effective in this 
respect, adenosine was completely ineffective and inclusion of either 
AMP or KH2P04 in the incubations was not only ineffective but
Table 9 Effect of three physiologically relevant divalent cations on 
the ability of KF to enhance high affinity cAMP-PDE activity 
in a crude membrane fraction from rat mammary acini
High affinity cAMP-PDE activity
Incubation % control
additions
/t/U/mg protein (Ca2+/Mg2+)
Ca2+/Mg2+ 24.6 100
Ca2+/Mg2+/KF 58.0 236
EDTA/KF 34.8 142
BAPTA/Mg2 + */KF 69.0 281
BAPTA*/Ca2 + */KF 74.0 301
Mn2 + /KF 25.7 105
Samples of particulate fraction were incubated, as described in
Materials and Methods (section 2.4), except that the incubation
2 + 2 +buffer contained no Ca or Mg unless otherwise indicated. Values 
given are means of 2 separate experiments. Incubation addition 
concentrations were: Ca2+, 100//M; or * ImM; Mg2+, 5mM or *, lOmM; 
Mn2+, ImM; EDTA, 5mM; BAPTA, 5mM or * 0.5mM and KF, lOOmM.
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resulted in a significant enhancement of the increase in particulate 
activity observed in response to KF (Table 10). The effect of 
protamine sulphate, an organic polyanion, on this system was 
indeterminate since, although a significant reduction in the 
KF-induced increase was observed in its presence, protamine sulphate 
also appeared to enhance particulate PDE activity in the absence of 
KF. The concentration-dependence of antagonism was the same for ATP 
and GTP with maximal inhibition of the KF effect at a concentration 
greater than ImM (Figure 22).
The increase in particulate high affinity cAMP-PDE activity 
observed following incubation of membranes with KF was accompanied by 
a dramatic fall in the activity contained in supernatants derived 
from such incubations (Figure 23). The loss of supernatant activity 
was not due to inhibition of the PDE assay by KF remaining in the 
samples after desalting (conducted as described in Materials and 
Methods, section 2.4.1.) since recoveries of PDE activity were 
identical (approximately 100%) whether or not KF (final concentration 
lOOmM) was added to samples of control supernatant before the 
desalting procedure. This apparent redistribution of PDE activity 
from supernatant to particulate fractions following incubation with 
KF was completely blocked by ATP (final incubation concentration 5mM, 
Figure 21) and at least partially blocked by pyrophosphate (also 5mM) 
(data not shown), as would be expected from previous results (Table 
10). The phenomenon was also characterised by a concomitant decrease 
in total PDE activity (Figures 23, 24 and 25) suggesting that 
redistribution from soluble to particulate fractions involved 
inhibition of the enzyme's catalytic activity.
Membrane incubations were performed as described in materials and 
methods (section 2.4). Values given are means of experimental 
results ± SE, where appropriate. Statistically significant 
differences (calculated from PDE activities expressed in /vU/mg 
protein) were determined using Student's t-test for paired 
observations. Asterisks denote values greater than that for 
incubations in the presence of KF (lOOmM) alone at PC0.025 (*) or 
PC0.005 (**). Daggers denote values less than that for incubations 
in the presence of KF (lOOmM) alone at P<0.005 (+) or P<0.0005 (++).
Table 10 Effect of various agents on the ability of KF to enhance
PDE activity associated with a crude membrane fraction from 
rat mammary acini
Incubation Number of
additions experiments
None 6
KF (lOOmM) 6
KF (lOOmM), ATP (5mM) 6
KF (lOOmM), ATP S (5mM) 1
KF (lOOmM), ADP (5mM) 1
KF (lOOmM), AMP (5mM) 5
KF (lOOmM), Adenosine (5mM) 4
KF (lOOmM), GTP (5mM) 1
PPi (5mM) 2
KF (lOOmM), PPi (5mM) 4
Protamine sulphate (lmg/ml) 2
KF (lOOmM), protamine
sulphate (lmg/ml) 4
KF (lOOmM), protamine
sulphate (5mg/ml) 2
KF (lOOmM), KH2P04 (5mM) 4
High affinity cAMP- 
activity 
(% control)
100
150±7
82±5tt
136
78
167±9**
155±11
86
91±2
84±lf
115±1
136±9+
139±25 
164± 7*
■PDE
Figure 22
Membrane incubations were performed, as described in section 2.4, at 
various concentrations of ATP (A) or GTP (B) in the presence of 
lOOmM KF. High affinity cAMP-PDE activity in the absence of KF, ATP 
or GTP was 28.5juU/mg protein (A) or -23.6/uU/mg protein (B). Each plot 
represents data from one experiment only.
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Figure 22. High A f f in it y  cAMP-PDE A c tiv ity  Associated w ith
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Figure 23
Samples of acinar membrane preparation were incubated, as described in 
section 2.4, in the presence or absence of KF at two final incubation 
concentrations, as indicated. The membranes were reisolated and the 
resulting supernatants treated, as described in section 2.4.1, to 
remove KF. Columns represent means of duplicate incubations from a 
single experiment. Black shading denotes whole incubation, red shading 
denotes particulate fraction and blue shading denotes soluble fraction. 
Dotted lines represent the sum of particulate and soluble activities.
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Figure 24
Samples of acinar membrane preparation were incubated, as described in 
section 2.4, in the presence or absence of KF or KF plus ATP as 
indicated. The membranes were reisolated and the resulting 
supernatants treated, as described in section 2.4.1, to remove KF. 
Columns represent means of duplicate incubations from a single 
experiment. Black shading denotes whole incubation, red shading 
denotes particulate fraction and blue shading denotes soluble fraction. 
Dotted lines represent the sum of particulate and soluble activities.
(sauejqujan >pcqs T*VnTi) 3Qd-dW\P A^iuijjv M&TH
Figure 25
Supernatants from membrane incubations, performed as described in 
section 2.4, were treated with KF and both these and control (no 
additions) supernatants were subjected to centrifugation under the
conditions employed for reisolation of the membrane fraction. The
'new' supernatant was treated, as described in section 2.4.1, to remove 
KF and any pellets were resuspended to the original supernatant volume.
Columns represent means of values from two separate experiments. Red
columns denote activity sedimented under the conditions stated above 
and blue columns denote soluble activity. Total activity (soluble plus 
sedimentable), expressed as % control is indicated above relevant 
columns.
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That the effects described above were manifestations of 
properties belonging to a soluble PDE was confirmed by the ability of 
KF to precipitate activity from supernatants in the apparent absence 
of any particulate material. As demonstrated in Figure 25, this 
process was also blocked by ATP and therefore displays the major 
distinguishing features characterising the effects observed in 
membrane incubations. Further evidence that membrane bound enzyme 
could not contribute to the effects investigated using membrane 
incubations was provided by observations in membranes that, prior to 
incubation, had been washed more rigorously than by the single 
sedimentation that preceeded the incubations discussed above, in 
order to remove residual contaminating supernatant activity. The PDE 
activity of such membranes was insensitive to KF (Table 11) under 
conditions that invariably elevated particulate PDE activity in 
incubations containing unwashed membranes (Table 6).
3.2. Protein Phosphorylation in Isolated Mammary Acini 
During incubation of cells with 32Pi, as described in Materials and 
Methods (section 2.3.2.), a pool of 32P-labelled ATP is established 
and the phosphoproteins revealed by autoradiography therefore, 
presumably, display the steady-state level of phosphorylation 
prevailing at the time when the incubation was terminated. Under 
these conditions, the predominance of casein phosphorylation was 
obvious in both unfractionated homogenate (Figure 26) and cytosolic 
fractions derived from similar acinus incubations (Figure 27). 
Although enzymes such as acetyl-CoA carboxylase and ATP-citrate lyase 
(identified by molecular weight and characteristic predominance in 
Coomassie blue-stained electrophoretic separations of cytosolic
Table 11 Effect of KF and ATP on high affinity cAMP-PDE activity
associated with a crude membrane fraction (washed prior to 
incubation) from rat mammary acini
Particulate high affinity cAMP-PDE activity 
Incubation (//U/ml
additions membrane suspension) (jt/U/mg protein)
None 14.91 15.8
KF (lOOmM) 16.22 17.9
KF (lOOmM), ATP (5mM) 14.51 16.6
Acinus membranes, prepared, as described in section 2.4, were washed 
by suspension in KHC03 (ImM) and reisolated by centrifugation at 
22500 xg for 10 min prior to use as a source of membranes for 
incubations. Incubations were then conducted as described in 
materials and methods. Values presented are means of duplicate 
incubations from a single experiment.
Figure 26
The proteins contained in mammary acini, incubated with 32Pi (as 
described in section 2.3.2), in the presence or absence of additions 
as indicated, were resolved electrophoretically on 7.5% (w/v) 
polyacrylamide SDS gels. An autoradiogram representative of two 
separate experiments is shown.
Figure 26 . E ffe c t o f In s u lin  and Agents Capable o f E lev a tin g  
In t r a c e l lu la r  cAMP Concentrations on P ro te in  
Phosphorylation in  In ta c t  Mammary A c in i
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Figure 27
Acini were incubated in the presence of 32Pi, as described in section 
2.3.2 and a cytosolic fraction prepared, as described later in 
the same section. Phosphoproteins present in the electrophoretic 
separations (on 8% (w/v) polyacrylamide SDS gels) of these samples were 
identified by autoradiography. A separation representative of two 
separate experiments is shown.
Figure 27. P ro te in  Phosphorylation in  Cytosols from Mammary 
A cin i E q u ilib ra te d  w ith  ^ P i
ACC
•ORIGIN
■240
ACL 120
96
50
42
27
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mammary proteins) are major phosphoprotein components of mammary 
cytosols (Figure 27), they did not give rise to prominent bands in 
autoradiogrpahs of unfractionated cellular homogenates following SDS 
polyacrylamide gel electrophoresis, even when the photographic plate 
was deliberately over-exposed in the region of the caseins in order 
to reveal less extensively phosphorylated or less abundant 
phosphoproteins of higher molecular weights (Figure 26). The fact 
that these (acetyl-CoA carboxylase and ATP-citrate lyase) and other 
major cytosolic phosphoproteins were easily detectable in 
SDS-polyacrylamide gels only if membrane fragments and casein 
micelles were removed (by centrifugation) prior to electrophoretic 
separation, suggests that the phosphoprotein complement of those 
structures served to mask the otherwise obvious phosphorylations of 
acetyl-CoA carboxylase, ATP-citrate lyase and other prominent 
cytosolic phosphoproteins.
In the intact mammary epithelial cell, caseins are confined to 
the lumen of Golgi and related vesicles. However, under the 
relatively harsh homogenisation procedures used to obtain the 
cytosols characterised here for mammary acini, it is likely that 
these vesicles would have been disrupted, releasing their contents 
into the cytosol. Although much of the released casein would 
initially be in micellar form, sequestration of Ca2+ by the 
Ca2+-chelating agents present in the homogenisation buffer would have 
rendered it non-sedimentable. This accounts for the presence of 
caseins in these cytosol fractions. Because of the intensity of 
casein labelling, all autoradiograms exposed to reveal 
phosphoproteins labelled less intensely will be over-exposed to 
saturation in the region of the caseins. Hence, although the
147
exposure of caseins appears approximately the same in Figures 27 and 
28, the difference in photographic intensity of other bands, such as 
those of acetyl-CoA carboxylase and ATP-citrate lyase, between the 
two Figures, is probably due, predominantly, to differences in 
exposure time (since the caseins are saturated in both 
autoradiograms, exposure time has little effect on their observed 
photographic intensity). Another possible contributory factor is a 
difference in the degree of carry-over of 105000xg pellet (containing 
casein-loaded vesicles) into the supernatant fraction.
The pattern of phosphorylation observed in both unfractionated 
homogenates and cytosol preparations following incubation of mammary 
acini under the conditions described above was unchanged whether the 
final 15 minutes of the incubation period were conducted in the 
presence or absence of insulin or agents known to raise intracellular 
cAMP concentrations (Ro7-2956, isoprenaline, forskolin, IBMX) [102] 
(see Figures 26 and 28). While changes in the phosphorylation state 
of many proteins with molecular weights between about 20kDa and 45kDa 
would have been obscured completely by the extremely high density of 
casein associated labelling, higher molecular weight proteins 
displaying susceptibility to cAMP or insulin dependent changes in 
phosphorylation state should have been readily identifiable, 
particularly in autoradiographs of 4% (w/v) total acrylamide gels, 
since caseins run at the dye-front in such gels. However, 
experiments of this type using both unfractionated homogenate (data 
not shown) and cytosols prepared from the acinus incubations (100a) 
failed to reveal anything that was not also discernable in the 8% 
gels shown in Figures 26 and 28.
Figure 28
Acini were incubated as described in section 2.3.2., in the 
presence and absence of isoprenaline and Ro7-2956 as indicated and a 
cytosolic fraction prepared as described later in the same section. 
Phosphoproteins present in the electrophoretic separations (on 8% (w/v) 
polyacrylamide SDS gels) of these samples were identified by 
autoradiography. A separation representative of two separate 
experiments is shown.
Figure 28. E ffe c t on C yto so lic  P ro te in  Phosphorylation o f  
Incubating  Mammary A c in i w ith  a Combination o f  
Iso p ren a lin e  and Ro 7-2956
dye
Mr
(KDa) isoprenaline +
control Ro 7-2956
origin-----
m   116
  97 —
( f e   67 -----
27
22
Coomassie blue 
stained
Autoradiograms
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Consistent with work of a similar nature conducted by Clegg et 
al. [100], slices of gels used to separate phosphoproteins labelled 
with 32P in intact cells showed no changes in the level of 
phosphorylation, as determined by liquid scintillation counting, of 
acetyl-CoA carboxylase isolated from homogenates (Table 12) or 
cytosols (Table 13) of cells incubated in the presence or absence of 
either insulin or agents that raise intracellular cAMP levels. This 
supports the visual evidence provided by autoradiographs such as the 
one shown in Figures 26, that steady state acetyl-CoA carboxylase 
phosphorylation was not affected either by exposure of intact acini 
to insulin or by elevation of their intracellular cAMP 
concentrations.
Allred et al. [9a] have shown that, in rat liver, acetyl-CoA 
carboxylase may associate with mitochondria and that the extent of 
association varies with nutritional status. It might therefore be 
reasoned that the explanation for an inability to observe effects of 
hormone and other agents on acetyl-CoA phosphorylation in acinus 
cytosols is that the hormone-sensitive acetyl-CoA carboxylase 
population is associated predominantly, if not totally with those 
cellular fractions removed during preparation of the cytosol. That 
this was not in fact the answer was demonstrated by experiments using 
unfractionated homogenates in which no change in the extent of 
phophorylation of acetyl-CoA carboxylase was observed following 
incubation of acini with insulin or agents known to raise 
intracellular cAMP concentration (data not shown). The strength of 
this evidence is perhaps undermined, to a certain extent, by the 
proposed obscuring of acetyl-CoA carboxylase phosphorylation by other 
membrane-associated phosphoproteins. However, it seems unlikely that
Table 12 Effect of insulin and forskolin treatment of rat mammary 
acini on the steady state level of phosphorylation of 
acetyl-CoA carboxylase
ACC
Associated
Incubation
additions
Radioactivity associated with 
gel slice (CPM x 10"2)
radioactivity 
(% of counts in 
control band)
ACC band Control band
None 9.9 7.5 132
Forskolin 9.6 6.9 139
Insulin 9.3 6 . 6 141
Acini were incubated as described in Materials and Methods (section 
2.3.2) with forskolin (10//M) or insulin (1.68 mU/ml) as indicated. 
Five replicate incubations were performed for each condition and 
samples of the disaggregated homogenate derived from each incubation 
were run on 4% (w/v) total acrylamide SDS-PAGE gels. Phosphoproteins 
were detected and 32P content quantitated as described in Section
_ 2
2.7. Values given (CPM x 10 ) are means of 5 replicate observations
obtained from 1 experiment only; individual determinations differed 
by not more than ± 12% of the means tabulated.
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significant changes in the phosphorylation of such an abundant 
protein could be masked in this manner.
3.3. Protein Phosphorylation in Mammary Cell Fractions 
A survey was conducted of the contributions made by four major 
effector-dependent protein kinases (cAMP-PrK, CC-PrK, PrK-C and 
polyamine-PrK see section 1.3.8.(i)) to the endogenous protein 
phosphorylations observed in each of four subcellular fractions 
prepared from mammary cells as described in Materials and Methods 
(section 2.5.). Differential centrifugation allowed the isolation of 
three membrane fractions and a high speed supernatant fraction with 
consistently reproducible protein separation patterns on 
SDS-polyacrylamide gel electrophoresis (Figure 29). The fractions 
correspond to a nuclear and large membrane fragment fraction (lOOOxg 
pellet), a mitochondrial fraction (3000xg pellet), a microsomal 
fraction (105000xg pellet) and a post-microsomal supernatant 
(cytosolic) fraction (105000xg supernatant). Marker enzyme assays, 
performed as described in Materials and Methods (section 2.8.2.) 
provided a quantitative characterisation of the general composition 
of these cellular fractions and once more demonstrated the 
reproducibility of the fractionation technique (Table 14).
The rate of incorporation of 32P into proteins present in 
mammary cell supernatant fractions incubated with [y-32P] ATP, as 
described earlier (section 2.6.), was approximately linear for at 
least 60 sec. at 37°C for most of the major phosphoproteins revealed 
by autoradiography of SDS polyacrylamide gels containing proteins 
labelled with 32P during such incubations (Figure 30).
Incorporations determined after 30 sec. incubation therefore probably
Table 14 Activities of enzyme markers, specific to mitochondria,
plasma membrane and cytosol, expressed by the subcellular 
fractions used in investigation of mammary protein 
phospho rylati ons
Fraction
Nuclear
5'nucleotidase +
(U/mg
protein)
1.15±0.05
(% 
total)
34±1
ENZYME ACTIVITY
Cytochrome-c
oxidase*
(U/mg (%
protein) total)
LDH*
5.1±2.2 30±5
(U/mg
protein)
52.8117.9
Mitochondrial 1.0710.13 3112 11.213.4 6712 31.61 7.8
Microsomal 0.9010.11 2612 0.610.7 314 74.51 8.0
Cytosolic 0.3110.02 911 0.010.0 010 613.91121.0
Assays for 5'nucleotidase, cytochrome-c-oxidase and lactate 
dehydrogenase (marker enzymes for plasma membrane, mitochondrial 
membrane and cytosol respectively) were performed as described in 
Materials and Methods (section 2.8.2). Values given are means 1 SE 
of data from 5 (t) or 3 (*) separate fractionations.
(% 
total)
711
411
1011
7912
Figure 29A
Mammary cell fractions were prepared by differential centrifugation, 
as described in section 2.5 and samples were resolved 
electrophoretically on a 5% (w/v) polyacrylamide SDS gel. Protein 
bands were detected by staining with Coomassie brilliant blue. The 
stained gel is shown. Each track within a particular fraction 
represents a sample taken from a separate fractionation performed on 
acini prepared from a separate animal. N denotes 'nuclear' fraction 
and M denotes 'mitochondrial' fraction.
Figure 29 A. E le c tro p h o re tic  Separations o f P ro te in s  Contained  
in  Mammary C e ll "Nuclear" and "M itochondria l"  
Fraction s
Mr
( KDa ) 
ORIGIN
N M
Figure 29B
Mammary cell fractions were prepared by differential centrifugation, 
as described in section 2.5 and samples were resolved 
electrophoretically on a 5% (w/v) polyacrylamide SDS gel. Protein 
bands were detected by staining with Coomassie brilliant blue. The 
stained gel is shown. Each track within a particular fraction 
represents a sample taken from a separate fractionation performed on 
acini prepared from a separate animal. M denotes 'microsomal' fraction 
and C denotes 'cytosolic' fraction.
Figure 29 B. E le c tro p h o re tic  Separations o f P ro te in s  Contained 
in  Mammary C e ll "Microsomal" and "C yto so lic"  
F raction s
Mr
( KDa )
ORIGIN
  240
120
97
80
67
DYE
M C
Figure 30
Acinus 'cytosols', prepared as described in section 2.5, were 
incubated for 0.5, 1.0, 3.0 or 10.0 minutes under the conditions 
described in section 2.6. Data points represent means of duplicate 
incubations from a single experiment representative of a pair of 
separate experiments. Results are presented for 32P-incorporation 
(determined by liquid scintillation counting, as described in section 
2.7) into bands in electrophoretic gels corresponding to proteins of 
molecular weights 57.3kDa (red), 47kDa (blue), 100.3kDa (green) and 
29.5kDa (black).
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approximated to measurements of initial rates of net incorporation of 
32P into those phosphoproteins.
Since the extent of net phosphate incorporation into any 
particular protein necessarily reflects the relative activities of 
both the kinase responsible for its phosphorylation and the 
phosphatase governing its dephosphorylation, the potential influence 
of phosphatase activity on the phosphorylation state of 
phosphoproteins detected following incubation of mammary acinar 
cytosols with [y-32P] ATP was assessed by the use of phosphatase 
inhibitors such as KF and vanadate and by delayed addition of excess 
unlabelled ("cold") ATP to phosphorylation incubations. Addition of 
large excess of "cold" ATP to incubations after 30 sec. completely 
blocked any further incorporation of 32P into all major cytosolic 
phosphoproteins but failed to initiate a measurable decrease in net 
incorporation over a period of 30 sec. following addition, as 
exemplified by the incorporation of 32P into a protein of molecular 
weight 57.3kDa shown in Figure 31. That at least limited capacity 
for protein bound phosphate turnover exists in such preparations was 
suggested by the small but measurable loss of labelled phosphate 
observed 10 minutes after delayed addition of excess "cold" ATP, 
however in this example, net 32P-incorporation appears to decline 
after 3 minutes of incubation, even in the absence of excess 
unlabelled ATP, indicating that conclusions of this kind might not be 
valid. Addition of phosphatase inhibitors, again after 30 sec. 
incubation with [y-32P] ATP, had little, if any effect on the 
subsequent rate of 32P-incorporation into this protein. In general, 
the same effect of phosphatase inhibitors was observed for most other 
major cytosolic phosphoproteins but while addition of KF, without
Figure 31
Samples of acinus cytosol, prepared as described in section 2.5, were 
incubated, under the conditions described in section 2.6, for 0.5 
minute before addition of phosphatase inhibitors (A) or a large excess 
of unlabelled ATP (A and B). Changes in incorporation of 32P into the 
57.3kDa protein, contained in these samples, were assessed by liquid 
scintillation counting, as described in section 2.7, after a further 
incubation period of either 0.5 min or 9.5 min as indicated. Data 
points represent mean values of duplicate incubations from a single 
experiment.
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exception, failed to elevate the level of 32P-incorporation into any 
of these proteins and addition of vanadate was similarly ineffective 
for most of the phosphoproteins studied, two proteins (molecular 
weights 47kDa and 240kDa [i.e. acetyl-CoA carboxylase]) displayed 
marked increases in the amount of 3 2 P incorporated following vanadate 
treatment (Figure 32). Based on the difference in amount of 32P 
incorporated during the 30 sec. of incubation following addition of 
vanadate, the stimulation, by vanadate, of the rate of incorporation 
was over 3 fold for the 47kDa protein and over 5^-fold for acetyl- 
CoA carboxylase.
3.3.1. Ca2+/calmodulin-Pependent Protein Kinase 
Only one major phosphoprotein (molecular weight 100.3kDa) showed 
any evidence of enhanced phosphorylation following incubation 
of each of the four subcellular fractions in the presence of Ca2+ 
(endogenous, i.e. incubation in the absence of EGTA, or added at a 
final concentration of 10/vM). Although representing a major 
phosphoprotein in all but the mitochondrial fraction, phosphorylation 
of the 100.3kDa protein was only sensitive to Ca2+ in the 
post-microsomal supernatant. In this fraction, its phosphorylation 
in the presence of Ca2+ (either at endogenous concentrations or with 
10/t/M additional Ca2+) was 323 ± 62.3% (mean ± SE of 4 separate 
experiments) of that achieved when the concentration of free Ca2+ was 
reduced to near zero in control incubations by the inclusion of 2mM 
EGTA. The increase in incorporation observed in response to Ca2+ was 
statistically significant at P < 0.05 as determined by Student's 
t-test for paired observations. This stimulation was increased to 
929% of control incorporation (single experiment) in the simultaneous
Figure 32
Samples of acinus cytosols, prepared as described in section 2.5, were 
incubated as described in section 2.6, for 0.5 minute before addition 
of phosphatase inhibitors. Changes in 32P-incorporation into proteins 
contained in the samples were assessed, as described in section 2.7, 
after a further incubation period of 0.5 minute. Data represent means 
of duplicate incubations from a single experiment. Blue shading 
denotes control, green shading denotes KF (lOOmM) and red shading 
denotes V043~ (lOOmM).
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presence of Ca2+ (endogenous plus 10//M) and calmodulin (5/yg/mg 
protein). The marked increase in phosphorylation of this protein, in 
the presence of Ca2+, is shown clearly in Figure 33. Although some 
further increase in phosphorylation is discernible in the 
simultaneous presence of Ca2+ and calmodulin, the full extent of this 
increase (indicated by the figures obtained from liquid scintillation 
counting, see above) is not apparent by inspection of the 
autoradiogram, due to saturation of the photographic emulsion during 
autoradiography.
3.3.2. Protein Kinase C
Once again, only the 100.3kDa protein of acinar post-microsomal 
supernatants showed any change in extent of phosphorylation in 
response to Ca2+ and neither phosphatidyl serine (incubation 
concentration 20/vg/ml) alone nor phosphatidyl serine (20/vg/ml) 
together with phorbol ester (incubation concentration lOOng/ml PMA) 
affected the level of 32P-incorporation into any of the major 
phosphoproteins visualised by autoradiography. The lack of 
phospholipid and phorbol ester sensitive phosphorylation in any of 
the three membrane fractions or post-microsomal supernatant fraction 
was confirmed by liquid scintillation counting of gel slices 
corresponding to the major phosphoproteins separated by SDS 
polyacrylamide gel electrophoresis. Phosphatidyl serine is known to 
be one of the most effective phospholipid activators of PrK-C 
[377,420,755] and PMA has been demonstrated to be a potent stimulator 
of PrK-C activity [84,567] by virtue of its ability to substitute for 
diacyl glycerol (see section 1.3.8(i)b). Since these agents were 
without effect, the implication is that either PrK-C activity was
Figure 33
The proteins contained in samples of mammary acinus 'cytosol', prepared 
as described in section 2.5. and incubated with [y_32P] ATP, as 
described in section 2.6., in the presence and absence of Ca2+ or Ca2+/ 
calmodulin, as indicated, were resolved electrophoretically on 8% (w/v) 
polyacrylamide SDS gels. Control incubations contained EGTA (2mM).
All other incubations were performed in the absence of EGTA and 
contained CaCl2 (final concentration 10/yM). Ca2+/calmodulin 
incubations contained calmodulin added at a final concentration of 
5yug/mg protein. The control and plus Ca2+ incubations are 
representative of 2 separate experiments and the autoradiogram 
presented is that obtained in the single experiment in which an 
incubation in the simultaneous presence of Ca2+ and calmodulin was 
included. The horizontal lines visible at intervals throughout the 
tracks were drawn during the experiment as an aid to subsequent slicing 
of the gel for liquid scintillation counting.
Figure 33. E ffe c t o f Ca2+ and Ca2+-calmodulin on P ro te in  
Phosphorylation in  Mammary Acinar Cytosols
_ _
0 0 It
Mr
(kDa)
ORIGIN
100.3
co n tro l Ca2+ Ca2+ 
calmod.
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extremely low in all fractions tested or that the kinase was 
predominantly confined to one fraction while its substrate(s) resided 
in another.
3.3.3. Polyamine-Dependent Protein Kinase
Incubation of mammary cell fractions with polyamine led to changes 
in the amount of 32P incorporated into many of the phosphoproteins 
identified by autoradiography. The pattern of polyamine associated 
changes in mammary protein phosphorylation was complex and the major 
phosphoproteins of each subcellular fraction appeared, in general, to 
show properties characteristic of the fraction in which they resided 
(Figure 34). Indeed all proteins common to two or more different 
fractions displayed characteristics of polyamine response apparently 
much more dependent on the fraction with which they were associated 
than the nature of the individual proteins themselves.
With the possible exception of two mitochondrial fraction 
phosphoproteins (molecular weights 47kDa and 51kDa), all membrane 
proteins exhibited obvious increases in phosphorylation in the 
presence of polyamine but only four of the eight cytosolic 
phosphoproteins analysed for 32P content showed any such response.
In the 'nuclear' fraction, spermidine was generally a more effective 
stimulator of protein phosphorylation than spermine with only two 
proteins (molecular weights 75.5kDa and 107kDa) showing convincing 
reversal of this ranking (Figure 34A). A similar pattern was evident 
in the major phosphoproteins of the 'mitochondrial' fraction (Figure 
34B) except that the degree of enhancement of phosphorylation was, 
with the exception of a 35kDa protein, lower than that displayed by 
the corresponding protein bands in electrophoretic separations of the
Figure 34
Samples of mammary cell 'cytosolic' (A), 'microsomal' (B), 
'mitochondrial' (C) and 'nuclear' (D) fractions, prepared as described 
in section 2.5, were incubated, under the conditions described in 
section 2.6, in the presence or absence of spermine (unshaded columns) 
or spermidine (shaded columns), both at final concentrations of ImM. 
Changes in 32P-incorporation into proteins contained in the samples 
were assessed as described in section 2.7. Proteins corresponding in Mr 
to the subunits of acetyl-CoA carboxylase (240kDa) and ATP-citrate 
lyase (116 kDa) underwent only a very small degree of phosphorylation 
that could not accurately be quantitated in these kind of experiments. 
Data are means of duplicate incubations from a single experiment and 
are representative of a pair of separate experiments.
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'nuclear' fraction. Two of the proteins associated with this 
fraction (molecular weights 47kDa and 51kDa) showed no increase in 
phosphorylation as a result of exposure to spermine and only a 
marginal increase in response to spermidine. In complete contrast, 
phosphorylation of all the major phosphoproteins residing in the 
'microsomal' fraction was much more sensitive to spermine than 
spermidine (Figure 34C). While the increase in phosphorylation 
induced by spermine ranged in magnitude from 157-196% control, that 
engendered by incubation with spermidine was generally less than 
about 120% and reached a maximum of only 139% control. The major 
'cytosolic' phosphoproteins may be divided readily into two groups; 
those whose phosphorylation was stimulated by spermine and those 
whose phosphorylation showed little or no response to spermine 
(Figure 34D). The degree of stimulation within the former group was 
remarkably consistent, presenting a mean increase ± SE of 131 ± 1% 
control. The lack of effect of spermidine on 32P-incorporation into 
this group of proteins was equally consistent, displaying a mean ± SE 
of 101 ± 3% control. Not only did polyamine fail to stimulate 
phosphorylation of the second group of cytosolic proteins but 
spermidine actually elicited a modest reduction in control 32P- 
incorporation into these proteins.
3.3.4. cAMP-Dependent Protein Kinase
No significant effects of cAMP on protein phosphorylation in 
any of the three membrane fractions were elicited by the inclusion of 
Bt2cAMP (final incubation concentration 1//M) in incubations performed 
as described in section 2.6 but at least two cytosolic 
phosphoproteins (molecular weights 47kDa and 57.3kDa) showed enhanced
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incorporation of 32P following incubation under such conditions 
(Figure 35). Although small increases in phosphorylation, in the 
presence of Bt2cAMP (or cAMP/IBMX), were observed for all the protein 
bands studied in cytosolic fractions (e.g. 24kDa "control" band in 
Table 15), only the 47kDa and 57.3kDa proteins consistently showed 
marked (usually over 2-fold) increases in phosphorylation under these 
conditions. Cyclic AMP itself was an equally effective stimulator of
3 2 P-mcorporation into these proteins both in the presence and 
absence of IBMX (added to inhibit endogenous cAMP-PDE activity)
(Table 15). The Bt2 cAMP dose-response relationships for 
phosphorylation of the 47kDa and 57.3kDa proteins both in the 
presence and absence of EGTA, are shown in Figure 36. As noted 
above, these two phosphoproteins were the only ones whose 
phosphorylation was consistently enhanced markedly by inclusion of 
Bt2cAMP in mammary acinar cytosol incubations, however, a third 
phosphoprotein (molecular weight 38.4kDa), displaying similar 
Bt2cAMP dose response characteristics was occasionally revealed in 
electrophoretic separations obtained from incubations in the absence 
of EGTA (Figure 37). While a 38.4kDa phosphoprotein was also readily 
identifiable in electrophoretic separations of cytosols incubated in 
the presence of EGTA (i.e. in the absence of endogenous Ca2+ and 
Mn2+), under these conditions there was no indication of its 
phosphorylation being cAMP-dependent. Although the apparent absolute 
requirement for endogenous divalent cation characterising 
cAMP-dependent phosphorylation of the 38.4kDa protein was not 
displayed by 32P-incorporation into the 47kDa and 57.3kDa protein, 
the responsiveness of phosphorylation of the latter two cytosolic 
proteins to stimulation by Bt2cAMP was enhanced markedly when EGTA 
was omitted from the incubation buffers (Figure 36).
Table 15 Comparison of the effects of cAMP (in the presence or
absence of IBMX) and Bt2 cAMP on 32P-incorporation into 
three cytosolic proteins
3 2 P-incorporation 
(% control ie no additions)
Incubation
additions 24kDa 47kDa 57.3kDa
None 100 100 100
Bt2 CAMP (1//M) 115 178 224
Bt2 CAMP (lOywM) 102 204 277
CAMP (1/vM) 93 158 218
CAMP (10//M) 115 297 266
CAMP (1/t/M) plus 
IBMX (ImM)
120 204 238
CAMP (10/yM) plus 134 224 285
IBMX (ImM)
Rat mammary acinar cytosols were incubated, in the absence of EGTA, 
as described in Materials and Methods (section 2.6). Incubation 
additions (final concentrations in parentheses) were as indicated and 
values given are means of duplicate incubations from a single 
experiment. Values for 32P-incorporation into a cytosolic protein of 
molecular weight 24kDa are presented as an example of 
cAMP-independent phosphorylation.
Figure 35
The proteins contained in samples of mammary acinus 'cytosol', 
prepared as described in section 2.5 and incubated with [y-32P]ATP as 
described in section 2.6, in the presence (+cAMP) or absence (-cAMP) 
of Bt2 cAMP (1/yM) as indicated, were,resolved electrophoretically on 8% 
(w/v) polyacrylamide SDS gels. Autoradiograms representative of 4 
separate experiments are shown alongside a corresponding Coomassie 
blue-stained gel.
Figure 35. E ffe c t o f D ib u ty ry l cAMP on P ro te in  Phosphorylation  
in  Mammary Acinar Cytosols
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Figure 36
Samples of mammary acinus 'cytosols' prepared as described in section
2.5, were incubated under the conditions described in section 2.6, at a 
range of Bt2cAMP concentrations, in the presence (A) or absence (B) of 
EGTA (2mM). Cyclic AMP-dependent phosphorylations were quantified as 
described in section 2.7. Data represent means of duplicate 
incubations from two separate experiments and relate to proteins of 
molecular weights 57.3kDa (circles) and 47kDa (squares).
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Figure 37
Samples of mammary acinus 'cytosols' prepared as described in section
2.5, were incubated, under the conditions described in section 2.6, at 
a range of Bt2cAMP concentrations, in the absence of EGTA. Data points 
represent means of duplicate incubations from a single experiment and 
relate to a protein of molecular weight 38.4kDa (triangles). Data for 
proteins of molecular weights 57.3kDa (circles) and 47kDa (squares) are 
redrawn from Figure 32, for comparison.
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In view of the pronounced reduction in background labelling 
observed in electrophoretic gels derived from Bt2cAMP dose-response 
incubations in the absence of EGTA (Figure 38) and the associated 
substantial decrease in radioactivity measured in specific protein 
containing bands of such gels, including the 38.4, 47 and 57.3kDa 
proteins (Figure 38), it is probable that the apparent increase in 
responsiveness of cAMP-dependent phosphorylation expressed in the 
presence of endogenous divalent cation reflects an increase in the 
sensitivity of the experimental techniques to changes in the 
phosphorylation of specific proteins, rather than necessarily 
implying an additional (Ca2+- or Mn2+-dependent) regulatory property 
of the cAMP dependent phosphorylation system(s).
The half maximally effective concentration for the stimulation 
of 32P-incorporation by Bt2 cAMP observed with these three 
phosphoproteins is difficult to assess due to the lack of a reliable 
figure for the maximally effective Bt2 cAMP concentration. However, 
all the dose-response curves showed maximum sensitivity to changes in 
Bt2cAMP concentration between the values of 0.1 and 1/yM and were 
apparently unaffected by the presence of endogenous divalent cations 
(except, as noted above, for the 38.4kDa protein) (Figures 36 and 
37).
Unlike previous experiments in which omission of EGTA from 
incubation buffers resulted in marked increases in the 
phosphorylation of a 100.3kDa protein (see section 3.3.1. and Figure 
33), in these experiments, phosphorylation of the 100.3kDa protein 
appeared, if anything, to decrease marginally in the absence of EGTA 
(Figure 38). However, bearing in mind the profound decrease in 
phosphorylation observed for all other proteins in cytosol fractions
Figure 38
The proteins contained in samples of mammary acinus 'cytosol 
prepared as described in section 2.5 and incubated under the conditions 
described in section 2.6, in the presence and absence of EGTA (2mM) as 
indicated, were resolved electrophoretically on 8% (w/v) polyacrylamide 
SDS gels. Autoradiograms representative of two separate experiments 
are shown.
figure 38. Effect of EGTA on Protein Phosphorylation 
in Mammary Acinar Cytosols
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under these conditions, the much less marked effect, on 
phosphorylation of the 100.3kDa protein (Figure 34) is, in effect 
qualitatively consistent with previous results. Why the absence of 
EGTA should have had such a pervasive effect in later experiments is 
unclear, since the experimental procedure employed was identical to 
that followed for the previous experiments in which no discernable 
reduction in protein phosphorylation was observed. One possible 
explanation for this effect might be that the cytosols prepared in 
the later series contained substantial broad specificity divalent 
cation-dependent protein phosphatase activity, absent in previous 
preparations, however, further characterisation of this putative 
divalent cation-dependent effect was hampered by its poor 
repeatability. Further speculation along this or other lines could 
not therefore be substantiated and is arguably unnecessary since the 
important finding was that, whether in the presence or absence of 
EGTA, phosphorylation of at least two cytosolic proteins varied, in a 
classic dose-dependent manner, with Bt2cAMP concentrations. 
Furthermore, while the results for Ca2+-dependence of phosphorylation 
of the lOOkDa protein appear at face value, to be contradictory, as 
noted above, when considered in context, these results are in fact 
consistent with the earlier finding that the phosphorylation of this 
protein was enhanced in the presence of Ca2 + .
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4. DISCUSSION
4.1. Insulin Sensitive High Affinity cAMP-phosphodiesterase
4.1.1. Adipose Tissue
High affinity cAMP-PDE activity measured in adipose tissue at 
substrate concentrations of lOji/M [491] and 0.45/vM [878] has been 
reported to be 4420pmol/min/g dry wt. and 1153.6pmol/min/g lipid 
respectively. Expressing the activity observed in adipocyte 
homogenates in this study in terms of adipocyte dry weight which, for 
such cells, is also a reasonable approximation to lipid weight gives 
a value of 476.3pmol/min/g dry wt. While, at first sight, this figure 
appears low in comparison, it represents PDE activity at a cAMP 
concentration of only 0.2/cvM and is therefore probably in reasonable 
agreement with the value of 1153.6pmol/min/g lipid reported by Zinman 
and Hollenburg [878]. Comparison with the higher value reported by 
Loten and Sneyd at a cAMP concentration of 10//M [491] is difficult 
because of the increasingly large, indeterminate contribution made by 
low affinity activity as substrate concentration is increased but, once 
again, allowing for such factors, these results may also be considered 
broadly comparable. Under various incubation, homogenisation and assay 
conditions, insulin stimulation of adipocyte high affinity cAMP-PDE 
activity in whole cell preparations has been reported to be 121% 
control [491], 140% control [506] and 140-150% control [878] at insulin 
concentrations of 800 U/ml, ImU/ml and 145/vU/ml respectively. The 
figure of 146% increase over control activity reported here in 
adipocytes exposed to ImU/ml insulin is therefore consistent with the 
upper end of the range of expected values. Although activations 
of this order may seem modest, it must be remembered that they are
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observed under conditions where the activity of insulin insensitive 
enzyme is likely to make a substantial contribution to the measured 
high affinity cAMP-PDE activity irrespective of the substrate 
concentration at which it is assayed. Simply by preparing a crude 
membrane fraction, much of the interfering activity (confined, as it 
is, largely to the cytosol) may be selectively removed, allowing 
detection of a stimulation approaching 2-fold in response to insulin 
[878] though Kono et al have been able to demonstrate a 2-3 fold 
activation in both unfractionated homogenates and crude endoplasmic 
reticulum preparations [429,502,803].
The compatibility of the results presented in this report with 
previously documented hormonal effects on the activity of adipose 
tissue high affinity cAMP-PDE validates the procedures employed and 
allows extension of the investigation to tissues such as mammary gland 
whose characteristics, with respect to such effects, have not 
previously been determined.
4.1.2. Mammary Gland
Techniques used to study the effect of insulin on adipose tissue 
high affinity cAMP-PDE were successfully applied to mammary gland but 
while the results obtained demonstrated that the mammary enzyme 
displays similar insulin-dependent regulatory properties to the 
corresponding PDE systems in adipose tissue and liver, neither tissue 
appears to provide a comprehensively consistent model for insulin- 
dependent high affinity cAMP-PDE activity in mammary cells.
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4.1.2.(i) Sulphydryl and Proteolytic Effects 
Activation, by dithiothreitol (DTT), of endogenous protease 
activity, apparently analagous to lysosomal thiol protease activity 
observed in liver [490,673] and kidney [742], has been demonstrated in 
a membrane fraction isolated from adipocytes [502,748]. Proteolytic 
activation of high affinity cAMP-PDE either by trypsin or endogenous 
protease(s) has been described in a number of tissues including rat 
kidney cortex [742,743], rat uterus [193], adipose tissue [501,502] 
and liver [490]. Since the buffer in which particulate fractions were 
resuspended in this study contained the thiol reagent |3-mereaptoethanol 
(l.lmM), an activation of endogenous protease similar to that observed 
in other tissues might be expected to occur during storage of the 
mammary membrane fraction, leading to proteolytic activation of the 
mammary high affinity cAMP-PDE. Proteolytic activation therefore 
provides an attractive explanation for the increase in high affinity 
cAMP-PDE activity observed during storage of the mammary acinar 
particulate fraction used in this study. However, activation of the 
mammary enzyme appears to be more rapid than that observed for the 
membrane bound high affinity cAMP-PDE of adipose tissue and less 
susceptible to inhibition by protease inhibitors such as antipain and 
leupeptin [502].
The loss of insulin-stimulated activity seen here during storage 
of particulate fractions at 0-4°C in the presence of p-mercaptoethanol 
is similar in nature to that observed in adipocyte membranes exposed to 
DTT ([501,502], see section 3.1.2.(ii)) and might be supposed to arise 
from reduction of S-S groups necessary for stability of 
insulin-stimulated activity as proposed by Kono and co-workers [501]. 
However, the percentage activation was preserved (absolute activation
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increased) during storage when particulate fractions were suspended in 
an inhibitor cocktail containing PMSF, leupeptin, pepstatin, antipain, 
trypsin inhibitor, c-amino caproate, benzamidine, EDTA, EGTA and KF. 
Besides preventing DTT-stimulated activation of membrane bound high 
affinity cAMP-PDE, protease inhibitors such as antipain, leupeptin, 
pepstatin, chymostatin, E-64, DFP and TLCK have been shown to 
alleviate, partially, the suppression of insulin-induced activation 
imposed by the presence of DTT during storage of adipocyte particulate 
fractions at 4°C [502]. Such interactions, which involve an increase 
in both absolute and percentage insulin activations with respect to 
their values in the presence of DTT alone, are broadly consistent with 
the above observation in mammary tissue that protease inhibitors 
maintained per cent activation while provoking an increase in the 
absolute values for insulin-induced stimulation of high affinity 
cAMP-PDE activity. With respect to their influence on the activation of 
non-insulin-stimulated PDE observed during storage at 0-4°C in 
the presence of reducing agents (DTT or p-mercaptoethanol), however, 
these inhibitors were less effective in the mammary membrane system 
than in the analogous adipocyte system. Whether this implies that 
other, non-proteolytic processes are involved, or whether the 
endogenous mammary protease is simply less sensitive to these 
inhibitors is a matter for conjecture.
It has been suggested that limited proteolysis, resulting in 
solubilisation and activation of membrane bound PDE catalysed by an 
endogenous protease may represent an important mechanism for regulation 
of PDE activity [227]. This being so, the putative protease of mammary 
tissue which appears to be much more active than its counterpart in 
adipose tissue, would seem, potentially, to provide an effective 
mediator of such a regulatory mechanism.
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4.1.2.(ii) Effects of Cycloheximide, 24hour Starvation and Diabetes 
Rather than inhibiting the stimulation, by insulin, of mammary high 
affinity cAMP-PDE activity, cycloheximide actually enhanced this 
response. The major inference from this observation was that insulin 
stimulated synthesis of PDE enzyme molecules could not account for 
the increase in PDE activity detected in response to insulin.
However, it does not necessarily follow that the enhancement of 
insulin activation provoked by exposure to cycloheximide is, 
therefore, entirely independent of its ability to block protein 
synthesis. Nevertheless, in order to propose an explanation based on 
such a premise, it would be necessary to construct mechanisms for which 
there is apparently little supporting evidence in the literature. As 
an illustration, one possible explanation would be that cycloheximide 
inhibits synthesis of a protein-antagonist of PDE activation. Under 
Houslay's scheme for PDE regulation via G-proteins analogous to those 
of the adenylate cyclase system (see Section 1.1.), a possible 
identity for this putative protein inhibitor might be envisaged to be 
the PDE G-protein corresponding to G.. However, this suggestion would 
require a disparity in either regulatory potency or synthetic turnover 
rate between stimulatory and inhibitory G-proteins. Furthermore, 
if the action of these putative G-proteins was also analogous to their 
adenylate cyclase counterparts, diminution of the effect of the G. 
analogue relative to the Gs analogue would result in an increase in 
control (unstimulated) high affinity cAMP-PDE activity. This was not 
observed (Table 2) and there is apparently little evidence in the 
literature to suggest the existence of any other system capable of 
modulating the hormone sensitivity of PDE in a manner consistent with
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these proposals. The alternative, i.e. that this effect of 
cycloheximide is not expressed via its well-documented ability to 
inhibit protein synthesis, is therefore perhaps more promising.
The enhanced response to insulin apparently displayed by PDE in 
mammary cells from diabetic or 24 hr starved rats (preliminary results, 
Table 5) is, in common with the effect of cycloheximide treatment of 
acini, unlikely to result from synthesis of extra enzyme molecules. 
Bearing in mind this and other similarities between the observed 
effects of cycloheximide and those revealed by preliminary results with 
manipulation of physiological state, it is tempting to speculate that 
the mechanisms involved might be related. However, in the absence of 
corroborative data for the latter results, it would be premature to 
discuss their implications further.
Treatment with cycloheximide appears to allow expression of an 
insulin-induced activation of PDE in unfractionated homogenates 
otherwise devoid of detectable insulin-sensitive activity. The obvious 
conclusion is that insulin-sensitive activity is not confined to the 
crude particulate fraction isolated in these experiments and that 
cycloheximide potentiates the effect of insulin on either a soluble 
high affinity cAMP-PDE or one associated with a less 
rapidly-sedimenting membrane fraction than that collected under the 
centrifugation conditions employed in this study. In view of the lack 
of supporting evidence in the literature for soluble insulin-sensitive 
PDE activity, a light microsomal membrane fraction might be supposed to 
represent the most likely source of latent insulin-sensitive PDE 
activity of this kind. While this model for the effect of 
cycloheximide on the observed distribution of insulin-sensitive PDE 
activity in mammary acini provides a convenient explanation for
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insulin-stimulated activity not directly attributable to the activation 
observed in particulate fractions, it does not represent the only 
possible interpretation of the available information. Perhaps a more 
attractive proposition would be to assume that all insulin-sensitive 
cAMP-PDE activity is confined largely to membranes constituting the 
particulate fraction but that activation of this enzyme renders it more 
susceptible to dissociation, releasing a fully active soluble catalytic 
domain from its membrane-associated regulatory domain, in 
accordance with the molecular arrangement proposed for 
insulin-sensitive PDE by Francis et al ([227, 490] see section
1.2.2.(ii)). In support of this, the insulin-stimulated form of high 
affinity cAMP-PDE in liver endoplasmic reticulum appears to be more 
sensitive than the basal form to solubilisation by an endogenous 
protease [490]. The corresponding effect in mammary tissue might 
therefore be envisaged to be mediated by the endogenous protease 
activity suggested to reside in mammary acinus particulate fractions 
(see section 4.1.2.(i)).
Inclusion of cycloheximide in the acinus incubation medium 
reveals an insulin-dependent stimulation of PDE activity in 
unfractionated homogenate which cannot be accounted for entirely by the 
activation expressed by the particulate fraction alone. Indeed, the 
particulate fraction activation may represent as little as 27% of the 
absolute increase observed in unfractionated homogenate under these 
conditions. That cycloheximide does not simply activate the putative 
endogenous protease is demonstrated, in cycloheximide-treated acini, by 
the lack of a decrease in insulin-stimulated activation of particulate 
fraction PDE if not by the fact that this effect would result, 
predominantly, in a redistribution, rather than overall activation of
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PDE activity. The latter statement would not necessarily hold true if 
a significant proportion of unstimulated PDE molecules were solubilised 
by the putative protease since such solubilisation has been reported to 
induce up to 4-fold activation of the adipocyte insulin-sensitive PDE 
[502], However, under these circumstances, an increase in the PDE 
activity of non-insulin-treated acini would be expected following 
incubation with cycloheximide: this effect is not observed. To 
account for the lack of such a response it would be necessary to 
propose a secondary effect of cycloheximide capable of suppressing this 
type of activation in control but not insulin-stimulated acini. 
Basically the same arguments may be used to dismiss the possibility 
that changes in the sensitivity to proteolytic attack of the 
insulin-stimulated form are responsible for the observed effects. 
Instead, it must be supposed that cycloheximide is capable of 
augmenting the insulin-dependent stimulation of membrane-bound PDE and 
that it is the increase in amount of activated enzyme that stimulates 
increased solubilisation rather than a direct effect of cycloheximide 
on the proteases, proposed to govern solubilisation. To account for 
the results presented here, the cycloheximide-stimulated increase in 
insulin-sensitive activation of particulate fraction PDE must then be 
assumed to be accompanied by an increase in proteolytic solubilisation 
of activated PDE sufficient to limit severely if not to obscure 
completely the cycloheximide-induced enchancement of particulate enzyme 
activation in response to insulin. The tendency towards a residual 
cycloheximide-dependent enhancement of the insulin response in the 
particulate fraction, suggested by the values in Table 2, both in terms 
of absolute values and per cent control values (except when expressed 
per Unit 5'nucleotidase activity) is therefore consistent with these 
proposals.
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It is perhaps premature to present detailed proposals outlining 
possible in vivo justifications for the existence of an arrangement 
capable of influencing the subcelluar distribution of high affinity 
cAMP-PDE in the manner described above. However such a regulatory 
system might be imagined to represent either a means of limiting the 
amount of PDE activity expressed at the membrane in order to prevent 
excessive deactivation of membrane associated cAMP-dependent processes 
or a mechanism capable of allowing dissemination of a membrane 
associated effect throughout the cell.
Protein synthesis inhibitors such as cycloheximide and puromycin 
have been shown to block hormone-induced increases in phosphatidyl 
inositols but not diacylglycerol [206]. This effect is thought to be 
a consequence of rapid enzymic hydrolysis of phospholipids induced by 
cycloheximide, particularly in hormone-stimulated tissues but while 
this leads to a decrease in the mass of phosphatidyl inositol, it is 
followed by a secondary increase in phosphate incorporation into 
phospholipid so that, in effect, cycloheximide treatment precipitates 
an increase in phospholipid turnover [205], Since changes in 
phosphatidyl inositol metabolism have been implicated in the mechanism 
of action of insulin [205, 325, 412, 494, 495], it is not surprising to 
find evidence for interaction between cycloheximide and insulin in the 
activation of high affinity cAMP-PDE. Phosphatidyl serine (PS) and, to 
a lesser extent, phosphatidic acid (PA) have been shown to activate 
microsomal high affinity cAMP-PDE in rat adipocytes, while phosphatidyl 
inositol 4 phosphate (diphospho inositide, Ptd Ins 4P or PIP) inhibits 
the activity of this enzyme [494, 495]. Insulin has been reported to 
raise cellular levels of phosphatidyl inositol (PI), PIP, phosphatidyl 
inositol 4,5 bisphosphate (triphosphoinositide, Ptd Ins 4,5 P2 or
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PIP2), PS and phosphatidyl ethanolamine [205] and therefore 
generates two potential stimulators of PDE activity (PA and PS). 
However, the synthesis of PIP, an inhibitor of PDE activity, is also 
increased by insulin and therefore any stimulatory effects of insulin 
on high affinity cAMP-PDE activity mediated by this mechanism will be 
at least partially antagonised. Perhaps the observation that 
cycloheximide, which blocks hormonally-stimulated increased in a number 
of phosphatidyl inositols (including PIP), PS and PA but cannot depress 
their levels to below control [205], appears to potentiate insulin 
activation of mammary high affinity cAMP-PDE, might be construed to 
imply that the mammary enzyme is more sensitive to inhibition by PIP 
than activation by PS or PA. In the context of the proteolytic 
solubilisation model proposed earlier, the fact that enhanced insulin 
activation is only apparent in unfractionated homogenates (when this 
reasoning would seem to suggest that the degree of activation should 
also be elevated in the particulate fraction) might be explained by 
assuming that under normal circumstances, the effect of insulin on 
mammary membrane-bound PDE is to a certain extent, self limiting, by 
virtue of the inhibition imposed by PIP. In the presence of 
cycloheximide, this inhibition would be abolished and insulin-induced 
activation of membrane-bound PDE would be enhanced as a result.
However, the increased activation effectively represents an increase in 
the proposed preferred substrate of the endogenous protease and would 
therefore lead to an increase in proteolytic solubilisation. The 
resulting increased loss of membrane bound PDE would then limit the 
increase in activation apparent in the particulate fraction, while 
adding to that expressed in the cytosol, which would then be registered 
as an increase in insulin-dependent activation of PDE observed in 
unfractionated homogenate.
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The observation that cycloheximide either completely inhibits 
insulin receptor down-regulation [602] or, at least, markedly 
decreases the rate and extent of such insulin-induced down-regulation 
[431, 643] may also have some bearing on the apparent synergism 
between insulin and cycloheximide. It has been reported, recently, 
that cycloheximide does not inhibit insulin receptor cycling but does 
block receptor inactivation [426], perhaps, therefore allowing an 
enhanced or prolonged response to insulin and conceivably 
contributing to the potentiation of insulin-induced activation of 
mammary high affinity cAMP-PDE observed here in the presence of this 
agent.
4.1.2. (iii) Membrane Incubations
Having tentatively identified membrane-bound high affinity 
cAMP-PDE as the major source of insulin-dependent PDE activity in 
mammary acini, in order to characterise the hormone sensitivity of this 
enzyme further, a broken cell system was developed, similar to that 
used previously in rat hepatocytes for investigation of the 
corresponding effect of insulin on liver PDE [511]. The failure to 
demonstrate any increase in membrane-bound high affinity cAMP-PDE 
activity following insulin-treatment of a crude membrane fraction in 
vitro under conditions known to elicit such a response in rat 
hepatocyte membranes [511] seems to suggest that the mammary high 
affinity cAMP-PDE system is more closely related to that of adipose 
tissue in which it has not yet proved possible to demonstrate 
hormone-induced activation in anything other than in intact cell 
preparations. Assuming the mammary and adipose PDE systems are indeed 
comparable and that, as in adipose tissue, mammary insulin-sensitive
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PDE resides in membranes of the endoplasmic reticulum, it seems 
unlikely that the relatively direct activation mechanism, via a unique 
GTP-binding modulator protein (G- or N-protein) proposed by Houslay and 
coworkers [310, 311, 312] to mediate in the activation of the plasma 
membrane-bound insulin sensitive PDE of liver (see section
1.2.2.(ii)) is involved in activation of the mammary enzyme. 
Insulin-dependent activation of liver plasma membrane-bound PDE appears 
to be achieved, ultimately, by phosphorylation of the enzyme [511] and 
while the intermediate mechanisms of signal transduction involved in 
activation of mammary PDE may differ from those expressed in 
hepatocytes, the possibility that mammary PDE activity is also 
influenced by phosphorylation should not be ignored. Therefore in 
order to optimise any phosphorylation-mediated effects involved in 
insulin-dependent activation of mammary PDE, ATP and the phosphatase 
inhibitor, KF were added to the mammary cell-free incubation system and 
comparison of ATP- and/or KF-containing incubations with appropriate 
controls revealed an interesting relationship between these agents and 
the observed PDE activity. The initial observation that addition of KF 
to membrane incubations resulted in an apparent divalent 
cation-dependent activation of membrane-associated PDE and that 
simulataneous addition of ATP would prevent expression of this effect 
was intriguing and seemed to point to the possibility of a regulatory 
mechanism involving protein phosphorylation, though not, perhaps, in a 
straightforward, conventional manner since ATP would not normally be 
expected to antagonise the effect of a phosphatase inhibitor 
(but see later). That this effect was not simply due to chelation of 
divalent cation by ATP was demonstrated by the dose response 
relationship for antagonism of the KF effect. As discussed earlier
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(Section 3.1.3.)/ ATP was effective in this respect at concentrations 
well below those required for significant chelation of the divalent 
cation present in the incubations. The discovery that GTP, ADP and even 
pyrophosphate are all effective substitutes for ATP would seem to 
preclude an explanation for antagonism of the KF effect involving 
increases in protein kinase activity. Therefore, in order to preserve 
the notion of a mechanism involving phosphorylation, it would be 
necessary to propose that mammary tissue contains a protein phosphatase 
with unusual regulatory properties, whether it is assumed that the 
apparent activation is provoked by phosphorylation, or conversely, by 
dephosphorylation. The possibility that the observed effects are 
mediated by a 'conventional', KF-inhibited protein phosphatase and that 
the apparent activation is therefore stimulated by phosphorylation may, 
at first sight, appear to provide a plausible explanation but this 
proposal would necessitate acceptance of regulatory characteristics 
not normally associated with such enzymes. Because ATP, ADP,
GTP, pyrophosphate and EDTA all antagonise the effect of KF, it 
would have to be assumed that these agent were capable of either 
activating the putative phosphatase or endowing it with substantial 
insensitivity to inhibition by KF. Although ATP-dependent activation 
of a phosphatase (protein phosphatase 1I , see section 1.3.9.(i)) has 
been demonstrated in other tissues [24, 305, 375, 805] there is no 
precedent for phosphatase activation in response to ADP, GTP, 
pyrophosphate or EDTA, indeed, pyrophosphate is normally considered to 
be a phosphatase inhibitor. The observation that NaF, a phosphatase 
inhibitor often substituted for KF, is considerably less effective than 
KF in raising particulate fraction PDE activity also runs contrary to 
expected phosphatase behaviour.
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In order to accommodate the alternative proposal that 
dephosphorylation stimulates the increase in particulate PDE activity, 
the protein phosphatase responsible for this effect would be required 
to display activation by KF and inhibition by ATP, ADP, GTP, 
pyrophosphate and EDTA (Table 10). However, even assuming such a 
phosphatase exists, in the absence of protein kinase activity (i.e. all 
incubations except, perhaps, those containing ATP), it is difficult to 
account for the ability of EDTA not only to prevent the increase in 
particulate PDE activity induced by KF but also to return KF-stimulated 
activity to near control levels (Table 7). In conclusion, then, 
bearing in mind the degree of anomolous behaviour required in order to 
satisfy the conditions inposed by experimental data, it seems extremely 
unlikely that phosphatase activity of any description could provide a 
plausible explanation for the effects of KF on particulate PDE 
activity.
Although experimentation designed to characterise further the 
effects of KF on this membrane system demonstrated that the apparent 
KF-induced activation of membrane associated high affinity cAMP-PDE 
described above was, in fact, wholly attributable to a redistribution 
of soluble PDE activity (present as a contaminant of the membrane 
system) to the particulate fraction (Figures 23, 24 and 25, Table 11) 
rather than activation of existing particulate enzyme, the reasoning 
employed to rule out participation of protein phosphorylation in this 
process is equally applicable to the revised model for KF-induced 
increases in particulate PDE activity and leads to the conclusion that 
the phosphorylation state of mammary high affinity cAMP-PDE is not an 
important factor determining whether the enzyme exists in a soluble or 
sedimentable (particulate) form. The observation that, unlike the
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activation of hepatocyte plasma membrane insulin-sensitive PDE, under 
the experimental conditions chosen for this study, there are no obvious 
phosphorylation-mediated effects on mammary high affinity cAMP-PDE 
activity is perhaps not surprising since no effects of this nature have 
yet been described for either the 'dense-vesicle' insulin-sensitive PDE 
of rat hepatocytes or the insulin-sensitive PDE of adipose tissue (see 
section 1.2.2.(ii)).
The inhibitory effect of fluoride ion on phosphatase activity 
and its ability to activate adenylate cyclase are both well known 
phenomena with widely recognised applications but the mechanisms 
involved in these processes remain unclear. Recent work with bovine 
transducin [382] provides evidence to suggest that activation of 
guanine nucleotide binding protein by fluoride involves binding of F" 
and Al3+ to the a-subunit and consequent promotion of its dissociation 
from 3y-subunits, however while proposed, previously, by Northup et al. 
[763], this has not yet been verified in the adenylate cyclase system. 
Perhaps the effect of KF on PDE activity and solubility (KF-induced 
precipitation of soluble PDE activity appears to be accompanied by a 
reduction in enzymic activity [see section 3.1.3.) will prove to be 
related to those involved in activation or inhibition of these other 
important regulatory enzymes but the complex nature of the interactions 
involved in the system described here makes assessment of possible 
mechanisms difficult, beyond suggesting that physical, rather than 
enzymic reactions are implicated. In this situation, however, 
documentation of the effects themselves may be of more value to future 
studies than a detailed assessment, on the molecular level, of reasons 
for their occurrence. In practical terms, this report of a major
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modification of the properties of a soluble enzyme by widely 
used phosphatase inhibitors, at the concentrations commonly employed 
for such enzyme inhibition (50-100mM), presents a strong case for 
caution in interpreting the results of studies designed to measure the 
relative activities of phospho and dephosphoenzymes using fluoride to 
preserve the phosphorylated form. In this respect alone, the 
observations made here are obviously of significant importance to 
future research but, on a more positive note, KF-induced precipitation 
may also prove to be a useful preliminary step in purification of 
certain soluble enzymes and, in relation to the mammary PDE system, it 
would be particularly interesting to identify the properties of the PDE 
enzyme(s) isolated by such a procedure.
Effects of salts on high affinity cAMP-PDE activity have been 
observed by others [501] in adipose tissue. The membrane preparation 
used by these authors to demonstrate effects similar in nature to those 
described here was basically the same as that used in this study. 
Although the adipocyte membrane incubations were performed at 37°C, 
rather than the 30°C adopted here, and apparent activation observed in 
the presence of high concentrations (150mM) of KCl was not maximal 
until approximately 20minutes after initiation (much slower than the 
effects observed with KF in this study), substantial increases 
(approximately 2-fold) in high affinity cAMP-PDE activity associated 
with the crude microsomal fraction were demonstrated under 'optimal' 
conditions. The incubation additions described as necessary for 
maximum effect are 150mM KCl and 5mM MgCl2 or CaCl2 but little, if any, 
effect is observed at an incubation KCl concentration of lOOmM. This 
latter observation is consistent with the results presented here (Table 
7) and although the effect noted at higher concentrations of KCl in the
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adipocyte membranes is not absolutely dependent on divalent cation, 
there is evidence of a certain degree of interaction. It is therefore 
conceivable that the effects observed following incubation of adipocyte 
membranes with 150mM KCl are analogous to those induced by incubation 
of mammary cell membranes with lOOmM KF.
4.2. Protein Phosphorylation in Mammary Acini
Although various protein kinase activities have already been 
ascribed to mammary tissue (see section 1.3.10.), a comprehensive study 
of the effector-dependence of endogenous protein phosphorylation has 
not, until now, been attempted in this tissue. In order to determine 
the potential importance of effector-dependent phosphorylation and, in 
particular, the role of cAMP-PrK, in the regulation of mammary cell 
metabolism, it is first necessary to establish whether a competent 
combination of effector-dependent kinase and endogenous substrate is 
expressed in these cells. The data presented in sections 3.2. and 3.3. 
represent the product of work directed towards addressing this issue 
and have revealed a number of interesting properties of mammary cell 
protein phosphorylation.
The relatively slow loss of protein-bound 32P observed following 
addition of excess unlabelled ATP to cytosolic fraction phosphorylation 
incubations (for example, see Figure 31) indicates a low rate of 
protein bound phosphate turnover and, since substantial incorporation 
of phosphate into protein occurred after as little as 30 seconds, 
indicating significant protein kinase activity, the implication is that 
phosphatase activity was comparatively low. Indeed, the level of 
protein phosphatase activity was probably sufficiently low, in relation 
to protein kinase activity, to preclude any significant effect on the
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level of 32P incorporation measured after 30 seconds. This conclusion 
is supported by the inability of KF, a potent inhibitor of protein 
phosphatase activity, to stimulate the rate of incorporation into any 
of the major phosphoproteins isolated (Figure 32). The reliability of 
this supporting evidence is, however, subject to certain reservations 
on the grounds that KF often substantially inhibited the accumulation 
of protein-bound 32P (Figure 32) suggesting that the influence of KF on 
32P-incorporation in this system was not confined to expression of its 
effect on phosphatase activity. The possibility that this ill-defined 
inhibitory effect might be capable of masking any stimulation of 
32P-incorporation mediated by KF-induced phosphatase inhibition cannot, 
therefore, be ruled out completely. Nevertheless, the combination of 
intrinsically low mammary protein phosphatase activity [281] and an 
incubation buffer containing the protein phosphatase inhibitor 
(3-glycerophosphate might easily give rise to sufficiently low protein 
phosphatase activity to be consistent with that implied by these 
experimental findings.
The loss of linearity of 32P-incorporation into cytosolic 
proteins may be due to saturation of phosphorylation sites or, 
alternatively, exhaustion of available ATP. The former is difficult to 
assess but some estimate of the rate of ATP depletion not attributable 
to kinase activity (the amount of 32P remaining unbound to protein 
following incubation indicates that protein kinase activity accounts 
for only a very small fraction of the available ATP) may be derived 
from ATPase activities reported by others in similar mammary tissue 
extracts. ATPase activity in mammary Golgi vesicles has been reported 
to release approximately 50-120 nmol Pi/min/mg protein [806, 828]. The 
protein content of each incubation in the present work was 0.05mg, so
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the maximum contribution of Golgi-associated ATPase activity to the 
total ATPase activity might be expected to be around 2.5-6.0nmol Pi 
released/min. Since each incubation contained only ~ 3nmol ATP, these 
figures would suggest that ATP supply might rapidly become limiting for 
kinase activity.
This conclusion is supported by ATPase activity data obtained 
using mammary cell fractions identical to those employed for the 
protein phosphorylation studies described here [100a]. Although the 
data refer to activity measured at protein concentrations less than 
half that used here and are therefore higher than would be expected to 
prevail under the conditions chosen for the present study (ATPase 
activity is non-linear with respect to protein concentration), they 
indicate that substantial ATP depletion almost certainly contributed to 
the observed loss of linearity of 32P-incorporation into mammary 
proteins. Indeed, under experimental conditions identical to those 
chosen for the present study, substantial ATP depletion (~ 50% and ~ 
36%, respectively, of ATP supplied initially to the "microsomal" and 
"cytosolic" fraction incubations) has been demonstrated after 2 minutes 
of incubation [100a].
The apparent ability of vanadate markedly to stimulate 
incorporation of label into just two of the major phosphoproteins 
detected in acinar cytosols incubated with [y-32P] ATP (preliminary 
results, see Section 3.3.) is interesting, particularly since one of 
these is almost certainly acetyl-CoA carboxylase (by virtue of their 
abundance in mammary tissue, acetyl-CoA carboxylase and fatty acid 
synthase are identifiable in Coomassie blue-stained SDS polyacrylamide 
gels) and the other is a 47kDa protein shown to undergo cAMP-dependent 
phosphorylation (see section 3.3.4.). Vanadate has been shown to
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stimulate the tyrosine phosphorylation of two membrane proteins from a 
human lymphoblastoid cell line [172], an effect thought to have three 
possible explanations: (i) vanadate inhibits phosphotyrosine 
dephosphorylation (it has been observed that vanadate inhibits 
phosphotyrosine phosphatase activities of human A431 cells [749], 
astrocytoma [469] and prostate gland [473]), (ii) vanadate directly 
stimulates tyrosine kinase activity, (iii) since vanadate forms 
complexes with protein [77], it might be capable of modifying 
substrate conformations to increase their susceptibility to tyrosine 
phosphorylation. Admittedly, these effects were observed at 
concentrations of vanadate several orders of magnitude lower than that 
used in the present study but it is not unreasonable to suppose that 
similar effects on tyrosine phosphorylation might be observed, even at 
concentrations many times higher than those required for saturation 
of such a system.
The definitive method for determining the identity of amino acid 
residues with which phosphate is associated in a phosphoprotein 
involves isolation of the phosphoprotein (labelled with 32P) of 
interest, followed by partial hydrolysis and analysis of the amino acid 
content of the resulting hydrolysate by, for example, TLC or HPLC.
This procedure is described in detail by Cooper et al. [127a] but the 
method can be summarised as follows. The 32P-labelled phosphoprotein 
of interest is identified and isolated, for example, by excision from 
SDS gels, by affinity chromatography (for acetyl-CoA carboxylase this 
would be achieved using avidin-Sepharose columns) or by immune 
precipitation and then subjected to partial acid hydrolysis. Both 
alkaline hydrolysis and conditions necessary for total acid hydrolysis 
(for example, 5.7M HCl for 18h at 110°C) result in hydrolysis 
of the phosphate ester linkage of phosphotyrosine in
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addition to peptide bonds, and are therefore unsuitable for 
determination of tyrosine-specific phosphorylation. Consequently, the 
period of acid treatment is reduced, for example, to lh [127a], in 
order to preserve phosphotyrosine. The hydrolysate can then be 
analysed using one of a number of techniques for separation of amino 
acids, the phospho residues being identified by their associated 
radioactivity. Perhaps the most convenient of the techniques available 
currently is either strong anion exchange or reversed-phase HPLC. 
However, when dealing with 32P-labelled samples, use of such systems 
may be impractical due to contamination of expensive chromatographic 
hardware. Less sophisticated techniques such as TLC or thin 
layer/paper electrophoresis may therefore be preferred. Use of 
this general method would establish conclusively whether, under any 
experimental conditions, either acetyl-CoA carboxylase or the 47kDa 
protein contains phosphotyrosine residues and therefore whether or not 
the increased phosphorylation observed in the presence of vanadate was 
tyrosine-specific. Essentially the same procedure could also be 
adopted to distinguish serine from threonine-specific phosphorylations.
The results of experiments involving treatment of 
phosphoprotein-containing gels, of a similar nature to those produced 
in this study, with 1M KOH at 55°C for 2h (according to a protocol 
described by Cooper et al. [127a]), suggest that neither the 
phosphorylations of acetyl-CoA carboxylase, nor that of the 47kDa 
protein is likely to be tyrosine-specific. Confirmation of these 
results could be obtained using the partial acid hydrolysis method 
described above. However, if, as now seems unlikely, the observed 
stimulation by vanadate of phosphate incorporation into acetyl-CoA 
carboxylase and the 47kDa protein were proved to be an indication that
179
these two cytosolic proteins are substrates for tyrosine kinase 
activity, several intriguing possibilities for novel potential 
regulatory interactions might be envisaged.
Insulin is known to stimulate acetyl-CoA carboxylase activity in 
liver and adipose tissue ([66, 276, 466, 848, 850], see also section 
1.3.4.(ii)) and, despite a lack of direct evidence (see section 3.2.), 
is also thought to activate mammary acetyl-CoA carboxylase [552]. Since 
tyrosine kinase activity is known to be associated with the insulin 
receptor, it is tempting to suggest that tyrosine phosphorylation of 
acetyl-CoA carboxylase might provide the necessary link between insulin 
binding and its effect on acetyl-CoA carboxylase activity. However, 
rather than being associated with increased phosphorylation of acetyl- 
CoA carboxylase, increases in plasma insulin have been shown to be 
accompanied by decreased phosphorylation of the mammary enzyme [552]. 
Hence, whether the increase in phosphorylation of acetyl-CoA 
carboxylase observed here in the presence of vanadate is attributable 
to tyrosine or, as seems more probable, to serine phosphorylation, this 
effect is unlikely to have any relevance to regulation of the enzyme in 
response to insulin. The significance of this observation is therefore 
unclear and since the data are uncorroborated (single experiment), 
further speculation would be inappropriate.
4.3. Effector-Dependent Protein Phosphorylation 
The most striking examples of effector-dependent phosphorylation 
revealed by in vitro incubation of mammary cell fractions 
with [y—3 2 P]ATP were the Ca2+-calmodulin dependent stimulation 
of 32P- incorporation into a 100.3kDa cytosolic protein 
(section 3.3.1.), cAMP-dependent phosphorylation of three other
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cytosolic proteins (molecular weights 38.4kDa, 47kDa and 57.3kDa) 
(section 3.3.4.) and polyamine-dependent stimulation of the 
phosphorylation of a number of proteins, particularly in the 
'nuclear' and 'microsomal' fractions (section 3.3.3.). The lack of 
identifiable protein kinase C activity in any of the mammary cell 
fractions (section 3.3.2.) is consistent with recent work in mouse 
mammary gland [86].
4.3.1. Calcium-Dependent Phosphorylation
On SDS polyacrylamide gel electrophoresis, the 100.3kDa protein 
migrated close to a standard sample of the enzyme glycogen 
phosphorylase and its phosphorylation also displayed the same 
regulatory characteristics with respect to Ca2+/calmodulin dependence 
as phosphorylation/activation of skeletal muscle glycogen 
phosphorylase (see section 1.3.1.). On the basis of these 
observations, it would therefore be reasonable to conclude that the 
100.3kDa phosphoprotein observed in mammary cell cytosols is in fact 
glycogen phosphorylase. However, since, characteristically, 
phosphorylase kinase is also activated by cAMP-dependent 
phosphorylation (see section 1.3.1.), 32 P-incorporation into both 
phosphorylase kinase a and (3-subunits and phosphorylase itself would 
be expected to increase in the presence of Bt2 cAMP. cAMP-PrK 
mediated activation of phosphorylase kinase is achieved by a 
reduction in the Ca2+ concentration required for half maximal 
stimulation of the enzyme and an increase in the maximum response to 
Ca2+ (see section 1.3.1.) and therefore may not be detectable at very 
low Ca2+ concentration such as might have prevailed in incubations 
containing EGTA. Nevertheless, incubations performed in the presence
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of Bt2cAMP, whether in the presence or absence of Ca2+, should have 
elicited an increase in phosphorylation of the a and 3 subunits of 
phosphorylase kinase (molecular weights 145kDa and 125kDa 
respectively). As a result, in the presence of Ca2+, the consequent 
activation of phosphorylase kinase should have precipitated a marked 
increase in the amount of 32P incorporated into phosphorylase.
An alternative identity for this protein, more consistent with its 
observed phosphorylation characteristics, is offered by a 
calcium/calmodulin-dependent phosphorylation of a lOOkDa cytosolic 
protein that has been described in several mammalian tissues including 
heart, liver and skeletal muscle [583] and a number of mammalian cell 
lines, in several of which it has also been shown to become 
phosphorylated during incubation of intact cells with 32 Pi [585]. This 
protein has been demonstrated to be unrelated to glycogen phosphorylase 
(molecular weight ~ 97kDa) on grounds of differences in migration on 
one and two dimensional polyacrylamide gels, distinct phosphopeptide 
maps obtained by four different methods, the presence of 
phosphothreonine (as opposed to the phosphoserine of glycogen 
phosphorylase), its failure to bind to glycogen and its failure to be 
recognised by anti-phosphorylase antibodies [583]. The finding that 
the 100.3kDa cytosolic protein phosphorylated by
Ca2+-calmodulin-dependent protein kinase during in vitro incubation of 
mammary acinar cytosols with [y-32P]ATP consistently migrated slightly 
behind purified phosphorylase marker protein in SDS polyacrylamide gels 
(e.g. Figure 38) suggests that this phosphoprotein may be analogous to 
the lOOkDa cytosolic protein described above and therefore not in fact 
related to glycogen phosphorylase. The inability to demonstrate
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cAMP-dependent phosphorylation of the cytosolic 100.3kDa mammary 
protein is also consistent with such a classification since the lOOkDa 
substrate for Ca2+-calmodulin-dependent protein kinase identified in 
other tissues is not phosphorylated by phosphorylase kinase [583], A 
97kDa cytosolic protein of pituitary adenoma cells, termed S97 [169], 
has been proposed to be identical to the lOOkDa protein [583] and the 
reported widespread tissue distribution of this major substate for 
Ca2+/calmodulin-dependent protein kinase [583, 585] would seem to 
suggest that it may fulfil an important function in mediating 
cytoplasmic propagation of Ca2+ signals. The identity of this 
potentially very interesting phosphoprotein has not yet been revealed 
but both this and the nature of the Ca2+/calmodulin-dependent protein 
kinase responsible for its phosphorylation are currently under 
investigation [583]. Since, in contrast to phosphorylase, this protein 
is phosphorylated on threonine residues, the possibility that it may 
provide an identity for the lOOkDa mammary protein could be 
investigated further using the partial acid hydrolysis technique [127a] 
described earlier for identification of tyrosine-specific 
phosphorylation (see section 4.2.).
The possibility of a further regulatory mechanism governing 
the phosphorylation of the 100.3kDa protein was revealed by 
incubations in the presence of polyamine (Figure 34). Irrespective 
of the subcellular fraction with which the 100.3kDa protein was 
associated, the magnitude of stimulation, by polyamine, of its 
phosphorylation was consistently high in relation to other major 
phosphoproteins of the same fractions (see section 3.3.3.). The 
stimulation observed was much more pronounced in membrane fractions, 
particularly the 'nuclear' and 'microsomal' fractions, than in the
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'cytosolic' fraction, in contrast to the Ca2+ sensitivity of its 
phosphorylation which was obvious in the cytosolic fraction but 
undetectable in any of the membrane fractions. Assuming membrane 
bound 100.3kDa and cytosolic 100.3kDa proteins represent two forms of 
the same protein, a convenient explanation for these observations 
would be that this protein is phosphorylated by at least two protein 
kinases; cytosolic Ca2+/calmodulin-dependent protein kinase and 
membrane associated polyamine-dependent protein kinase(s) since the 
nature of the in vitro incubations performed in this study precludes 
interaction between kinases exclusive to one fraction and substrates 
associated with another. Although the potential for such interaction 
would exist in vivo, cytosolic proteins might be expected to be more 
accessible to a cytosolic kinase than a membrane bound enzyme and, 
conversely, a membrane bound protein more accessible to a membrane 
associated kinase. Consequently, membrane bound 100.3kDa protein 
would be phosphorylated preferentially by polyamine-dependent 
protein kinase while phosphorylation of the cytosolic form would be 
governed, essentially, by Ca2+/calmodulin-dependent protein kinase 
activity. This reasoning provides an attractive interpretation of the 
results in terms of the potential it implies for independent regulation 
of the phosphorylation of the 100.3kDa protein in different cellular 
compartments, but without knowing the identity of this protein it is 
difficult to assess the potential physiological significance of such an 
arrangement.
At least nine rat hepatocyte cytosolic proteins have been 
demonstrated to show increased phosphorylation in response to 
Ca2+-mobilising hormones [238]. Of these, two are apparently 
substrates for protein kinase C while phosphorylation of the
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remainder is stimulated equally well by treatment of hepatocytes with
the Ca2+ ionophore A23187 and are suggested to be substrates for
Ca2+/calmodulin-dependent protein kinase [238]. In view of the
apparent lack of endogenous protein kinase C activity in mammary cell
fractions (discussed below), only the Ca2+/calmodulin-dependent
phosphorylations would be expected to be revealed by incubation in
the presence of Ca2+. Although phosphoproteins with similar
molecular weights to those described for the seven putative 
2 +Ca /calmodulin-dependent protein kinase substrates of rat hepatocyte 
cytosols including phosphorylase (97kDa), pyruvate kinase (61kDa) and 
phenylalanine hydroxylase (52kDa) can be identified in mammary acinar 
cytosols, none, except perhaps, phosphorylase, exhibit detectable 
Ca2+/calmodulin dependence. These observations suggest that while 
containing significant amounts of Ca2+/calmodulin-dependent protein 
kinase (as evidenced by the phosphorylation characteristics of the 
100.3kDa cytosolic protein), either its substrate specificity differs 
from the analogous hepatocyte enzyme or the mammary proteins of 
similar molecular weight to hepatic substrates for 
Ca2+/calmodulin-dependent protein kinase are in fact structurally 
distinct and therefore mammary tissue is deficient in these 
substrates.
The second major type of Ca2+-dependent protein kinase,
Ca2+/phospholipid-dependent protein kinase (protein kinase C, see 
section 1.3.8.(i)b), is known to be predominantly cytosolic in several 
non-neuronal tissues with membrane associated activity accounting for 
only 2% total activity in tissues such as muscle and platelets. If its 
distribution is similarly uneven in mammary cells, many of the kinase's 
established substrates such as hormone receptors [139, 334, 361, 396,
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705, 757], eIF-2 [683] and ribosomal protein S6 [471] would be 
inaccessible, confined, as they are, to membrane fractions. It might 
seem incongruous for a predominantly cytosolic kinase to have 
exclusively particulate substrates, however, in intact cells, these 
substrates would in fact be accessible. Furthermore, activation of 
protein kinase C involves redistribution to membranes, a mechanism that 
would bring the kinase into closer association with these substrates 
and therefore augment further the effect of its activation. 
Nevertheless, in hepatocytes this enzyme has also been shown to 
phosphorylate at least two endogenous cytosolic proteins [238]. 
Unfortunately, as exemplified by the differences between mammary and 
hepatic Ca2+/calmodulin-dependent protein kinase activities, 
there is no guarantee that cytosolic substrates for protein kinase C, 
corresponding to those observed in other tissues, will be found in 
mammary cytosols. Notwithstanding this, if, as suggested earlier 
(section 4.2.), fragments of insulin receptor bearing serine/threonine 
phosphorylation sites were present in the acinar cytosols, protein 
kinase C would be expected to participate in their phosphorylation 
([139], see sections 1.3.8.(i)b and 1.3.8.(ii)). Since there is no 
evidence for increased phosphorylation (in response to Ca2+ or phorbol 
ester) of the 47kDa cytosolic protein suggested to be an insulin 
receptor fragment, it must be assumed either that such fragments do 
not, after all, populate cytosolic fractions or that protein kinase C 
activity is negligible in these rat mammary cytosols. Evidence in 
support of the latter is provided by work with protein kinase C in 
mouse mammary glands at various stages of the reproductive cycle [86]. 
The activity of mouse mammary protein kinase C falls throughout 
pregnancy, reaching a minimum value by the fourth day of lactation.
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At this point, protein kinase C activity is very low and remains 
so throughout lactation. Assuming rat mammary tissue behaves 
in a similar manner, protein kinase C activity would indeed be 
expected to be negligible in the mammary extracts used in this study 
since the subcellular fractions were prepared from mammary glands of 
rats in mid-lactation (10-12 days post-partum) and therefore likely 
to contain minimal levels of such activity. It would therefore seem 
reasonable to conclude that protein kinase C activity of lactating 
mammary tissue is too low to be credited with a significant role in 
the acute regulation of cellular metabolism. There is evidence to 
suggest, however, that protein kinase C inhibits mammary cell 
differentiation [86] and reduction in its activity may therefore 
represent an important part of the longer-term mechanisms governing 
cell function during mammary gland development.
4.3.2. cAMP-Dependent Protein Phosphorylation
Of the two cAMP-dependent phosphorylations observed consistently, 
phosphorylation of the 57.3kDa protein showed the greater 
response to incubation with Bt2cAMP (Figure 35) or cAMP itself (Table 
15). The only major cytosolic phosphoproteins with molecular weights in 
the region of 57.3kDa described by Garrison et al. [238] in rat 
hepatocytes are fructose 2, 6-bisphosphatase (55kDa) and an 
unidentified 56kDa protein. Phosphorylation of the 56kDa protein is 
unaffected by incubation with glucagon but the same treatment provokes 
a large (approximately 15-fold) increase in fructose 2,6-bisphosphatase 
phosphorylation indicating the involvement of cAMP-dependent protein 
kinase (cAMP-PrK). The fructose 2,6-bisphosphatase/6-phosphofructo2- 
kinase (F2,6-P2ase/PFK2) dimer is known to be an excellent
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substrate for cAMP-PrK [617, 622] and is phosphorylated on 
one serine residue per 55kDa subunit [180, 183]. Whether
phosphorylase kinase is also capable of phosphorylating the 
F2,6-P2ase/PFK2 dimer [233] or not [662] is controversial but even 
assuming it is, there is no guarantee that such an effect would be 
observed in mammary tissue. While F2,6-P2ase/PFK2 therefore displays 
phosphorylation characteristics broadly consistent with those observed 
for the 57.3kDa phosphoprotein of mammary acinar cytosols, it does not 
represent the only known protein displaying properties indicative of a 
possible identity for the unknown protein. Another such 
candidate is the R-subunit of type II cAMP-PrK itself (see section 
1.3.8.(i)a) which is autophosphorylated on one serine residue per 
subunit [82, 196 317, 629, 639], has a molecular weight of 52-55kDa 
[556] and is predominantly cytosolic in most tissues, including liver 
and muscle [318]. Although not normally regarded as a cytosolic 
enzyme, HMG-CoA reductase may also be envisaged to provide a possible 
identity for the unknown 57.3kDa protein since a 50-56kDa soluble 
peptide is released from the membrane bound enzyme by limited 
proteolysis [398] and microsomal HMG-CoA reductase has been shown to be 
phosphorylated by cAMP-PrK in vitro [245, 398]. The soluble 
proteolytic fragment contains the enzyme active site [398] and its 
presence in mammary acinar cytosols could therefore be verified by 
assaying for HMG-CoA reductase activity. Although such assays were not 
performed on fresh samples, a frozen sample of cytosol used in a 
previous experiment and known to contain the 57.3kDa substrate for 
cAMP-PrK was screened for HMG-CoA reductase activity. Despite the fact 
that little, if any, HMG-CoA reductase activity is normally expected to 
survive freezing, measurable activities were detectable in these
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samples [715], suggesting that sufficient quantities of the soluble 
HMG-CoA reductase fragment might be expected to be found in the 
cytosols used for in vitro phosphorylations in this study. While not 
representing evidence in support of a positive identification for the 
57.3kDa protein, the indications are that soluble HMG-CoA reductase may 
provide an equally plausible alternative to F2,6-P2ase/PFK2 complex and 
type II cAMP-PrK R-subunit in any speculation regarding the identity of 
this mammary phosphoprotein. The apparent enhancement of response to 
Bt2 cAMP observed in mammary cytosols incubated in the presence of Ca2 + 
(Figure 36) might be regarded as evidence in favour of F2,6-P2ase/PFK2 
which, as mentioned above, has been suggested to be a substrate for the 
Ca2+-dependent enzyme phosphorylase kinase [233]. However, the same 
effect of Ca2+ was observed for cAMP-dependent phosphorylation of the 
47kDa protein and a more likely explanation for this phenomenon 
(as discussed in section 3.3.4.) is afforded by increased sensitivity 
of the technique employed to detect cAMP-dependent phosphorylation, 
resulting from divalent cation-dependent suppression of background 
phosphorylation. In addition, if these divalent cation-dependent 
effects were indeed mediated by phosphorylase kinase, increased 
phosphorylation of the two substrates for cAMP-dependent 
phosphorylation would be expected to occur in the presence of Ca2+ 
alone and not, as observed (see section 3.3.4.), solely in concert with 
Bt2cAMP.
In the absence of further relevent information, it is 
difficult to assess properly the likely identity of the 57.3kDa 
protein. However, on the basis of the (optimistic) assumption that 
the true identity of this protein will be ultimately selected from 
among the three enzymes cited above, then whichever is finally
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adopted will command an important role in the regulation of mammary 
cell metabolism since all three enzymes have well documented 
regulatory functions in other tissues (see sections 1.3.2., 1.3.5. 
and 1.3.8.(i)a).
Although cAMP-dependent phosphorylation of the 47kDa protein of 
mammary acinar cytosols is not as responsive to Bt2 cAMP as that of the 
57.3kDa protein, it is equally consistent and appears to share a 
similar cAMP sensitivity (see section 3.3.4.). Once again, the 
identity of this protein is uncertain with possibilities including the 
Ex component of branched chain 2-oxoacid dehydrogenase (46kDa, see 
section 1.3.3.(ii)) and a proteolytic fragment of the insulin receptor 
(45-50kDa, see section 1.3.8.(ii)a). The latter is attractive in a 
number of respects but is subject to uncertainties associated with the 
assumption that sufficient quantities of the receptor might be 
solubilised, during the homogenisation procedure, to account for the 
observed effects. Since the 0X fragment of the receptor might be 
expected to remain membrane-associated, whereas the 47kDa 
phosphoprotein was identified in mammary acinar cytosols, there would 
seem to be little justification for suggesting that they may represent 
the same peptide. If however, substantial internalisation and 
processing of insulin receptors proceeds during preparation of acini, 
homogenisation might be expected to liberate, from lysosomes, a 
sufficient quantity of receptors at various stages of degradation to 
establish a population of "cytosolic" 0X-fragments, perhaps still bound 
to their counterpart a-subunits or subunit fragments (reducing 
conditions encountered later during preparation for SDS-polyacrylamide 
gel electrophoresis would lead to dissociation of these a-0 subunit 
pairs, allowing identification of the 45-50kDa 0 receptor fragments).
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Alternatively, the homogenisation procedure itself may be sufficiently 
vigorous to solubilise membrane bound receptors which would then be 
susceptible to attack by endogenous proteases released from ruptured 
lysosomes.
Similar misgivings might be expressed with respect to the 
branched chain dehydrogenase (BCDH) complex but since BCDH is an enzyme 
of the mitochondrial matrix and no steps were taken to ensure 
preservation of the structural integrity of mammary cell mitochondria 
during preparation of the subcellular fractions, it is not 
inconceivable that sufficient numbers of mitochondria might have been 
disrupted to create a detectable 'cytosolic' population of the enzyme. 
Although the Ex component is known to be a substrate for cAMP-PrK in 
vitro, phosphorylation of the enzyme, catalysed by this kinase, appears 
to have no effect on BCDH activity ([604, 637], see section 1.3.3. (ii)) 
and is unlikely to represent a physiologically relevant event since 
BCDH would normally be confined to the interior of mitochondria and 
therefore inaccessible to endogenous cAMP-PrK. Consequently, if the 
47kDa protein were to be identified positively as the component of 
BCDH, the potential regulatory significance of its phosphorylation in 
mammary acinar 'cytosols' would be, at best, obscure and unlikely to 
have any importance in vivo.
Three unidentified cytosolic proteins whose phosphorylation is 
enhanced by incubation of hepatocytes with glucagon and are, therefore, 
presumably substrates for cAMP-PrK, share molecular weights similar to 
the 47kDa protein described here. Two of these share the molecular 
weight of 45kDa, while the third is a 49kDa protein and, unlike the two 
45kDa proteins, is apparently, also phosphorylated by Ca2+/ 
calmodulin-dependent protein kinase [238]. The latter characteristic is
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not shared by the 47kDa mammary protein and the probability of homology 
between the 49kDa hepatocyte protein and the mammary protein is 
therefore diminished as a result, leaving only the two 45kDa hepatocyte 
proteins as possible candidates for homology between the two cell 
types. One of these may also correspond to a 46kDa hepatocyte protein 
reported by LeCam [464] to be phosphorylated, at the same sites, in 
response to both insulin and glucagon. This property is particularly 
interesting in that the 45-50kDa fragment of insulin receptor 3-subunit 
(see section 1.3.8.(ii)a), would also be expected to become 
phosphorylated in response to both insulin and glucagon. However, both 
effects on phosphorylation of the 46kDa hepatic protein are 
predominantly attributable to increases in phosphoserine with no 
indication of insulin-stimulated tyrosine phosphorylation [464]. While 
serine/threonine phosphorylation of the insulin receptor might also be 
expected to occur at the same sites following insulin or glucagon 
treatment (see section 1.3.8.(ii)a), tyrosine phosphorylations in 
response to insulin should be equally obvious. It might, therefore, be 
suggested that the 46kDa hepatocyte protein is unlikely to 
correspond to the 46kDa insulin receptor fragment, on grounds 
that the hepatocyte protein shows no evidence of tyrosine 
phosphorylation. However, the evidence supporting tyrosine 
phosphorylation of the 47kDa mammary protein is too tenuous to draw any 
conclusions as to which of these two hepatocyte proteins is more likely 
to have phosphorylation characteristics akin to its own.
Although not observed consistently, the cAMP-dependent 
phosphorylation of a 38.4kDa protein (Figure 37), identified in the 
same mammary cytosols that also gave rise to the two prominent 
substrates for mammary cAMP-PrK described above, perhaps deserves
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comment. However, there are few immediately obvious candidates for the 
identity of this protein and of the cytoplasmic hepatocyte proteins 
whose phosphorylation is stimulated by pre-treatment of the cells with 
glucagon [238], only fructose 1,6-bisphosphatase (42kDa) exhibits a 
molecular weight comparable to that of the mammary phosphoprotein 
(38.4kDa). While interesting, in itself, such a classification would 
offer little opportunity for speculation regarding the role of its 
phosphorylation in metabolic regulation since phosphorylation of 
fructose 1,6-bisphosphatase is known to be without effect on this 
enzymes's activity [622]. The possibility that the 38.4kDa protein 
does not in fact represent any recognisable native protein but is, 
instead, a proteolytic fragment of one of the other two endogenous 
substrates for cAMP-dependent phosphorylation should not be ignored and 
the intermittent nature of its detection might be presented as evidence 
in favour of this alternative.
Indeed, since there is no evidence to the contrary, it remains 
possible that all three substrates for endogenous mammary cAMP-Prk are 
in fact proteolytic fragments of larger native proteins. Inclusion of 
protease inhibitors in the homogenisation and incubation buffers should 
provide some indication of the general importance of proteolytic 
effects in determining the molecular weights of substrates for 
cAMP-dependent phosphorylation. However, even under such conditions, 
proteolytic peptides such as intermediates of insulin receptor 
degradation might be expected to be in evidence, since lysosomes (the 
ultimate site of receptor processing) might, as suggested earlier 
(section 4.2.) be imagined to release such peptides when ruptured 
during homogenisation. Possibilities of this kind could be probed 
using antibodies to the insulin receptor. While there is no guarantee
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that these antibodies would necessarily recognise any proteolytic 
fragment of insulin receptor, a positive result would provide strong 
evidence in favour of such an identity.
4.3.3. Polyamine-Dependent Protein Phosphorylation 
Polyamines appear to be potent stimulators of the phosphorylation 
of most major mammary phosphoproteins, although the effect on 
cytosolic proteins is more variable (Figure 34). Spermine and 
spermidine were the only two agents shown to affect noticably the 
extent of 32P-incorporation into proteins contained in the 
"microsomal", "mitochondrial" and "nuclear" fractions. Furthermore, 
unlike cAMP and Ca2+, polyamine appeared to influence incorporation 
into all proteins studied. Indeed, in all the particulate fractions, 
treatment with spermine provoked a consistent and often marked increase 
in protein phosphorylation. Such generalised effects may suggest that 
polyamine was affecting the availability of ATP, rather than the 
activities of any kinase(s) or phosphatase(s). As indicated earlier 
(see section 4.2.), the major limiting factor in the phosphorylation 
incubations was likely to be ATP-depletion due to ATPase activity. It 
might therefore be suggested that polyamine-dependent inhibition of 
ATPase activity could account for the observed effects of this agent on 
protein phosphorylation in particulate fractions. Various effects of 
polyamine on ATPase activities have been reported in a number of 
different tissues, including rabbit muscle [150], rabbit kidney [762], 
rat brain [633] and human erythrocytes [23]. However, no significant 
effect of spermine was observed on ATPase activity in any of the 
mammary cell fractions under the conditions prevailing in the 
phosphorylation experiments (results not shown). It is therefore
194
unlikely that the observed polyamine-dependent increases in 
32P-incorporations were merely manifestations of an effect on 
ATP-ava i1abi1i ty.
Since polyamine is thought to interact with the substrate 
protein, rather than the kinase itself, to achieve activation (see 
section 1.3.8.(i)c), it might be speculated that in the mammary system, 
polyamine simply modifies the structure of all proteins, generally 
rendering them more susceptible to phosphorylation by their own 
particular endogenous kinases. Such an argument would obviate the need 
to infer the existence, in mammary tissue, of a specific 
polyamine-dependent protein kinase (poly A-PrK) or group of protein 
kinases. However, the striking subcellular fraction-specific nature of 
the phosphorylation enhancement profile for the two individual 
polyamines is difficult to explain in terms of this model without 
resorting to the proposal that each membrane type provides an 
environment capable of imposing a characteristic influence on the 
interaction of its consituent proteins with polyamine. Since, in 
addition, there are no previous reports of polyamine-dependent 
enhancement of phosphorylation catalysed by anything other than 
specific, otherwise modulator-independent protein kinases, a more 
probable explanation of the observed effects of polyamine could be 
constructed on the basis of a population of two or more distinct types 
of poly A-PrK. If it is assumed that phosphoproteins associated with 
various subcellular fractions but sharing the same molecular weight, 
are in fact identical proteins, more direct evidence for the 
existence of at least one poly A-PrK may be provided by the observation 
that membrane-associated forms of both the 47kDa protein and the 
100.3kDa protein show marked enhancement of phosphorylation in the
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presence of polyamine but no evidence of cAMP dependent or Ca2+ 
calmodulin-dependent phosphorylation, respectively (see sections 3.3.4 
and 3.3.1). Since such effects are prominent in mammary cytosols (see 
section 3.3.1 and Figures 36 and 37), their absence from membrane 
fractions may imply a lack of significant membrane-associated cAMP-PrK 
or Ca2+ calmodulin-dependent protein kinase activities. It would 
therefore appear that the effects of polyamine on 32P-incorporation 
into the 47 and 100.3kDa proteins are not mediated by stimulation of 
these two kinases, leading to the obvious conclusion that at least one 
other endogenous kinase is capable of phosphorylating these two mammary 
proteins and that phosphorylation mediated by this enzyme is 
polyamine-dependent.
Having adopted the assumption that the observed effects are 
indeed mediated by the activity of poly A-PrK, the fraction-specific 
patterns of stimulation of particulate protein phosphorylation by 
spermine and spermidine evident, particularly in the 'nuclear' and 
'microsomal' fractions (Figure 34), may be explained by the existence 
of two forms of particulate poly A-PrK with distinct regulatory 
characteristics. At least one polyamine-dependent protein kinase, 
nuclear casein kinase Nil, has been identified in nuclei [104, 435,
660, 661, 775] and, although not yet screened for polyamine-dependence, 
a casein kinase associated with the Golgi apparatus of bovine mammary 
gland [48, 49] may prove to have regulatory properties similar to those 
of the polyamine-dependent cytosolic enzyme, casein kinase G (casein 
kinase II, see section 1.3.8.(i)c), recently identified in mouse 
mammary tissue [468]. The evidence presented here strongly suggests 
the existence of microsomal poly A-PrK in rat mammary tissue and since 
Golgi vesicles would be expected to sediment in the 'microsomal'
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fraction, an enzyme analogous to the bovine Golgi-associated casein 
kinase represents an attractive candidate for the identity of this 
kinase. To be consistent with the observed polyamine response, the 
putative Golgi-associated poly A-PrK must display a marked preference 
for spermine over spermidine as an activator, while, in contrast, the 
nuclear poly A-PrK must either show little polyamine specificity 
(with respect to spermine and spermidine) or a preference for 
spermidine. In the latter situation, the pronounced spermine induced 
increases in phosphorylation observed in the 'nuclear' fraction (Figure 
34) would be proposed to arise from contamination with Golgi-associated 
poly A-PrK. The pattern of polyamine-dependent stimulation displayed 
by 'mitochondrial' fraction protein phosphorylations is more 
reminiscent of that observed in the 'nuclear' fraction than that of the 
'microsomal' fraction (Figure 34) suggesting either contamination with 
nuclear-type poly A-PrK or the existence of a distinct mitochondrial 
poly A-PrK, similar to the nuclear form. The reduced responses of 
mitochondrial protein phosphorylations to polyamine, in comparison with 
those observed in the 'nuclear' fraction argues in favour of the latter 
but the existence of a distinct mitochondrial form cannot be dismissed.
The most extensively characterised polyamine-dependent protein 
kinase, casein kinase G (CKG, see section 1.3.8.(i)c) has been purified 
from cytosols of at least two different tissues (bovine lung [105], 
bovine adrenal cortex [108]) and has also been identified in mouse 
mammary gland [468]. It is surprising, therefore that the 
polyamine-dependent phosphorylation reported here was much less obvious 
in mammary acinar cytosols than in either 'nuclear' or 'microsomal' 
fractions. This does not necesarily imply that rat mammary cytosols 
are substantially deficient in polyamine-dependent protein kinase, it
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may simply indicate that the major substrates for the cytosolic kinase 
are membrane-associated and therefore not accessible under the 
experimental conditions employed in this study. Considering the 
aliphatic character of polyamines, it is not difficult to imagine that 
many of the substrates for polyamine-dependent protein kinase might be 
membrane-associated where interactions between polyamine and the 
hydrophobic environment of biological membranes might be envisaged to 
participate in the activation mechanism. Non-membrane proteins may 
then be poor substrates for polyamine-stimulated phosphorylation, thus 
accounting for the limited response, to polyamine, of protein 
phosphorylation in the mammary cytosols.
Incubation of isolated hepatocytes with 7.5-10mM spermine has 
been shown to promote dephosphorylation of three cytosolic proteins 
with molecular weights of 46kDa, 34kDa (ribosomal protein S6) and 22kDa 
[17]. Of these, only the 34kDa phosphoprotein appears not to have a 
representative in the mammary complement of major cytosolic 
phosphoproteins. Neither of the mammary proteins with similar 
molecular weights (21.5kDa and 47kDa) to these hepatocyte proteins 
showed any spermine-dependent reduction in 32P-incorporation (Figure 
34). However, whether this discrepancy indicates some kind of tissue- 
specific effect or is more related to differences in the behaviour of 
intact cells and broken cell systems to treatment with polyamine cannot 
be deduced from the available information. The discrepant responses of 
the two systems to this polyamine might also reflect a dose-dependent 
effect since it is unknown whether the concentration of polyamine 
achieved in the cytoplasm of hepatocytes exposed to 7.5-10mM spermine 
is comparable with the ImM spermine added to mammary cytosol 
incubations in this study.
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The whole field of polyamine-mediated effects on enzyme 
activities is fraught with apparent paradox. The complex nature of 
the protein-polyamine interactions responsible for this confusion 
predisposes towards a situation in which the reliability of 
interpretations put upon the results generated by the present 
investigation into polyamine-dependent phosphorylation is 
questionable. Notwithstanding this, it is clear that 
polyamine-mediated modulation of protein phosphorylation represent a 
potentially major regulatory mechanism in lactating mammary tissue.
4.4. General Discussion
The most significant discoveries arising from work reported here 
are that mammary high affinity cAMP-PDE is susceptible to regulatory 
influences very similar to those found in other tissues and that 
despite an apparent lack of effect of increased intracellular cAMP 
concentrations on either steady-state protein phosphorylation or 
cellular metabolism, mammary tissue does in fact possess functional 
cAMP-PrK whose activity, in vitro, is susceptible to modulation by cAMP 
concentrations within the physiological range. Perhaps equally 
important is the observation that while enzymes such as cAMP-PrK and 
Ca2+ calmodulin-dependent protein kinase are represented in mammary 
tissue, the number of substrates attributable to both these kinases 
together forms only a very small fraction of the number attributable to 
poly A-PrK alone. As discussed earlier, this picture may be distorted, 
to a certain extent, by the constraints of the experimental design 
since interaction between kinases confined to one fraction and 
substrates residing in another is precluded by the very nature of the 
study. Further work is therefore necessary to establish the potential
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importance of such interactions before reliable assessment of the 
relative significance of both cAMP-PrK and Ca2+ calmodulin-dependent 
protein kinase can be attempted. It seems unlikely, however, that 
future experimentation of this kind will reveal a sufficient number of 
additional substrates for these two kinases to rival the comprehensive 
range of proteins apparently subject to polyamine-dependent 
phosphorylation.
The observation that neither exposure to insulin nor elevation 
of intracellular cAMP levels are capable of affecting the steady state 
phosphorylation of any protein detectable in one-dimensional SDS 
polyacrylamide gel electrophoretic separations of unfractionated 
homogenates derived from mammary acini incubated under appropriate
conditions (see section 3.2.) is surprising. In other tissues,
increased intracellular cAMP concentrations are known to raise markedly 
the level of phosphorylation of a number of proteins including glycogen 
phosphorylase, phosphorylase kinase, glycogen synthase, 
phosphofructokinase, pyruvate kinase, fructose 2,6-bisphosphatase and 
acetyl-CoA carboxylase [116, 238, 323, 325, 868]. Treatment of 
adipocytes with insulin has been shown to stimulate the incorporation 
of 32P into a peptide of molecular weight 123kDa [18] and stimulation
of the phosphorylation of both peripheral plasma membrane insulin
sensitive PDE [511, 512] and a 46kDa cytosolic protein [590] has also 
been demonstrated in response to insulin treatment of hepatocytes. In
addition, it has been suggested, recently, that insulin is capable of
regulating the phosphorylation state and therefore activity of 
acetyl-CoA carboxylase in rat mammary gland in vivo [552] but there is
at present no evidence to suggest that such an effect can be
reproduced in mammary acini [102]. Equally puzzling is the inability
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of raised intracellular cAMP concentrations to inactivate mammary 
acinar acetyl-CoA carboxylase, an observation supported by the 
inability to identify any cAMP-dependent changes in the phosphorylation 
pattern of tryptic peptides derived from acetyl- CoA carboxylase 
purified from mammary acini incubated in the presence of 32 Pi [102].
In view of the apparent prominence of poly A-PrK activity in lactating 
mammary tissue ([468], see section 3.3.3.), one possible explanation 
for the inability to observe cAMP-dependent acetyl-CoA carboxylase 
phosphorylation is that the level of polyamine-dependent 
phosphorylation of this enzyme is sufficiently high to block or mask 
any minor changes in phosphorylation attributable to the activity of 
other kinases, such as cAMP-PrK. If the mechanism for the proposed 
blocking of cAMP-PrK mediated phosphorylation involved competition with 
a more active kinase, such as poly A-PrK, for the same phosphorylation 
sites, acetyl-CoA carboxylase would be expected to be permanently 
inactive. However, since acetyl-CoA carboxylase activity is known to 
be high in lactating mammary acini [102, 656], polyamine-dependent 
phosphorylation at sites distinct from the cAMP-dependent 
phosphorylation sites might, instead, be imagined to induce 
conformational changes capable of preventing cAMP dependent 
phosphorylation of the sites responsible for enzyme inactivation. In 
the latter situation, acetyl-CoA carboxylase would constantly be fully 
active, perhaps explaining the inability of insulin treatment of 
mammary acini to elevate acetyl-CoA carboxylase activity further [656]. 
The ability of acetyl-CoA carboxylase to influence the rate of 
de novo fatty acid synthesis would therefore be lost and acute 
regulation of this pathway would then rely entirely on control exerted 
at other points in the synthetic sequence. This contention is
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supported by the observation that insulin treatment stimulates the rate 
of lipogenesis in rat mammary acini without influencing the activity of 
acetyl-CoA carboxylase [656]. In the absence of acetyl- CoA 
carboxylase-governed control of fatty acid synthesis, perhaps the most 
obvious alternative enzyme activities at which regulation of this 
pathway may be exerted are the glucose transporter, PFKl and PDH. 
Glucose uptake is known to be stimulated by insulin in other tissues 
and there is mounting evidence [72a, 73, 370a, 582a] to suggest that 
this is also the case for the mammary gland. Furthermore, there is 
evidence to suggest that monosaccharide transport is a rate-limiting 
factor in the utilisation of carbohydrate by mammary gland [776] and 
recent work with mammary tissue of starved/re-fed rats [73, 582a] 
appears to show a good correlation between rate of monosaccharide 
transport and the contribution of glucose to de novo fatty acid 
synthesis.
The rate of lactose synthesis appears to be governed by 
intracellular glucose concentration [73], yet no increase in synthetic 
rates has been recorded in response to insulin (see section 1.4.2.). 
This apparent paradox may be explained by increased glucose utilisation 
for lipogenesis, if not due to elevated acetyl-CoA carboxylase 
activity, perhaps as a result of activation of PFKl and/or PDH. The 
increase in glucose uptake, in response to insulin, would not, 
therefore, necessarily be translated into raised intracellular glucose 
concentrations. Consequently, in the absence of a direct effect of 
insulin on the lactose synthetic pathway, increased glucose uptake 
would, effectively, be "funnelled" into lipogenesis, at the expense of 
lactose synthesis.
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Whatever the reasons for defective regulation of acetyl-CoA 
carboxylase activity by reversible phosphorylation in mammary acini, 
this enzyme undoubtedly represents a major phosphoprotein of mammary 
acinar cytosols, as demonstrated by its steady-state level of 
32P-incorporation following equilibration of mammary acini with 32 Pi 
([102], see section 3.2.)* Curiously, however, incubation of mammary 
acinar cytosols with [y-32P]ATP in vitro reveals remarkably little 
acetyl-CoA carboxylase phosphorylation, suggesting that it is a 
comparatively poor substrate for the endogenous cytosolic kinases 
identified in this study, including cAMP-PrK and poly A-PrK. One 
obvious possible solution to this apparent paradox is that in the 
intact cell, acetyl-CoA carboxylase is phosphorylated by a 
membrane-bound kinase such as the particulate polyamine-dependent 
protein kinase(s) since such a phosphorylation would not be detected in 
the in vitro incubation system. Inconsistency of this nature is not 
confined to the phosphorylation of acetyl-CoA carboxylase; cAMP and 
Ca2+ both show marked effects on the initial rates of protein 
phosphorylation measured in vitro but modulation of the intracellular 
concentrations of these agents in intact mammary acini has no obvious 
effects on the observed level of steady-state phosphorylation of any 
endogenous proteins ([100, 103], see sections 3.2, 3.3.1. and
3.3.4.). Unlike the previous example (acetyl-CoA carboxylase 
phosphorylation), separation of kinase and substrate as a result of in 
vitro experimental protocol cannot be invoked to explain these effects 
unless phosphorylation of the cytosolic substrates for cAMP-PrK and 
Ca2+ calmodulin-dependent PrK is supposed to be masked, in vivo, by 
overwhelming phosphorylation mediated by membrane-bound kinase 
activity. However, it is equally probable that these substrates are
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quantitatively minor components of mammary cytosols, in comparison with 
proteins such as acetyl-CoA carboxylase or ATP-citrate lyase. In this 
situation, under conditions where the level of phosphorylation of the 
more abundant proteins becomes appreciable, the amount of 32P 
associated with any particular protein is likely to be more dependent 
on the actual number of protein molecules present than on the rate of 
their phosphorylation. Under these circumstances, the amount of 32P 
incorporated into quantitatively minor proteins might easily be 
imagined to be insignificant in comparison with phosphoproteins such as 
acetyl CoA carboxylase and ATP-citrate lyase and, perhaps even 
indistinguishable from background phosphorylation. Consequently, 
the less abundant the protein, the less likelihood there is of 
observing any changes in its steady-state level of phosphorylation, 
even if measurements of its initial rate of phosphorylation indicate 
that it is an excellent substrate for one of the effector-dependent 
protein kinases. The only workable alternative solution would seem to 
be that in the intact cell, stimulation of phosphorylation is 
accompanied by a parallel increase in dephosphorylation capable of 
exactly balancing the effect of increased kinase activity and therefore 
preventing any expression of increased net phosphate-incorporation. In 
the in vitro system, control of this nature might be expected to be at 
least partially disabled by the inclusion of the phosphatase inhibitor 
^-glycerophosphate in all incubation buffers, thus allowing any 
increase in kinase activity to be reflected by increases in net 
phosphate-incorporation. While the existence of such a finely balanced 
homeostatic mechanism might seem improbable and difficult to justify in 
terms of functional significance, an analogous situation is known to 
exist in the control of mammary intracellular cAMP concentrations.
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Mammary adenylate cyclase activity can be stimulated markedly by 
^-adrenergic agonists such as isoproterenol [449] but incubation 
of mammary acini with these agents does not result in raised 
intracellular cAMP concentrations unless a PDE inhibitor such as IBMX 
or Ro 7-2956 is also present in the incubation medium [101]. The 
implication is therefore that ^-adrenergic stimulation of adenylate 
cyclase also provokes a concomitant increase in cAMP-PDE activity 
sufficient to preserve resting levels of net cAMP production. The 
increases in high affinity cAMP-PDE activity in response to agents 
capable of stimulating cAMP synthesis, demonstrated in both adipose 
tissue [597, 721, 878] and liver [312, 490], provide support for this 
assertion but no corresponding effects on mammary high affinity 
cAMP-PDE have yet been identified. While confirmation of the 
mechanism(s) involved in antagonism of stimulated intracellular cAMP 
accumulation in mammary tissue therefore remains elusive, there is no 
doubt that mammary cell cAMP levels are extremely resistant to 
regulation by external stimuli. The discovery, made here, that insulin 
treatment of mammary acini stimulates high affinity cAMP-PDE activity 
was, consequently, of great interest since it provided a potential 
mechanism whereby intracellular cAMP levels might be depressed in 
mammary tissue. However, while local cAMP concentration gradients may 
be modified by changes in membrane-bound high affinity cAMP-PDE 
activity [212], it is now known that insulin treatment of mammary acini 
does not in fact provoke any changes in overall intracellular cAMP 
concentration [275].
The picture emerging from all this apparently paradoxical 
information is that elaborate mechanisms have evolved in lactating 
mammary tissue to prevent cAMP-dependent regulation of metabolic
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processes, in the short term, despite the existence of both a competent 
system for coupling external stimuli to the activity of enzymes 
involved in cAMP metabolism and a functional effector system comprising 
at least one form of cAMP-PrK. The same would also appear to be true 
for acute regulation of mammary metabolism by Ca2+-dependent 
phosphorylation, although the characteristics of mechanisms involved in 
mo,dulation of intracellular Ca2+ concentrations have not yet been 
established in this tissue. Both polyamine-dependent protein kinase 
activity [468] and polyamine levels [843] are high in lactating mammary 
tissue but the potential for acute regulation of mammary protein 
phosphorylation represented by such a situation may not in fact be 
exploited by mammary cells. Various agents including Bt2cAMP, insulin 
and prolactin have been demonstrated to influence mammary ornithine 
decarboxylase activity [5, 57] and since the activity of this enzyme 
generally determines the rate of polyamine synthesis (see section 
1.3.8.(i)c), these agents would be expected to modulate mammary cell 
polyamine concentrations and consequently the activity of poly A-PrK, 
leading to changes in the level of phosphorylation of a number of 
endogenous proteins (see section 3.3.3.). That no such changes are 
observed following exposure of mammary acini to either insulin or 
agents capable of elevating intracellular cAMP concentrations (see 
section 3.2.), would seem, once again, to indicate that mammary protein 
phosphorylation is invulnerable to acute regulation despite the 
presence of systems capable of translating external stimuli into 
changes in kinase activity.
From a simplistic viewpoint, based on the generalisation that 
phosphorylation stimulates catabolism and dephosphorylation stimulates 
synthetic activity, the inability of increases in kinase activity to
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effect increases in mammary protein phosphorylation might be imagined 
to have evolved in order to maintain maximum lactogenic rates 
independent of 'trivial' (with respect to mammary cell function) acute 
regulatory stimuli. The secretory cells of mammary tissue (mammary 
epithelial cells) have no efferent autonomic nerve supply and any 
regulatory stimuli must therefore be humoral. The systems discussed 
above would then serve to insulate further mammary lactogenic activity 
from 'irrelevent' stimuli and allow metabolic regulation to be governed 
solely by substrate availability. The only important factors 
influencing mammary cell metabolism in the short term would, therefore, 
be serum concentration of lactogenic precursors and their rate of 
uptake across the plasma membrane. Restriction of synthetic rates 
during food deprivation would, according to this scheme, be achieved by 
reduced glucose uptake in response to the low levels of circulating 
insulin and, as discussed earlier, the insulin-stimulated increase in 
lipogenesis in mammary acini, known not to involve increases in 
acetyl-CoA carboxylase activity [656], would be explained by 
increased glucose uptake. It should, however, perhaps be re-emphasised 
that observations in mammary acini may not be representative of the 
response of mammary cells to insulin in intact animals where dietary 
manipulation of circulating insulin levels have been shown to influence 
acetyl-CoA carboxylase activity [552]. The most obvious objection to 
an explanation of this kind, beside the dangers of over-simplification, 
is that it provides no indication of why mammary cells should retain 
elaborate regulatory systems, as exemplified by the adenylate 
cyclase/PDE/cAMP-PrK system, when, in evolutionary terms, such systems 
would appear to be superfluous and, therefore, obsolete. Perhaps an 
answer to this criticism might be afforded by a proposal asserting that
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protein phosphorylation is essential for maintenance of long term, 
rather than acute regulatory mechanisms. There is already good 
evidence that both protein kinase C [86, 758] and poly A-PrK [468] are 
involved in the control of mammary gland development. While the 
activities of Ca2+ calmodulin-dependent protein kinase and cAMP-PrK 
have not yet been demonstrated to correlate with cellular 
growth or differentiation (but see below), both may prove to 
have important regulatory effects on protein synthesis. In other 
tissues, both Ca2+ calmodulin-dependent protein kinase [262] and 
CAMP-PrK [170, 837, 839] are known to phosphorylate ribosomal protein 
S6 and cAMP-PrK also phosphorylates histone H 1[454, 505]. 
Interestingly, the onset of lactation in rats and mice is accompanied 
by a reduction in the level of cAMP in mammary cells [651, 681, 682] 
and treatment of a' variety of mammary culture preparations with Bt2cAMP 
or PDE inhibitors for extended periods has been shown to suppress both 
lactose and fatty acid synthesis [75, 487, 488, 682, 722]. The 
apparent ability of cAMP to limit lactogenesis might therefore justify 
the development of systems capable of nullifying the effect of stimuli 
normally expected to raise intracellular cAMP concentrations and 
therefore activate cAMP-PrK. However, the potential to express such 
effects may be important in relation to initiation of involution at the 
end of lactation, thus rationalising the existence of systems which, 
during lactation, are apparently antagonistic to the major function of 
the tissue. Although there is no guarantee that these effects of cAMP 
are mediated by cAMP-PrK (as discussed earlier [section 4.2.], raised 
intracellular cAMP concentrations appear to be without effect on the 
steady state level of protein phosphorylation in mammary acini), there 
is, at present, no known alternative mechanism for effecting a cellular
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response to cAMP. These observations therefore imply that, despite 
evidence to the contrary, under the right conditions, cAMP-dependent 
protein phosphorylation can be induced in mammary cells. Evidence 
in favour of some, as yet, undetermined role for cAMP-PrK is 
provided by the observation that prolactin stimulates induction of 
cAMP-PrK synthesis in mouse mammary stem cells [500]. However, it is 
difficult to understand why cAMP-PrK synthesis should be induced at a 
time when, as described above, cAMP-dependent effects are known to 
antagonise lactose and fatty acid synthesis. Perhaps the best 
explanation would be that a certain level of cAMP-dependent 
phosphorylation is required for normal cell function and that at the 
lower intracellular cAMP concentrations prevailing during lactation, 
such levels can only be maintained by increasing the cellular 
complement of cAMP-PrK.
In conclusion then, it might easily be imagined that a certain 
level of activity of these kinases is required in order to maintain 
lactogenesis but that acute regulation might interfere with the balance 
of protein synthesis necessary for normal milk production, perhaps 
resulting in modification of milk composition. The value of developing 
a system capable of preventing such undesirable interference during 
lactation, while preserving potential flexibility of response would 
then be obvious. The elaborate nature of the two tier 'fail-safe' 
mechanism represented by the resistance of intracellular cAMP levels to 
modulation and the inability of increased cAMP-PrK activity to be 
translated into raised levels of steady-state protein phosphorylation, 
might therefore be regarded as a reflection of the importance of 
maintaining correct milk composition regardless of acute external 
stimuli normally irrelevent to mammary tissue during lactation.
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